講座　精神疾患の臨床　1　気分症候

出版社： 中山書店
著者：
発行日： 2020-06-15
分野： 臨床医学：内科  >  精神医学
ISBN： 9784521748214
電子書籍版： 2020-06-15 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

16,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

16,500 円(税込)

購入する

商品紹介

現代社会において身近な病とされている「うつ病」「躁うつ病」ならびのその周辺の疾患について，最新の国際疾病分類ICD-11の診断カテゴリー「気分症群 mood disorders」に準拠して徹底解説．
疾患概念の変遷や診断・鑑別診断，年代別・性別の症状・症候の特徴，病態，各種治療法等について，各領域の専門家が詳細に言及している．
診断や治療に難渋することの多い気分症群の実地臨床に必携の一冊である

目次

  • 1章　概念・診断・疫学
    　疾患概念と分類の歴史
    　今日の分類と診断
    　気分症群の概念と診断，鑑別診断
    　境界を接する精神疾患との鑑別と併存精神疾患
    　内因性うつ病概念は何のために
    　気分症群の疫学と社会負担

    2章　症候・症状論と精神鑑定
    　児童・思春期の気分症群
    　若年者の抑うつ症－「現代抑うつ症候群」の提唱
    　高齢者の気分症群
    　女性の気分症群
    　退行期メランコリー
    　気分症群と身体疾患
    　気分症群と自殺
    　気分症群と創造性
    　気分症群の精神鑑定

    3章　病態
    　抑うつ症群のゲノム研究
    　抑うつ症群の画像研究
    　Topics　ニューロフィードバック
    　抑うつ症群の大規模臨床研究
    　抑うつ症群のバイオマーカー
    　双極症の生物学的研究
    　双極症のゲノム研究
    　うつ病をめぐるグローバルとローカル－医療人類学的視点
    　気分症群と産業精神衛生
    　　Topics　うつ病は「こころの風邪」ではない！

    4章　治療
    　治療総論
    　薬物療法
    　精神療法
    　作業療法
    　気分症群の復職支援
    　抑うつ症群の治療ゴールと再燃・再発予防
    　ニューロモデュレーション
    　新しい診断技術
    　情報通信技術（ICT）の活用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 概念・診断・疫学

P.7 掲載の参考文献
1) Craddock N, Owen M. The Kraepelinian dichotomy-going, going... but still not gone. Br J Psychiatry 2010 ; 196 : 92-95.
 
2) Schneider K. Klinische Psychopathologie. 15. Aufl. Thieme ; 2007/針間博彦 (訳). 新版 臨床精神病理学. 文光堂 ; 2007.
 
3) Friborg A, et al. Comorbidity of personality disorders in mood disorders : A meta-analytic review of 122 studies from 1988 to 2010. J Affect Disord 2014 ; 152-154 : 1-11.
 
4) Patel V, et al. Income inequality and depression : A systematic review and meta-analysis of the association and a scoping review of mechanisms. World Psychiatry 2018 ; 17 : 76-89.
 
5) Yu S. Uncovering the hidden impacts of inequality on mental health : A global study. Translational Psychiatry 2018 ; 8 : 98. doi : 10.1038/s41398-018-0148-0.
 
6) Kendler KS, Prescott CA. Genes, Environment, and Psychopathology : Understanding the Causes of Psychiatric and Substance Use Disorders. Guilford Press ; 2006.
 
7) Siette J, et al. Effectiveness of befriending interventions : A systematic review and meta-analysis. BMJ Open 2017 ; 7 : e014304. doi : 10.1136/bmjopen-2016-014304.
 
8) Pavlova B, et al. Lifetime prevalence of anxiety disorders in people with bipolar disorder : A systematic review and meta-analysis. Lancet Psychiatry 2015 ; 2 : 710-717.
PubMed
9) Simon GE, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999 ; 341 : 1329-1335.
 
10) Horwitz AV, Wakefield JC. The Loss of Sadness : How Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford University Press ; 2007/伊藤和子 (訳). それは「うつ」ではない-どんな悲しみも「うつ」にされてしまう理由. CCCメディアハウス ; 2011.
 
11) James W. The Varieties of Religious Experience : A Study in Human Nature. Longmans, Green and Co. ; 1902/桝田啓三郎 (訳). 宗教的経験の諸相 (上・下). 岩波文庫 ; 1969.
 
12) Ghaemi N. A First-Rate Madness : Uncovering the Links Between Leadership and Mental Illness. The Penguin Press ; 2011/山岸洋, 村井俊哉 (訳). 一流の狂気-心の病がリーダーを強くする. 日本評論社 ; 2016.
 
13) McCabe JH, et al. Excellent school performance at age 16 and risk of adult bipolar disorder : National cohort study. Br J Psychiatry 2010 ; 196 : 109-115.
 
14) Kyaga S, et al. Creativity and mental disorder : Family study of 300,000 people with severe mental disorder. Br J Psychiatry 2011 ; 199 : 373-379.
PubMed
15) Cooney GM et al. Exercise for depression. Cochrane Database Syst Rev 2013 ; (9) : CD004366. doi : 10.1002/14651858.CD004366.pub6.
 
16) 香山リカ. 私は若者が嫌いだ! KKベストセラーズ ; 2008.
 
17) 野口悠紀雄. 1940年体制-さらば戦時経済 (増補版). 東洋経済新報社 ; 1995/2010.
 
18) 本田由紀. もじれる社会-戦後日本型循環モデルを超えて. 筑摩書房 ; 2014.
 
Jackson SW. Melancholia and Depression : From Hippocratic Times to Modern Times. Yale University Press ; 1986.
 
Radden J (ed). The Nature of Melancholy : From Aristotle to Kristeva. Oxford University Press ; 2000.
 
Kendell RE. The classification of depressions : A review of contemporary confusion. Br J Psychiatry 1976 ; 129 : 15-28.
PubMed
Brown GW, Harris T. Social Origins of Depression. Routledge ; 1978/2011.
 
Bonanno GA. The Other Side of Sadness : What the New Science of Bereavement Tells Us About Life After Loss. Basic Books ; 2009/高橋祥友 (監訳). リジリエンス 喪失と悲嘆についての新たな視点. 金剛出版 ; 2013.
 
Styron W. Darkness Visible : A Memoir of Madness. Random House ; 1990/大浦暁生 (訳). 見える暗闇-狂気についての回想. 新潮社 ; 1992.
 
P.19 掲載の参考文献
1) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition. American Psychiatric Association ; 2015.
 
2) World Health Organization. ICD-11 for Mortality and Morbidity Statistics (version : 04/2019). https://icd.who.int/browse11/l-m/en (2020.3.1閲覧).
 
3) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders : Clinical Descriptions and Diagnostic Guidelines. World Health Organization, 1992.
 
4) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Association ; 1994.
 
5) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. American Psychiatric Association ; 1980.
 
6) Krupinski J, Tiller JW. The identification and treatment of depression by general practitioners. Aust N Z J Psychiatry 2001 ; 35 (6) : 827-832.
PubMed
7) Kendler KS, et al. Does bereavement-related major depression differ from major depression associated with other stressful life events? Am J Psychiatry 2008 ; 165 : 1449-1455.
PubMed
8) Wakefield JC, et al. Extending the bereavement exclusion for major depression to other losses : Evidence from the National Comorbidity Survey. Arch Gen Psychiatry 2007 ; 64 : 433-440.
PubMed
9) Keeley JW, et al. Disorders specifically associated with stress : A case-controlled field study for ICD-11 mental and behavioural disorders. Int J Clin Health Psychol 2016 ; 16 (2) : 109-127.
 
10) Goldberg DP, et al. Screening for anxiety, depression, and anxious depression in primary care : A field study for ICD-11 PHC. J Affect Disord 2017 ; 213 : 199-206.
PubMed
11) Maruta T, et al. Towards the ICD-11 : Initiatives taken by the Japanese Society for Psychiatry and Neurology to address needs of patients and clinicians. Psychiatry Clin Neurosci 2013 ; 67 (5) : 283-284.
PubMed
12) 日本精神神経学会 精神科病名検討連絡会. DSM-5 病名・用語翻訳ガイドライン. 精神神経学雑誌 2014 ; 116 (6) : 429-457.
 
本村啓介. 気分障害群. 精神医学 2019 ; 61 (3) : 245-253.
 
佐藤晋爾, 朝田隆. 激越型うつ病. 精神医学 2013 ; 55 (6) : 571-574.
 
American Psychiatric Association. Mixed Features Specifier. 2013. https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM-5-Mixed-Features-Specifier.pdf
 
Maj M. Mood Disorders in ICD-11. European Psychiatry 2015 ; 30 (Suppl 1) : 98.
 
Regier DA, et al. The DSM-5 : Classification and criteria changes. World Psychiatry 2013 ; 12 (2) : 92-98.
PubMed
神庭重信. DSM-5の日本語病名・用語について. 臨床精神医学 2014 ; 43 (増刊) : 17-20.
Medical*Online
P.34 掲載の参考文献
1) 本村啓介. 気分症群. 分子精神医学 2019 ; 19 : 205-211.
Medical*Online
2) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition. American Psychiatric Association ; 1980.
 
3) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders : Clinical descriptions and diagnostic guidelines. 1992/融道男ほか (監訳). ICD-10 精神および行動の障害, 臨床記述と診断ガイドライン 新訂版. 医学書院 ; 2005.
 
4) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association ; 2013/高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
5) 日本精神神経学会. ICD-11 診断ガイドライントレーニングセミナー 2019年版資料.
 
6) Kendler KS. DSM disorders and their criteria ; how should they inter-relate? Psychol Med 2017 ; 47 : 2054-2060.
PubMed
7) Kendler KS. The phenomenology of major depression and the representativeness and nature of DSM criteria. Am J Psychiatry 2016 ; 173 : 771-780.
PubMed
8) Kendler KS. The genealogy of major depression : Symptoms and signs of melancholia from 1880 to 1900. Mol Psychiatry 2017 ; 22 : 1539-1553.
PubMed
9) McGlinchey JB, et al. Diagnosing major depressive disorder VIII : Are some symptoms better than others? J Nerv Ment Dis 2006 ; 194 : 785-790.
PubMed
10) Reed GM, et al. Innovations and changes in the ICD-11 classification of mental, behavioural and neurodevelopmental disorders. World Psychiatry 2019 ; 18 : 3-19.
PubMed
11) Fried EI, et al. What are 'good' depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 2016 ; 189 : 314-420.
 
12) Kendler KS, et al. The centrality of DSM and non-DSM depressive symptoms in Han Chinese women with major depression. J Affect Disord 2018 ; 227 : 739-744.
 
13) Cassidy WL, et al. Clinical observation in manic-depressive disease : A quantitative study of one hundred manic-depressive patients and fifty medically sick controls. JAMA 1957 ; 164 : 1535-1546.
 
14) Kendler KS, et al. The development of the Feighner criteria : A historical perspective. Am J Psychiatry 2010 ; 167 : 134-142.
PubMed
15) Maj M. When does depression become a mental disorder? Br J Psychiatry 2011 ; 199 : 85-86.
PubMed
16) Maj M. Differentiating depression from ordinary sadness : Contextual, qualitative and pragmatic approaches. World Psychiatry 2012 ; 11 (Suppl 1) : 43-47.
 
17) Kendell RE. The classification of depressions : A review of contemporary confusion. Br J Psychiatry 1976 ; 129 : 15-28.
PubMed
18) Koukopoulos A, et al. Mixed features of depression : Why DSM-5 is wrong (and so was DSM-IV). Br J Psychiatry 2013 ; 203 : 3-5.
PubMed
19) Paykel E, el al. Changes needed in the classification of depressive disorders : Options for ICD-11. World Psychiatry 2012 ; 11 (Suppl 1) : 37-42.
 
20) Taylor MA, Fink M. Catatonia in psychiatric classification : A home of its own. Am J Psychiatry 2003 ; 160 : 1233-1241.
 
21) 本村啓介. 抑うつ障害群-精神医学に何が起こったか. 臨床精神医学 2014 ; 43 (増刊) : 79-95.
Medical*Online
22) Malhi GS, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Austral NZ J Psychiatry 2015 ; 49 : 1087-1206.
 
23) Torpey DC, Klein DN. Chronic depression : Update on classification and treatment. Curr Psychiatry Rep 2008 ; 10 : 458-464.
PubMed
24) Frances A. DSM in philosophyland : Curiouser and curiouser. In : Paris J, et al (eds). Making the DSM-5 : Concepts and Controversies. Springer ; 2013.
 
Zachar P. A Metaphysics of Psychopathology. MIT Press ; 2014/植野仙径ほか (訳). 精神病理の形而上学. 学樹書院 ; 2018.
 
Horwitz AV, Wakefield JC. The Loss of Sadness : How psychiatry transformed normal sorrow into depressive disorder. Oxford University Press ; 2007/伊藤和子 (訳). それは「うつ」ではない. 阪急コミュニケーションズ ; 2011.
 
P.46 掲載の参考文献
1) Sadock BJ, et al. Mood disorders. In : Sadock BJ, et al (eds). Kaplan & Sadock's Synopsis of Psychiatry : Behavioral Sciences/Clinical Psychiatry, 9th edition. Lippincott Williams & Wilkins ; 2003/井上令一 (監修), 四宮滋子ほか (監訳). 気分障害. カプラン臨床精神医学テキスト-DSM-IV-TR 診断基準の臨床への展開. メディカル・サイエンス・インターナショナル ; 2004, pp582-583.
 
2) 石井厚, 浅野弘毅. 躁うつ病研究の歴史. 大熊輝雄 (編), 躁うつ病の臨床と理論. 医学書院 ; 1990, pp1-12.
 
3) Healy D. From mania to bipolar disorder. In : Yatham LN, et al (eds), Bipolar Disorder : Clinical and Neurobiological Foundations, 1st edition. Wiley ; 2010, pp1-2.
 
4) Angst J, Marneros A. Bipolarity from ancient to modern times : Conception, birth and rebirth. J Affect Disord 2001 ; 67 : 3-19.
PubMed
5) Perris C. A study of bipolar (manic-depressive) and unipolar recurrent depressive psychoses. Acta Psychiatr Scand 1966 ; 194 (Suppl) : 1-89.
 
6) Akiskal HS, Mallya G. Criteria for the "Soft" bipolar spectrum : Treatment implications. Psychopharmacol Bull 1987 ; 23 : 68-73.
PubMed
7) Ghaemi SN. The bipolar spectrum and the antidepressant view of the world. J Psychiatr Pract 2001 ; 7 : 287-297.
 
8) Akiskal HS. The interface of affective and schizophrenic disorders : A cross between two spectra. In : Marneros A, Akiskal HS. The overlap of affective and schizophrenic spectra. Cambridge ; 2007, pp277-291.
 
9) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. APA ; 2013/日本精神神経学会 (監修), 高橋三郎ほか (監訳). DSM-5 精神疾患の診断・統計マニュアル, 医学書院 ; 2014.
 
10) クレッチマー E. 相場均 (訳). 体格と性格. 文光堂 ; 1960.
 
11) 下田光造. 躁鬱病に就いて. 米子医学雑誌 1950 ; 2 : 1-2.
 
12) Tellenbach H. Melancholie. Springer ; 1961. 4. Aufl., 1983/木村敏 (訳). メランコリー. みすず書房 ; 1978. 改訂増補版, 1985.
 
13) フロイト S. 新宮一成ほか (編). 喪とメランコリー. フロイト全集 14. 岩波書店 ; 2010 (1915), pp273-293.
 
14) Ghaemi SN, et al. Lack of insight in bipolar disorder : the acute manic episode. J Nerv Ment Dis 1995 ; 183 : 464-467.
PubMed
15) グレン・O・ギャバード. 奥寺崇ほか (監訳). 感情障害. 精神力動的精神医学-その臨床実践 第5版 (DSM-5準拠). 岩崎学術出版社 ; 2019, pp183-211.
 
16) Mortensen PB, et al. Individual and familial risk factors for bipolar disorders in Denmark. Arch Gen Psychiatry 2003 ; 60 : 1209-1215.
PubMed
17) Levitan RD, et al. Major depression in individuals with a history of childhood physical or sexual abuse : Relationship to neurovegetative features, mania and gender. Am J Psychiatry 1998 ; 155 : 1746-1752.
PubMed
18) Sadock BJ, et al. Mood disorders. In : Sadock BJ, et al (eds). Kaplan & Sadock's Synopsis of Psychiatry : Behavioral Sciences/Clinical Psychiatry, 9th edition. Lippincott Williams & Wilkins ; 2003/井上令一 (監修), 四宮滋子ほか (監訳). 気分障害. カプラン臨床精神医学テキスト-DSM-IV-TR 診断基準の臨床への展開. メディカル・サイエンス・インターナショナル ; 2004, pp583-584.
 
19) William W. The Epidemiologic Catchment Area Program of the National Institute of Mental Health. Public Health Reports 1981 ; 96 : 319-325.
 
20) 大熊輝雄 (原著). 第8章 統合失調症, 妄想性障害と気分障害 VII 気分障害, 感情障害, 躁うつ病. 「現代臨床精神医学」第12版改訂委員会 (編), 現代臨床精神医学 改訂第12版. 金原出版 ; 2013, pp374-375.
 
21) Sadock BJ, et al. Mood disorders. In : Sadock BJ, et al (eds). Kaplan & Sadock's Synopsis of Psychiatry : Behavioral Sciences/Clinical Psychiatry, 9th edition. Lippincott Williams & Wilkins ; 2003/井上令一 (監修), 四宮滋子ほか (監訳). 気分障害. カプラン臨床精神医学テキスト-DSM-IV-TR 診断基準の臨床への展開. メディカル・サイエンス・インターナショナル ; 2004, pp608-609.
 
22) 日本精神神経学会. ICD-11 診断ガイドライントレーニングセミナー 2019年版資料.
 
23) ヒーリー D. 江口重幸 (監訳). 双極性障害の時代, マニーからバイポーラーへ. みすず書房 ; 2012.
 
24) 加藤忠史. 双極II型障害は過剰診断されているか. 臨床精神医学 2017 ; 46 (3) : 325-329.
Medical*Online
P.53 掲載の参考文献
1) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM-III). American Psychiatric Association ; 1980.
 
2) World Health Organization. International Classification of Diseases and Related Health Problems, 10th revision (ICD-10). World Health Organization ; 1990.
 
3) World Health Organization. International Classification of Diseases and Related Health Problems, 11th revision (ICD-11). World Health Organization ; 2018.
 
4) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). American Psychiatric Association ; 2013.
 
5) Reed GM, et al. The WPA-WHO global survey of psychiatrists' attitudes towards mental disorders classification. World Psychiatry 2011 ; 10 : 118-131.
PubMed
6) Evans SC, et al. Psychologists' perspectives on the diagnostic classification of mental disorders : Results from the WHO-IUPsyS Global Survey. Int J Psychol 2013 ; 48 : 177-193.
PubMed
7) 笠原嘉, 木村敏. うつ状態の臨床的分類に関する研究. 精神神経学雑誌 1975 ; 77 : 715-735.
 
8) Moller HJ, et al. The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 2016 ; 266 : 725-736.
PubMed
9) Freedman R, et al. The initial field trials of DSM-5 : New blooms and old thorns. Am J Psychiatry 2013 ; 170 : 1-5.
PubMed
10) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-III-revised (DSM-III-R). American Psychiatric Association ; 1987.
 
11) Kessler RC, et al. Comorbidity of DSM-III-R major depressive disorder in the general population : Results from the US National Comorbidity Survey. Br J Psychiatry 1996 ; 168 (Suppl 30) : 17-30.
 
12) Hirschfeld RMA. The Comorbidity of Major Depression and Anxiety Disorders : Recognition and Management in Primary Care. Primary Care Companion J Clin Psychiatry 2001 ; 3 : 244-254.
 
13) Kendler KS, et al. Major depression and generalized anxiety disorder. Same genes, (partly) different environments? Arch Gen Psychiatry 1992 ; 49 (9) : 716-722.
PubMed
14) Friborg O, et al. Comorbidity of personality disorders in mood disorders : A meta-analytic review of 122 studies from 1988 to 2010. J Affective Disorders 2014 ; 152-154 ; 1-11.
 
15) American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd edition. American Psychiatric Association ; 2010.
 
16) Zanarini MC, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998 ; 155 (12) : 1733-1739.
PubMed
17) McIntyre RS, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Ann Clin Psychiatry 2012 ; 24 (1) : 56-68.
PubMed
18) Chandrasekhar T, et al. Challenges in the diagnosis and treatment of depression in autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 2015 ; 17 : 219-227.
PubMed
19) Vannucchi G et al. Bipolar disorder in adults with Asperger's Syndrome : A systematic review. J Affect Disord 2014 ; 168 : 151-160
 
20) Kessler RC, et al. The prevalence and correlates of adult ADHD in the United States : Results from the National Comorbidity Survey Replication. Am J Psychiatry 2006 ; 163 (4) : 716-723.
PubMed
21) Bond DJ, et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry 2012 ; 24 (1) : 23-37.
PubMed
22) Katzman MA, et al. Adult ADHD and comorbid disorders : Clinical implications of a dimensional approach. BMC Psychiatry 2017 ; 17 : 302.
PubMed
Maercker A, Lorenz L. Adjustment disorder diagnosis : Improving clinical utility. World J Biol Psychiatry 2018 ; 19 (Suppl 1) : S3-S13.
 
Moller HJ, et al. The relevance of 'mixed anxiety and depression' as a diagnostic category in clinical practice. Eur Arch Psychiatry Clin Neurosci 2016 ; 266 : 725-736.
PubMed
McIntyre RS, et al. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. Ann Clin Psychiatry 2012 ; 24 (2) : 163-169.
PubMed
Roth M, et al. Studies in the Classification of Affective Disorders. The Relationship between Anxiety States and Depressive Illnesses. I. Br J Psychiatry 1972 ; 121 : 147-161.
PubMed
P.66 掲載の参考文献
1) 平澤一. 軽症うつ病の臨床と予後. 医学書院 ; 1966.
 
2) 笠原嘉. 軽症うつ病-「ゆううつ」の精神病理. 講談社 ; 1996.
 
3) 諏訪望. 最新精神医学-精神科臨床の基本. 新改訂第31版. 南江堂 ; 1984.
 
4) 大熊輝雄. 現代臨床精神医学 第2版. 金原出版 ; 1983.
 
5) Kaplan HI, Sadock BJ, Grebb JA (eds). Kaplan and Sadock's Synopsis of Psychiatry : Behavioral Sciences, Clinical Psychiatry, 7th edition. Williams & Wilkins ; 1994/井上令一, 四宮滋子 (監訳). 臨床精神医学テキスト-DSM-IV 診断基準の臨床への展開. 医学書院MYW ; 1996.
 
6) 大前晋. 双極性障害を「双極性」障害と認識するのはなぜですか? そして双極性「障害」はモノですか? それともコトですか? 臨床精神医学 2017 ; 46 : 749-758.
Medical*Online
7) Mendels J. Depression : The distinction between syndrome and symptom. Br J Psychiatry 1968 ; 114 : 1549-1554.
PubMed
8) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition : DSM-5(TM). American Psychiatric Association ; 2013/高橋三郎, 大野裕 (監訳), 染矢俊幸, 神庭重信ほか (訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
9) Watts CAH. Endogenous depression in general practice. Br Med J 1947 ; 1 (4487) : 11-14.
PubMed
10) Watts CAH. The incidence and prognosis of endogenous depression. Br Med J 1956 ; 1 (4980) : 1392-1397.
 
11) Watts CAH. The mild endogenous depression. Br Med J 1957 ; 1 (5009) : 4-8.
 
12) 大前晋. 内因性うつ病-概念史と現代的意義. 臨床精神医学 2013 ; 42 : 825-839.
Medical*Online
13) Bonhoeffer K. Zur Differentialdiagnose der Neurasthenie und der endogenen Depressionen. Berliner klinische Wochenschrift 1912 ; 49 : 1-4.
 
14) Lange C. Om Periodiske Depressionstilstande og deres Patogenese. Lund, 1886./Schioldann JA (trans). On Periodical Depressions and their Pathogenesis. Hist Psychiatry 2011 ; 22 : 116-130.
 
15) Hecker E. Die Cyclothymie, eine cirkulare Gemutserkrankung. Zeitschrift fur praktische Aerzte 1898 ; 7 : 6-15./Baethge C, Salvatore P, et al (trans). Cyclothymia, a circular mood disorder. Hist Psychiatry 2003 ; 14 : 377-399. Koukopoulos A (trans). Ewald Hecker's description of cyclothymia as a cyclical mood disorder : Its relevance to the modern concept of bipolar II. J Affect Disord 2003 ; 73 : 199-205.
 
16) World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders : Clinical Descriptions and Diagnostic Guidelines. World Health Organization ; 1992/融道男, 中根允文ほか (監訳). ICD-10 精神および行動の障害-臨床記述と診断ガイドライン. 医学書院 ; 1993.
 
17) 平沢一. うつ病の臨床精神医学的研究の現況 (1945-1958). 精神医学 1959 ; 1 : 211-223.
 
18) 大前晋. うつ病の文化論的理解-ニッポンの「うつ病」1959-1978. 精神科 2018 ; 32 : 13-18.
 
19) 内村祐之. 鬱病の診斷と治療. 日本醫事新報 1946 ; 1188 : 3-5, 10.
 
20) 大前晋. 反応性と内因性の境界にて-よみがえれ! うつ病の状況論. 精神医学 2019 ; 61 : 801-815.
 
21) 笠原嘉, 木村敏. うつ状態の臨床的分類に関する研究. 精神経誌 1975 ; 77 : 715-735. (笠原嘉. うつ病臨床のエッセンス 新装版. みすず書房 ; 2015, pp15-70.)
 
22) Hamilton M. Mood disorders : Clinical features. In : Kaplan HI, Sadock BJ (eds). Comprehensive Text-book of Psychiatry, 5th edition. Williams & Wilkins ; 1989, pp892-913.
 
23) 野村章恒. うつ病と神経症との鑑別と治療. 臨床の日本 1959 ; 5 : 412-414.
 
24) Ascher E. A criticism of the concept of neurotic depression. Am J Psychiatry 1952 ; 108 : 901-908.
 
25) Klein DF. Endogenomorphic depression : A conceptual and terminological revision. Arch Gen Psychiatry 1974 ; 31 : 447-454.
PubMed
26) Wender PH, Klein DF. Mind, Mood, and Medicine. A Guide to the New Biopsychiatry. Farrar, Strauss and Giroux ; 1981/松浪克文, 福本修 (訳). 現代精神医学への招待-生物学的アプローチへの射程 <上・下>. 紀伊國屋書店 ; 1990.
 
27) 大前晋. 個人が悩みをかかえきれなくなったとき, 社会的に求められる機能を果たせなくなったとき, 精神科医療は何ができるのか-うつ病概念と, それが指し示す範囲すなわちスペクトラム. 村井俊哉, 村松太郎 (責任編集), 精神医学の基盤 [3] 特集 精神医学におけるスペクトラムの思想. 学樹書院 ; 2016, pp127-139.
 
28) Horwitz AV, Wakefield JC. The Loss of Sadness : How Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford University Press ; 2007/伊藤和子 (訳). それは「うつ」ではない-どんな悲しみも「うつ」にされてしまう理由. 阪急コミュニケーションズ ; 2011.
 
29) Spitzer RL. Foreword. In : Horwitz AV, Wakefield JC. The Loss of Sadness : How Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford University Press ; 2007, ppvii-x/伊藤和子 (訳). それは「うつ」ではない-どんな悲しみも「うつ」にされてしまう理由. 阪急コミュニケーションズ ; 2011, pp1-5.
 
30) Frances A. Saving Normal. An Insider's Revolt against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life. Morrow ; 2013/大野裕 (監訳), 青木創 (訳). <正常> を救え-精神医学を混乱させるDSM-5への警告．講談社 ; 2013.
 
31) Frank JD. Psychotherapy : The restoration of morale. Am J Psychiatry 1974 ; 131 : 271-274.
PubMed
32) Frank JD, Frank JB. Persuasion and Healing : A Comparative Study of Psychotherapy, 3rd edition. The Johns Hopkins University Press ; 1991/杉原保史 (訳). 説得と治療-心理療法の共通要因. 金剛出版 ; 2007.
 
33) Klein DF, Gittelman R, Quitkin F, et al. Diagnosis and Drug Treatment of Psychiatric Disorders : Adult and Children, 2nd edition. Williams and Wilkins ; 1980.
 
34) 玉田有, 大前晋. 大うつ病性障害に『励まし』は禁忌か-Demoralizationという概念とその有用性. 精神経誌 2015 ; 117 : 431-437.
 
35) 玉田有, 大前晋. 慢性うつ病の臨床におけるdemoralization概念の重要性-患者を励ます時機と自殺への配慮. 臨床精神医学 2017 ; 46 : 607-612.
Medical*Online
36) 大前晋. 「大うつ病性障害」ができるまで-DSM-III以前の「うつ病」 (内因性抑うつ) と現代の「うつ病」 (大うつ病性障害) の関係. 精神経誌 2012 ; 114 : 886-905.
 
37) Eysenck HJ. The classification of depressive illness. Br J Psychiatry 1970 ; 117 : 241-250.
 
38) 大前晋. 「軽症内因性うつ病」の発見とその現代的意義-うつ病態分類をめぐる単一論と二分論の論争, 1926～1957年の英国を中心に. 精神経誌 2009 ; 111 : 486-501.
 
39) Lewis A. States of Depression. Br Med J 1938 ; 2 (4060) : 875-878.
PubMed
40) Schneider K. Klinische Psychopathologie, 3. Aufl. Thieme ; 1950.
 
41) Schneider K. Klinische Psychopathologie, 6. Aufl. Thieme ; 1962/平井静也, 鹿子木敏範 (訳). 臨床精神病理学. 文光堂 ; 1962.
 
42) Gillespie RD. The clinical differentiation of types of depression. Guy's Hospital Reports 1929 ; 79 : 306-344.
 
43) Schulte W. Psychotherapeutische Bemuhungen bei den Melancholie. Deutsche medizinische Wochenschrift 1962 ; 87 : 2225-2231/飯田眞, 中井久夫 (訳). うつ病の精神療法. 精神療法研究. 岩崎学術出版社 ; 1994, pp63-85.
 
44) Klein DF. Depression and anhedonia. In : Clark DC, Fawcett J (eds). Anhedonia and Affect Deficit State. PMA Publishing ; 1987, pp1-14.
 
45) American Psychiatric Association. DSM-III : Diagnostic and Statistical Manual of Mental Disorders (Third Edition). American Psychiatric Association ; 1980.
 
46) Schneider K. Die Schichtung des emotionalen Lebens und der Aufbau der Depressionszustande. Zeitschrift fur die gesamte Neurologie und Psychiatrie. Originalien. 1920 ; 59 : 281-286/赤田豊治 (訳・解説). 感情生活の成層性と抑うつ状態の構造. 精神医学 1976 ; 18 : 441-447.
 
47) Westermann J. Uber die vitale Depression. Zeitschrift fur die gesamte Neurologie und Psychiatrie 1922 ; 77 : 391-422.
 
48) Schneider K. Zur Psychologie und Psychopathologie der Gefuhlserlebnisse. Zeitschrift fur die gesamte Neurologie und Psychiatrie 1928 ; 112 : 233-246.
 
49) Schneider K. Die Untergrunddepression. Fortschritte der Neurologie, Psychiatrie und ihrer Grenzgebiete 1949 ; 17 : 429-434.
 
50) Kraepelin E. Psychiatrie : Ein Lehrbuch fur Studierende und Arzte, 8. Aufl, III. Band, Klinische Psychiatrie, II. Teil. Barth ; 1913/西丸四方, 西丸甫夫 (訳). <精神医学> 1. 精神分裂病. <精神医学> 2. 躁うつ病とてんかん. みすず書房 ; 1986, 1986.
 
51) Ross TA. The Common Neuroses : Their Treatment by Psychotherapy. Arnold ; 1923.
 
52) Schneider K. Zur Frage der Psychotherapie endogener Psychosen. Deutsche medizinische Wochenschrift 1954 ; 79 : 873-875.
PubMed
53) Beck AT. Depression : Clinical, Experimental, and Theoretical Aspects. Harper & Row ; 1967.
 
54) Rush AJ, Beck AT, Kovacs M, et al. Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. Cognitive Therapy and Research 1977 ; 1 : 17-37.
 
55) Beck AT, Alford BA. Depression : Cause and Treatment, 2nd editon. University of Pennsylvania Press ; 2009.
 
56) Frank JD. Discussion of Dr. Gurland's Paper. In : Zubin J, Freyhan FA (eds). Disorders of Mood. The Johns Hopkins Press ; 1972, pp29-31.
 
57) Cook LC. Convulsion therapy. J Ment Sci 1944 ; 90 : 453-464.
 
58) Sargant W, Slater E. An Introduction to Physical Methods of Treatment in Psychiatry. Livingstone ; 1944.
 
59) Kuhn R. Uber die Behandlung depressiver Zustande mit einen Iminobenzylderivat (G22355). Schweizerische medizinische Wochenschrift 1957 ; 87 : 1135-1140/立山萬里 (訳). VI. イミプラミン (スイス, 1957年). 保崎秀夫 (監訳), 八木剛平 (編集・解説). 精神病治療薬の原点-国外重要文献全訳集. 金剛出版 ; 1987. pp70-83.
 
60) 諏訪望. 神經症と鬱病-診斷上の諸問題. 日本醫事新報 1956 ; 1692 : 8-15.
 
笠原嘉. うつ病臨床のエッセンス 新装版. みすず書房 ; 2015.
 
原田憲一. 不安・憂うつ・眠れない. 読売新聞社 ; 1988.
 
新福尚武. 仮面デプレッション. 日本メルク万有 ; 1969.
 
Ayd F Jr. Recognizing the Depressed Patient : With Essentials of Management and Treatment. Grune & Stratton ; 1961.
 
Klein DF, Wender PH. Understanding Depression : A Complete Guide to Its Diagnosis and Treatment, Revised and Expanded. Oxford University Press ; 2005.
 
飯田真 (編集・解説). 現代のエスプリ No.88 躁うつ病. 至文堂 ; 1974.
 
大前晋. 抑うつ障害群 : 診断概念の変遷-DSM-IIIまで. 神庭重信 (総編集), 内山真 (編). DSM-5を読み解く-伝統的精神病理, DSM-IV, ICD-10をふまえた新時代の精神科診断 3. 双極性障害および関連障害群, 抑うつ障害群, 睡眠-覚醒障害群. 中山書店 ; 2014, pp105-127.
 
P.76 掲載の参考文献
1) Nishi D, et al. Prevalence of mental disorders and mental health service use in Japan. Psychiatry Clin Neurosci 2019 ; 73 (8) : 458-465.
PubMed
2) 川上憲人. こころの健康についての疫学調査に関する研究. 2007. https://www.khj-h.com/wp/wp-content/uploads/2018/05/soukatuhoukoku19.pdf
 
3) Ishikawa H, et al. Lifetime and 12-month prevalence, severity and unmet need for treatment of common mental disorders in Japan : Results from the final dataset of World Mental Health Japan Survey. Epidemiol Psychiatr Sci 2016 ; 25 (3) : 217-229.
PubMed
4) 川上憲人. 精神疾患の有病率等に関する大規模疫学調査研究 : 世界精神保健日本調査セカンド総合研究報告書. 2016. http://wmhj2.jp/WMHJ2-2016R.pdf
 
5) Ishikawa H, et al. Prevalence, treatment, and the correlates of common mental disorders in the mid 2010's in Japan : The results of the World Mental Health Japan 2nd Survey. J Affect Disord 2018 ; 241 : 554-562.
 
6) 厚生労働省. 国民生活基礎調査 https://www.mhlw.go.jp/toukei/list/20-21.html
 
7) Nishi D, et al. Trends in the prevalence of psychological distress and the use of mental health services from 2007 to 2016 in Japan. J Affect Disord 2018 ; 239 : 208-213.
PubMed
8) 厚生労働省. 患者調査 https://www.mhlw.go.jp/toukei/list/10-20.html
 
9) 厚生労働省. レセプト情報・特定健診等情報の提供に関するホームページ https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/reseputo/index.html
 
10) 国立精神・神経医療研究センター 精神保健研究所 精神医療政策研究部. 精神保健福祉資料 http://www.ncnp.go.jp/nimh/keikaku/data/
 
11) Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020 : Global Burden of Disease Study. Lancet 1997 ; 349 (9064) : 1498-1504.
PubMed
12) Institution for Health Metrics and Evaluation. GBD Compare https://vizhub.healthdata.org/gbd-compare/.
 
13) Sado M, et al. Cost of depression among adults in Japan in 2005. Psychiatry Clin Neurosci 2011 ; 65 (5) : 442-450.
PubMed
14) Okumura Y, Higuchi T. Cost of depression among adults in Japan. Prim Care Companion CNS Disord 2011 ; 13 (3).
PubMed
15) 学校法人慶應義塾. 「精神疾患の社会的コストの推計」事業実績報告書. 2011. https://www.mhlw.go.jp/bunya/shougaihoken/cyousajigyou/dl/seikabutsu30-2.pdf
 
16) Jorm AF, et al. Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry 2017 ; 16 (1) : 90-99.
PubMed
17) Demyttenaere K, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004 ; 291 (21) : 2581-2590.
PubMed
18) Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications : Results from the U. S. National Health and Nutrition Examination Survey. J Clin Psychiatry 2014 ; 75 (2) : 169-177.
PubMed
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)/日本精神神経学会 (日本語版用語監修). DSM-5 精神疾患の分類と診断の手引. 医学書院 ; 2014.
 
World Health Organization. ICD-11 for Mortality and Morbidity Statistics, version : 04/2019. https://icd.who.int/browse11/l-m/en
 
P.84 掲載の参考文献
1) 鈴木映二. よし, 当事者になろう. 精神医学 2016 ; 58 (10) : 816-817.
 
2) 中西正司, 上野千鶴子. 当事者主権. 岩波書店 ; 2003.
 
3) Katz AH, Bender EI. Self-help groups in western society : History and prospects. J Appl Behav Sci 1976 ; 12 (3) : 265-282.
 
4) Katz AH. Self-Help in America : A Social Movement Perspective. Twayne Pub ; 1992.
 
5) Borman LD. Introduction : Self-help/mutual aid groups in strategies for health. In : Katz AH, et al. Self-Help : Concepts and Applications. Charles Press ; 1992.
 
6) Moeller ML. History, concept and position of self-help groups in Germany. Group Anal 1999 ; 32 (2) : 181-194.
 
7) 鈴木映二. サポート体制-双極性障害の当事者会. 最新医学 2014 ; 69 : 1192-1195.
Medical*Online
8) Davidson L, et al. Peer support among individuals with severe mental illness : A review of the evidence. Clin Psychol Sci Pract 1999 ; 6 (2) : 165-187.
 
9) Schubert MA, Borkman TJ. An organizational typology for self-help groups. Am J Community Psychol 1991 ; 19 (5) : 769-787.
 
10) 鈴木映二. ノーチラス会 (特定非営利活動法人日本双極性障害団体連合会). 精神科 2015 ; 26 (3) : 224-228.
 
11) Forcehimes A, Tonigan JS. Self-efficacy to remain abstinent and substance abuse : A meta analysis. Alchol Treat Q 2008 ; 26 : 480-489.
 
12) Zemore SE, Kaskutas LA. Helping, spirituality and Alcoholics Anonymous in recovery. J Stud Alcohol 2004 ; 65 (3) : 383-391.
 
13) Kyrouz EM, et al. Chapter 4 : A review of research on the effectiveness of self-help mutual aid groups. In : White BJ, et al (eds). American Self-Help Group Clearinghouse Self-Help Group Sourcebook, 7th edition. American Self-Help Group Clearinghouse ; 2002, pp71-86.
 
14) Dean SR. The role of self-conducted group therapy. Am J Psychiatry 1971 ; 127 (7) : 934-937.
PubMed
15) 小砂哲太郎ほか. 精神科作業療法へのピアサポートの導入が精神科病院入院患者に与える影響-地域生活に対するイメージや行動の変化に着目して. 東京作業療法 2017 ; 5 : 51-58.
Medical*Online
16) 松本真由美, 上野武治. 精神障害者地域移行支援事業におけるピアサポートの導入と事業実績および事業実施状況との関連に関する全国横断調査. 精リハ誌 2016 ; 20 (1) : 72-81.
 
17) Pagano ME, et al. Helping other alcoholics in alcoholics anonymous and drinking outcomes : Findings from project MATCH. J Stud Alcohol 2004 ; 65 (6) : 766-773.
PubMed
18) Riessman F. The "helper" therapy principle. Soc Work 1965 ; 10 : 27-32.
 
19) 宮本有紀. リカバリー-変革と実践のために. 医学のあゆみ 2017 ; 261 (10) : 1015-1021.
Medical*Online
20) 川崎洋子. 家族が期待する支援. 精神科臨床サービス 2010 ; 10 (3) : 284-289.
 
21) Sagarin E. Chapter 3. Gamblers, addicts, illegitimates, and others : Imitators and emulators. In : Sagarin E. Odd man in ; societies of deviants in America. Quadrangle Books ; 1969, pp56-77.
 
22) Chiba R, et al. Reliability and validity of the Japanese version of the Recovery Assessment Scale (RAS) for people with chronic illness : Scale development. Int J Nurs Stud 2009 ; 47 (3) : 314-322.
PubMed
23) 公益法人全国保健福祉社会連合会. 2012 (平成24) 年度「家族会」全国調査. 2013.
 
24) 相川章子. プロシューマーの歴史と動向. 精神療法 2012 ; 38 (2) : 253-264.
 
25) Anthony WA. Recovery from mental illness : The guiding vision of the mental health service system in the 1990s. Psychosocial Rehabilitation Journal 1993 ; 16 (3) : 11-23.
 
26) The President's New Freedom Commission On Mental Health (2003). Retrieved June 21, 2012, from http://www.cartercenter.org/documents/1701.pdf.
 
27) Corrigan PW, Phelan SM. Social support and recovery in people with serious mental illness. Community Ment Health J 2004 ; 40 : 513-523.
PubMed
28) Resnick SG, et al. An exploratory analysis of correlates of recovery. Psychiatr Serv 2004 ; 55 (5) : 540-547.
PubMed
29) Copeland ME. Getting Well : the Seeds of WRAP. History of WRAP. 1995. http://mentalhealthrecovery.com/info-center/getting-well-the-seeds-of-wrap-2/
 
30) 宮本有紀. リカバリーと精神科地域ケア. 石原孝二ほか (編). 精神医学と当事者. 東京大学出版会 ; 2016, pp110-132.
 

2章 症候・症状論と精神鑑定

P.95 掲載の参考文献
1) Spitz RA. Anaclitic depression ; an inquiry into the genesis of psychiatric conditions in early childhood. Psychoanal Study Child 1946 ; 2 : 313-342.
PubMed
2) Bowlby J. Maternal Care and Mental Health. 1951 ; World Health Organisation.
 
3) 高木隆郎. 前思春期における周期性精神病について. 精神神経学雑誌 1959 ; 61 (9) : 1194-1208.
 
4) 村上仁. 変質性精神病に関する一考察. 精神神経学雑誌 1953 ; 55 (1) : 22-32.
 
5) 鳩谷龍. 非定型的内因精神病の精神-生理学的研究 (第1報). 精神神経学雑誌 1955 ; 57 (3) : 144-166.
 
6) 鳩谷龍. いわゆる周期性精神病の内分泌学的研究 (III). 精神神経学雑誌 1962 ; 64 (1) : 29-43.
 
7) 山下格. 若年周期精神病. 精神科治療学 2000 ; 15 : 617-622.
 
8) Kraepelin E. Manic-Depressive Insanity and Paranoia. translated by Barclay RM, edited by Robertson GM. E & S Livingstone ; 1921. reprinted Arno Press ; 1976.
 
9) Weinberg WA, Brumback RA. Mania in childhood : Case studies and literature review. Am J Dis Child 1976 ; 130 (4) : 380-385.
PubMed
10) Davis RE. Manic-depressive variant syndrome of childhood : A preliminary report. Am J Psychiatry 1979 ; 136 (5) : 702-706.
PubMed
11) Biederman J, et al. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991 ; 148 (5) : 564-577.
PubMed
12) Lewinsohn PM, et al. Bipolar disorder during adolescence and young adulthood in a community sample. Bipolar Disord 2000 ; 2 (3 Pt 2) : 281-293.
 
13) Goodwin FK, Jamison KR. Manic-Depressive Illness : Bipolar Disorders and Recurrent Depression. Oxford University Press ; 2007.
 
14) Brotman MA, et al. Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biol Psychiatry 2006 ; 60 (9) : 991-997.
PubMed
15) Stringaris A, et al. Pediatric bipolar disorder versus severe mood dysregulation : Risk for manic episodes on follow-up. J Am Acad Child Adolesc Psychiatry 2010 ; 49 (4) : 397-405.
PubMed
16) Stringaris A, et al. Adult outcomes of youth irritability : A 20-year prospective community-based study. Am J Psychiatry 2009 ; 166 (9) : 1048-1054.
PubMed
17) Kowatch RA, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005 ; 44 (3) : 213-235.
PubMed
18) 鈴木太. 双極性障害と重篤気分調節症. 本城秀次ほか (編), 臨床児童青年精神医学ハンドブック. 西村書店 ; 2016, pp275-285.
 
National Institute for Health and Clinical Excellence. Depression in children and young people : identification and management https://www.nice.org.uk/guidance/ng134
 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association ; 2013/高橋三郎, 大野裕 (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
World Health Organization. ICD-11 for Mortality and Morbidity Statistics (version : 04/2019). https://icd.who.int/browse11/l-m/en (2020.3.1閲覧).
 
日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン I. 双極性障害 2017. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/180125.pdf
 
日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5)/大うつ病性障害 2016. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724.pdf
 
P.108 掲載の参考文献
1) 神庭重信. 下田執着気質論の現代的解釈. 九州神経精神医学 2006 ; 52 : 79-88.
 
2) 樽味伸. 現代の「うつ状態」-現代社会が生む "ディスチミア親和型". 臨床精神医学 2005 ; 34 : 687-694.
 
3) 樽味伸, 神庭重信. うつ病の社会文化的試論-特に「ディスチミア親和型うつ病」について. 日本社会精神医学会雑誌 2005 ; 13 : 129-136.
Medical*Online
4) 下田光造. 余ノ教室二於ケル初老期鬱憂症ノ治療二就テ. 台湾医学雑誌 1932 ; 31 : 113-115.
 
5) 下田光造. 躁うつ病に就いて. 米子医誌 1950 ; 2 : 1-2.
 
6) Tellenbach H. Melancholie. Springer ; 1976/木村敏 (訳). メランコリー (増補改訂版). みすず書房 ; 1985.
 
7) Kato TA, Kanba, S. Modern-Type Depression as an "Adjustment" Disorder in Japan : The Intersection of Collectivistic Society Encountering an Individualistic Performance-Based System. Am J Psychiatry 2017 ; 174 : 1051-1053.
PubMed
8) Kato TA, et al. Multidimensional anatomy of 'modern type depression' in Japan : A proposal for a different diagnostic approach to depression beyond the DSM-5. Psychiatry Clin Neurosci 2016 ; 70 : 7-23.
PubMed
9) Kato TA, et al. Are Japan's hikikomori and depression in young people spreading abroad? Lancet 2011 ; 378 : 1070.
 
10) Kato TA, et al. Introducing the concept of modern depression in Japan ; An international case vignette survey. J Affect Disord 2011 ; 135 : 66-76.
PubMed
11) 加藤隆弘ほか. 「現代抑うつ症候群 (新型うつ・現代うつ) 」は閾値下うつ, あるいは, 適応障害か? -精神医学的知見に鑑みて. ストレス科学 2017 ; 32 : 63-73.
Medical*Online
12) 加藤隆弘ほか. 現代抑うつ症候群 (現代うつ・新型うつ) に対する多軸的評価システムの構築-大学病院気分障害外来での取り組み紹介. 精神科臨床サービス 2016 ; 16 : 183-191.
 
13) Kato TA, et al. Development and validation of the 22-item Tarumi's Modern-Type Depression Trait Scale : Avoidance of Social Roles, Complaint, and Low Self-Esteem (TACS-22). Psychiatry Clin Neurosci 2019 ; 73 : 448-457.
 
14) Kuwano N, et al. Tryptophan-kynurenine and lipid related metabolites as blood biomarkers for firstepisode drug-naive patients with major depressive disorder : An exploratory pilot case-control study. J Affect Disord 2018 ; 231 : 74-82.
 
15) Kaiya H. Concerns Regarding the Proposed New Diagnosis of "Modern-Type Depression" in Japan. Am J Psychiatry 2018 ; 175 : 483.
PubMed
16) Zimmerman M, et al. "Subthreshold" depression : Is the distinction between depressive disorder not otherwise specified and adjustment disorder valid? J Clin Psychiatry 2013 ; 74 : 470-476.
 
17) O'Donnell ML, et al. A Longitudinal Study of Adjustment Disorder After Trauma Exposure. Am J Psychiatry 2016 ; 173 : 1231-1238.
 
18) Koyama A, et al. Lifetime prevalence, psychiatric comorbidity and demographic correlates of "hikikomori" in a community population in Japan. Psychiatry Res 2010 ; 176 : 69-74.
 
19) Kato TA, et al. Hikikomori : Multidimensional understanding, assessment, and future international perspectives. Psychiatry Clin Neurosci 2019 ; 73 : 427-440.
PubMed
20) Kato TA, et al. Hikikomori : Experience in Japan and international relevance. World Psychiatry 2018 ; 17 : 105-106.
PubMed
21) Teo AR, et al. Psychopathology associated with social withdrawal : Idiopathic and comorbid presentations. Psychiatry Res 2015 ; 228 : 182-183.
PubMed
22) Kashihara J, et al. Perceptions of traditional and modern types of depression : A cross-cultural vignette survey comparing Japanese and American undergraduate students. Psychiatry Clin Neurosci 2019 ; 73 : 441-447.
PubMed
23) Kubo H, et al. Development of MHFA-based 2-h educational program for early intervention in depression among office workers : A single-arm pilot trial. PLoS One 2018 ; 13 : e0208114.
PubMed
P.117 掲載の参考文献
1) Blazer D, et al. The epidemiology of depression in an elderly community population. Gerontologist 1987 ; 27 : 281-287.
 
2) Blazer D. Depression in the elderly : Myths and misconceptions. Psychiatr Clin North Am 1997 ; 20 : 111-119.
PubMed
3) Ilomaki J, et al. Psychotropic drug use and alcohol drinking in community-dwelling older Australian men : The CHAMP study. Drug Alcohol Rev 2013 ; 32 : 218-222.
PubMed
4) Haigh EAP, et al. Depression among older adults : A 20-year update on five common myths and misconceptions. Am J Geriatr Psychiatry 2018 ; 26 : 107-122.
PubMed
5) Beekman AT, et al. The natural history of late-life depression : A 6-year prospective study in the community. Arch Gen Psychiatry 2002 ; 59 : 605-611.
PubMed
6) Hopkinson G. A genetic study of affective illness in patients over 50. Br J Psychiatry 1964 ; 110 : 244-254.
PubMed
7) Sheline YI, et al. Greater loss of 5-HT2A receptors in midlife than in late life. Am J Psychiatry 2002 ; 159 : 430-435.
PubMed
8) Gottfries CG. Neurochemical aspects on aging and diseases with cognitive impairment. J Neurosci Res 1990 ; 27 : 541-547.
PubMed
9) Alexopoulos GS, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry 1997 ; 54 : 915-922.
PubMed
10) Krishnan KR, et al. MRI-defined vascular depression. Am J Psychiatry 1997 ; 154 : 497-501.
PubMed
11) Krishnan K, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry 2004 ; 55 : 390-397.
PubMed
12) Taylor WD, et al. The vascular depression hypothesis : Mechanisms linking vascular disease with depression. Mol Psychiatry 2013 ; 18 : 963-974.
PubMed
13) Kraaij V, et al. Negative life events and depression in elderly persons : a meta-analysis. J Gerontol B Psychol Sci Soc Sci 2002 ; 57 : 87-94.
 
14) Morse JQ, Lynch TR. A preliminary investigation of self-reported personality disorders in late life : Prevalence, predictors of depressive severity, and clinical correlates. Aging Ment Health 2004 ; 8 : 307-315.
PubMed
15) Sullivan MD, et al. Functional status in coronary artery disease : A one-year prospective study of the role of anxiety and depression. Am J Med 1997 ; 103 : 348-356.
PubMed
16) Blazer DG, et al. Depression in diabetes and obesity : Racial/ethnic/gender issues in older adults. J Psychosom Res 2002 ; 53 : 913-916.
PubMed
17) Magaziner J et al. Predictors of functional recovery one year following hospital discharge for hip fracture : A prospective study. J Gerontol 1990 ; 45 : M101-M107.
PubMed
18) Robinson RG, Price TR. Post-stroke depressive disorders : A follow-up study of 103 patients. Stroke 1982 ; 13 : 635-641.
PubMed
19) Bruce ML. Depression and disability in late life : directions for future research. The Am J Geriatr Psychiatry 2001 ; 9 : 102-112.
 
20) Holvast F, et al. Late-life depression and the association with multimorbidity and polypharmacy : A cross-sectional study. Fam Pract 2017 ; 34 : 539-545.
PubMed
21) Byers AL, et al. High occurrence of mood and anxiety disorders among older adults : The National Comorbidity Survey Replication. Arch Gen Psychiatry 2010 ; 67 : 489-496.
PubMed
22) King-Kallimanis B, et al. Comorbidity of depressive and anxiety disorders for older Americans in the national comorbidity survey-replication. Am J Geriatr Psychiatry 2009 ; 17 : 782-792.
PubMed
23) Almeida OP, et al. Anxiety, depression, and comorbid anxiety and depression : Risk factors and outcome over two years. Int Psychogeriatr 2012 ; 24 : 1622-1632.
PubMed
24) Wilson KC, et al. Psychotherapeutic treatments for older depressed people. Cochrane Database Syst Rev 2008 ; 23 ; (1) : CD004853.
 
25) Gould RL, et al. Cognitive behavioral therapy for depression in older people : A meta-analysis and metaregression of randomized controlled trials. J Am Geriatr Soc 2012 ; 60 : 1817-1830.
 
26) Cuijpers P, et al. Managing depression in older age : Psychological interventions. Maturitas 2014 ; 79 : 160-169.
PubMed
27) Kok RM, et al. Management of depression in older adults : A review. JAMA 2017 ; 317 : 2114-2122.
PubMed
28) 稲村圭亮, 繁田雅弘. 高齢者の精神科薬物療法における処方適正化とその考え方-うつ病治療を中心に. Depression Strategy 2017 ; 7 : 1-3.
Medical*Online
29) Pollock BG. The pharmacokinetic imperative in late-life depression. J Clin Psychopharmacol 2005 ; 25 : S19-S23.
PubMed
30) Task Force on Electroconvulsive Therapy. The practice of electroconvulsive therapy : Recommendations for treatment, training, and privileging, 2nd edition. American Psychiatric Association ; 2001.
 
31) 松田勇紀, 鬼頭伸輔. 老年期うつ病に対する反復経頭蓋磁気刺激 (rTMS) 療法. 老年精神医学雑誌 2018 ; 29 : 1266-1272.
Medical*Online
32) Morimoto SS, et al. Diagnosis and treatment of depression and cognitive impairment in late life. Ann N Y Acad Sci 2015 ; 1345 : 36-46.
PubMed
33) 植草朋子, 品川俊一郎. うつ病とアルツハイマー型認知症. 老年精神医学雑誌 2018 ; 29 : 249-257.
Medical*Online
34) Kral VA, Emery OB. Long-term follow-up of depressive pseudodementia of the aged. Can J Psychiatry 1989 ; 34 : 445-446.
PubMed
35) Devanand DP, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996 ; 53 : 175-182.
PubMed
36) Ownby RL, et al. Depression and risk for Alzheimer disease : Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006 ; 63 : 530-538.
PubMed
37) Starkstein SE, et al. The construct of minor and major depression in Alzheimer's disease. Am J Psychiatry 2005 ; 162 : 2086-2093.
PubMed
38) Lyketsos CG, Lee HB. Diagnosis and treatment of depression in Alzheimer's disease. A practical update for the clinician. Dement Geriatr Cogn Disord 2004 ; 17 : 55-64.
PubMed
39) Chemerinski E, et al. The specificity of depressive symptoms in patients with Alzheimer's disease. Am J Psychiatry 2001 ; 158 : 68-72.
PubMed
40) Olin JT, et al. Provisional diagnostic criteria for depression of Alzheimer disease : Rationale and background. Am J Geriatr Psychiatry 2002 ; 10 : 129-141.
PubMed
41) Orgeta V, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment : Systematic review and meta-analysis. Br J Psychiatry 2015 ; 207 : 293-298.
PubMed
42) 繁田雅弘, 稲村圭亮. 認知症疾患における精神療法. 精神科治療学 2018 ; 33 : 1185-1190.
 
43) Orgeta V, et al. Efficacy of antidepressants for depression in Alzheimer's disease : Systematic review and meta-analysis. J Alzheimers Dis 2017 ; 58 : 725-733.
 
44) Weissman MM, et al. Affective disorders. In : Robins LN, Regier DA (eds). Psychiatric Disorders in America : The Epidemiologic Catchment Area Study. Free Press ; 1991, pp53-80.
 
45) Depp CA, Jeste DV. Bipolar disorder in older adults : A critical review. Bipolar Disord 2004 ; 6 : 343-367.
PubMed
46) Spar JE, et al. Bipolar affective disorder in aged patients. J Clin Psychiatry 1979 ; 40 : 504-507.
PubMed
Alexopoulos GS. Depression in the elderly. Lancet 2005 ; 365 : 1961-1970.
PubMed
Kok RM, et al. Management of depression in older adults : A review. JAMA 2017 ; 317 : 2114-2122.
PubMed
Ownby RL, et al. Depression and risk for Alzheimer disease : Systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006 ; 63 : 530-538.
PubMed
Haigh EAP, et al. Depression among older adults : A 20-year update on five common myths and misconceptions. Am J Geriatr Psychiatry 2018 ; 26 : 107-122.
PubMed
植草朋子, 品川俊一郎. うつ病とアルツハイマー型認知症. 老年精神医学雑誌 2018 ; 29 : 249-257.
Medical*Online
P.134 掲載の参考文献
1) 川上憲人ほか. 「地域住民における心の健康問題と対策基盤の実態に関する研究-3地区の総合解析結果」平成14年度厚生労働科学研究費補助金 (厚生労働科学特別研究事業) 心の健康問題と対策基盤の実態に関する研究, 分担研究報告書.
 
2) 厚生労働省. 患者調査. http://www.mhlw.go.jp/toukei/list/10-20.html
 
3) 加茂登志子. 女性のライフサイクルとうつ. 公衆衛生 2008 ; 72 (5) : 368-373.
 
4) 加茂登志子. 女性のメンタルヘルス, 臨牀と研究 2016 ; 93 (5) : 657-662.
Medical*Online
5) 加茂登志子. 現代社会とうつ病 (32) 女性とうつ病. 最新医学 2013 ; 68 (12) : 2688-2691.
 
6) 世界経済フォーラム. https://www.weforum.org/reports
 
7) 総務省統計局. 労働力調査. http://www.stat.go.jp/data/roudou/
 
8) 厚生労働省. 相対的貧困率等に関する調査分析結果について. http://www.mhlw.go.jp/seisakunitsuite/soshiki/toukei/tp151218-01.html
 
9) 加茂登志子. 現代女性と家族内人間関係. 臨床精神医学 1996 ; 25 : 933-939.
Medical*Online
10) 加茂登志子. 女性の若い成人期における「私であること」と「女性であること」の葛藤と統合について. 産業精神保健 1995 ; 3 (3) : 171-175.
 
11) 加茂登志子. ライフサイクルにおける「女性であること」. 精神神経学雑誌 2004 ; 106 (2) : 208-212.
 
12) 内閣府男女共同参画局. 「女性に対する暴力」に関する調査研究. http://www.gender.go.jp/policy/no_violence/e-vaw/chousa/index.html
 
13) 加茂登志子. DV被害者の医療現場における対応と治療. 治療 2005 ; 87 (12) : 3239-3244.
Medical*Online
14) 加茂登志子. 医学的見地からのDV被害者の状況等について. ケース研究 2019 ; 2019 (1) : 4-37.
 
15) マージョリー・H・シェイヴィッツ. 谷川素子ほか (訳). スーパーウーマン・シンドローム-仕事を持つ女性にとってほんとうの幸せとは. 光文社 ; 1987.
 
16) Beghini V, et al. A quantum leap for gender equality : For a better future of work for all. https://www.ilo.org/global/publications/books/WCMS_674831/lang--en/index.htm
 
17) 帝国データバンクによる「女性登用に対する企業の意識調査」 (2019年) https://www.tdb.co.jp/report/watching/press/pdf/p190803.pdf
 
18) 加茂登志子. 産業における性差とメンタルヘルス-就労女性のメンタルヘルスの観点から. 産業人メンタルヘルス白書 2009年版・論文 ([日本] 生産性本部) -「ストレス時代」の健康対策を考察 職場環境の悪化で不調者が増える). 労経ファイル 2009 ; (508) : 10-17.
 
19) 大坪天平. 月経前不快気分障害と更年期のうつ病とその対応. 日本女性医学学会雑誌 2019 ; 26 (2) : 175-179.
 
20) 日本産婦人科学会ほか. 産婦人科診療ガイドライン-婦人科外来編 2017. http://www.jsog.or.jp/activity/pdf/gl_fujinka_2017.pdf
 
21) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎ほか (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
22) Steiner M, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities : The role of SSRIs. J Womens Health (Larchmt) 2006 ; 15 (1) : 57-69.
PubMed
23) Altshuler LL, et al. The Expert Consensus Guideline Series : Treatment of Depression in Women 2001. A postgraduate medicine special report. McGraw-Hill Companies ; 2001/大野裕 (訳). エキスパートコンセンサスガイドラインシリーズ-女性のうつ病治療 2001. アルタ出版 ; 2002.
 
24) Stahl SM. Stahl's Essential Psychopharmacology, 4th edition. Cambridge University Press ; 2013/ストール精神薬理学エセンシャルズ 第4版-神経科学的基礎と応用. 仙波純一ほか (監訳). メディカル・サイエンス・インターナショナル ; 2015.
 
25) 加茂登志子. 妊娠・出産とうつ病. 最新医学 2016 ; 71 (7) : 1582-1589.
 
26) Victoroff VM. Dynamics and management of para partum neuropathic reactions. Diseases of the nervous system. Dis Nerv Syst 1952 ; 13 : 291-298.
PubMed
27) 岡野禎治. 産褥精神病における非定型病像と診断. 臨床精神医学 2003 ; 32 : 805-812.
Medical*Online
28) McGorry P, Connell S. The nosology and prognosis of puerperal psychosis : A review. Compr Psychiatry 1990 ; 31 (6) : 519-534.
PubMed
29) Pitt B. "Atypical" depression following childbirth. Br J Psychiatry 1968 ; 114 (516) : 1325-1335.
PubMed
30) 岡野禎治ほか. 日本版エジンバラ産後うつ病自己評価票 (EPDS) の信頼性と妥当性. 精神科診断学 1996 ; 7 (4) : 525-533.
 
31) Shakespeare J, et al. A qualitative study of the acceptability of routine screening of postnatal women using the Edinburgh Postnatal Depression Scale. Br J Gen Pract 2003 ; 53 (493) : 614-619.
PubMed
32) Lewis G. Why Mothers Die 2000-2002. RCOG Press ; 2004.
 
33) Centre for Maternal and Child Enquiries (CMACE). Saving Mothers' Lives : Reviewing maternal deaths to make motherhood safer : 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011 ; 118 : 1-203.
 
34) 岡野禎治. 周産期メンタルヘルス・ケア体制の国内外比較. 精神神経学雑誌 2014 ; 116 (12) : 990-995.
 
35) Munk-Olsen T, et al. Risks and predictors of readmission for a mental disorder during the postpartum period. Arch Gen Psychiatry 2009 ; 66 (2) : 189-195.
PubMed
36) Munk-Olsen T, et al. New parents and mental disorders : A population-based register study. JAMA 2006 ; 296 (21) : 2582-2589.
PubMed
37) O'Connor TG, et al. Prenatal anxiety predicts individual differences in cortisol in pre-adolescent children. Biol Psychiatry 2005 ; 58 (3) : 211-217.
 
38) O'Connor TG, et al. Maternal antenatal anxiety and behavioural/emotional problems in children : A test of a programming hypothesis. J Child Psychol Psychiatry 2003 ; 44 (7) : 1025-1036.
 
39) 吉田敬子. 胎児期からの親子の愛着形成. 母子保健情報 2006 ; 54 : 39-46.
 
40) Kitamura T, et al. Psychological and social correlates of the onset of affective disorders among pregnant women. Psychol Med 1993 ; 23 (4) : 967-975.
PubMed
41) 岡野禎治. 周産期とメンタルヘルス. 周産期医学 2014 ; 44 (7) : 873-876.
Medical*Online
42) Meltzer-Brody, S. New insights into perinatal depression : Pathogenesis and treatment during pregnancy and postpartum. Dialogues Clin Neurosci 2011 ; 13 (1) : 89-100.
PubMed
43) 濱田洋実. 添付文書情報の捉え方. 伊藤真也ほか (編). 向精神薬と妊娠・授乳. 南山堂 ; 2013.
 
44) 加茂登志子. 女性の更年期とうつ病. 分子精神医学 2010 ; 10 (3) : 233-236.
Medical*Online
45) 寺内公一. 更年期女性のメンタルヘルスとそのケア. Hormone Frontier in Gynecology 2018 ; 25 (3) : 219-226.
Medical*Online
46) Parry B. Perimenopausal depression. Am J Psychiatry 2008 ; 165 (1) : 23-27.
PubMed
47) Kornstein S, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000 ; 157 : 1445-1452.
PubMed
48) 加茂登志子. ライフサイクルに応じた向精神薬の使い方 更年期. 日本医師会雑誌 2014 ; 143 (7) : 1482-1486.
 
P.143 掲載の参考文献
1) 古茶大樹, 古野毅彦. 退行期メランコリーについて. 精神神経誌 2009 ; 111 : 373-387.
 
2) Kraepelin E. Psychiatrie. Ein Lehrbuch fur Studierende und Aerzte. 5 Auflage. Johann Ambrosius Barth ; 1896.
 
3) Dreyfus GL. Die Melancholie. Ein Zustandsbild des manisch-depressiven Irreseins. Gustav Fischer ; 1907.
 
4) 古茶大樹. メランコリー-躁うつ病の一状態像 (G. L.ドレイフス). 濱田秀伯, 古茶大樹 (編). メランコリー-人生後半期の妄想性障害. 弘文堂 ; 2008, pp45-106.
 
5) Akiskal HS. Classification, Diagnosis and Boundaries of Bipolar Disorders : A Review. "Bipolar Disorder" In : Maj M, et al (eds). WPA Series Evidence and Experience in Psychiatry. John Wiley & Sons ; 2002, pp1-52.
 
6) Kraepelin E. Psychiatrie. Ein Lehrbuch fur Studierende und Aerzte. 8 Auflage. Johann Ambrosius Barth ; 1910.
 
7) Kranz H. Depressiver Autismus. In : Hippius H, et al (eds). Das depressive Syndrom. Urban & Schwarzenberg ; 1969, pp409-414.
 
8) Peters UH. Dissimulation. In : Peters UH. Lexikon Psychiatrie Psychotherapie Medizinische Psychologie. 6 Auflage. Urban & Fisher ; 2007, p135.
 
9) 古茶大樹. 臨床精神病理学-精神医学における疾患と診断. 日本評論社 ; 2019.
 
10) 古茶大樹, 針間博彦. 病の「種」と「類型」, 「階層原則」-精神障害の分類の原則について. 臨床精神病理 2010 ; 31 : 7-17.
 
11) 古茶大樹. 精神医学における理念型の役割. こころと文化 2016 ; 15 : 144-150.
 
P.153 掲載の参考文献
1) Prince M, et al. No health without mental health. Lancet 2007 ; 370 : 859-877.
PubMed
2) Krebber AM, et al. Prevalence of depression in cancer patients : A meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 2014 ; 23 : 121-130.
PubMed
3) Mitchell AJ, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings : A meta-analysis of 94 interview-based studies. Lancet Oncol 2011 ; 12 : 160-174.
PubMed
4) Khaledi M, et al. The prevalence of comorbid depression in patients with type 2 diabetes : An updated systematic review and meta-analysis on huge number of observational studies. Acta Diabetol 2019 ; 56 : 631-650.
PubMed
5) Wang F, et al. Prevalence of comorbid major depressive disorder in Type 2 diabetes : A meta-analysis of comparative and epidemiological studies. Diabet Med 2019 ; 36 : 961-969.
PubMed
6) Feng L, et al. Prevalence of depression in myocardial infarction : A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2019 ; 98 : e14596.
PubMed
7) Lichtman JH, et al ; American Psychiatric Association. Depression and coronary heart disease : Recommendations for screening, referral, and treatment : A science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research : endorsed by the American Psychiatric Association. Circulation 2008 ; 118 : 1768-1775.
PubMed
8) Matte DL, et al. Prevalence of depression in COPD : A systematic review and meta-analysis of controlled studies. Respir Med 2016 ; 117 : 154-161.
PubMed
9) Matcham F, et al. The prevalence of depression in rheumatoid arthritis : A systematic review and meta-analysis. Rheumatology (Oxford) 2013 ; 52 : 2136-2148.
PubMed
10) Zhang L, et al. Prevalence of depression and anxiety in systemic lupus erythematosus : A systematic review and meta-analysis. BMC Psychiatry 2017 ; 17 : 70.
PubMed
11) Hackett ML, et al. Neuropsychiatric outcomes of stroke. Lancet Neurol 2014 ; 13 : 525-534.
PubMed
12) Reijnders JS, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008 ; 23 : 183-189 ; quiz 313.
 
13) van Duijn E, et al ; European Huntington's Disease Network Behavioural Phenotype Working Group. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry 2014 ; 85 : 1411-1418.
 
14) Kim M, et al. Major depressive disorder in epilepsy clinics : A meta-analysis. Epilepsy Behav 2018 ; 84 : 56-69.
PubMed
15) Fiest KM, et al. Depression in epilepsy : A systematic review and meta-analysis. Neurology 2013 ; 80 : 590-599.
PubMed
16) Satin JR, e al. Depression as a predictor of disease progression and mortality in cancer patients : A meta-analysis. Cancer 2009 ; 115 : 5349-5361.
 
17) Suzuki T, et al. Depression and Outcomes in Japanese Outpatients With Cardiovascular Disease-A Prospective Observational Study. Circ J 2016 ; 80 : 2482-2488.
PubMed
18) Mitchell AJ, et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls : A systematic review and meta-analysis. Lancet Oncol 2013 ; 14 : 721-732.
PubMed
19) Unutzer J, et al. Healthcare costs associated with depression in medically Ill fee-for-service medicare participants. J Am Geriatr Soc 2009 ; 57 : 506-510.
PubMed
20) Hare DL, et al. Depression and cardiovascular disease : A clinical review. Eur Heart J 2014 ; 35 : 1365-1372.
PubMed
21) Luger TM, et al. How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. Addict Behav 2014 ; 39 : 1418-1429.
PubMed
22) Strine TW, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. Gen Hosp Psychiatry 2008 ; 30 : 127-137.
PubMed
23) DiMatteo MR, et al. Depression is a risk factor for noncompliance with medical treatment : Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000 ; 160 : 2101-2107.
PubMed
24) Pan A, et al. Bidirectional association between depression and metabolic syndrome : A systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012 ; 35 : 1171-1180.
PubMed
25) Mezuk B, et al. Depression and type 2 diabetes over the lifespan : A meta-analysis. Diabetes Care 2008 ; 31 : 2383-2390.
PubMed
26) Petrak F, et al. Depression and diabetes : Treatment and health-care delivery. Lancet Diabetes Endocrinol 2015 ; 3 : 472-485.
PubMed
27) Hasnain M, et al. Depression screening in patients with coronary heart disease : A critical evaluation of the AHA guidelines. J Psychosom Res 2011 ; 71 : 6-12.
PubMed
28) Thombs BD, et al. Depression screening and patient outcomes in cardiovascular care : A systematic review. JAMA 2008 ; 300 : 2161-2171.
 
29) Koenig HG, et al. Depression in medically ill hospitalized older adults : Prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 1997 ; 154 : 1376-1383.
PubMed
30) Rayner L, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010 : CD007503.
PubMed
31) Baumeister H, et al. Psychological and pharmacological interventions for depression in patients with diabetes mellitus : An abridged Cochrane review. Diabet Med 2014 ; 31 : 773-786.
PubMed
32) Ostuzzi G, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev 2018 ; 4 : CD011006.
PubMed
33) Baumeister H, et al. Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 2011 : CD008012.
PubMed
34) Glassman AH, et al ; Sertraline Antidepressant Heart Attack Randomized Trial Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002 ; 288 : 701-709.
PubMed
35) O'Connor CM, et al ; SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure : Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010 ; 56 : 692-699.
 
36) Kronish IM, et al. The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes : Findings from the COPES trial. Am Heart J 2012 ; 164 : 524-529.
PubMed
37) Dickens C, et al. Characteristics of psychological interventions that improve depression in people with coronary heart disease : A systematic review and meta-regression. Psychosom Med 2013 ; 75 : 211-221.
PubMed
38) Okuyama T, et al. Psychotherapy for depression among advanced, incurable cancer patients : A systematic review and meta-analysis. Cancer Treat Rev 2017 ; 56 : 16-27.
PubMed
39) Jassim GA, et al. Psychological interventions for women with non-metastatic breast cancer. Cochrane Database Syst Rev 2015 : CD008729.
PubMed
40) Uchendu C, Blake H. Effectiveness of cognitive-behavioural therapy on glycaemic control and psychological outcomes in adults with diabetes mellitus : A systematic review and meta-analysis of randomized controlled trials. Diabet Med 2017 ; 34 : 328-339.
PubMed
41) Freedland KE, et al. Cognitive Behavior Therapy for Depression and Self-Care in Heart Failure Patients : A Randomized Clinical Trial. JAMA Intern Med 2015 ; 175 : 1773-1782.
PubMed
42) Cape J, et al. What is the role of consultation-liaison psychiatry in the management of depression in primary care? A systematic review and meta-analysis. Gen Hosp Psychiatry 2010 ; 32 : 246-254.
PubMed
43) Katon WJ, Seelig M. Population-based care of depression : Team care approaches to improving outcomes. J Occup Environ Med 2008 ; 50 : 459-467.
PubMed
44) Unutzer J, et al ; IMPACT Investigators. Collaborative care management of late-life depression in the primary care setting : A randomized controlled trial. JAMA 2002 ; 288 : 2836-2845.
PubMed
45) National Institute for Health and Clinical Excellence. Depression in adults with a chronic physical health problem : Recognition and management. Clinical guideline 91. https://www.nice.org.uk/guidance/cg91, 2009.
 
46) Huang Y, et al. Collaborative care for patients with depression and diabetes mellitus : A systematic review and meta-analysis. BMC Psychiatry 2013 ; 13 : 260.
PubMed
47) Tully PJ, Baumeister H. Collaborative care for comorbid depression and coronary heart disease : A systematic review and meta-analysis of randomised controlled trials. BMJ Open 2015 ; 5 : e009128.
PubMed
48) Li M, et al. Systematic review and meta-analysis of collaborative care interventions for depression in patients with cancer. Psychooncology 2017 ; 26 : 573-587.
PubMed
49) Siegmann EM, et al. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis : A Systematic Review and Meta-analysis. JAMA Psychiatry 2018 ; 75 : 577-584.
PubMed
50) Feldman AZ, et al. Neuropsychiatric manifestations of thyroid disease. Endocrinol Metab Clin North Am 2013 ; 42 : 453-476.
PubMed
51) Hanly JG, et al ; Systemic Lupus International Collaborating Clinics. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010 ; 69 : 529-535.
 
52) Nishimura K. Psychiatric Symptoms. In : Hirohata S (ed). Neuropsychiatric Systemic Lupus Erythematosus : Pathogenesis, Clinical Aspects and Treatment. Springer ; 2018, pp129-140.
 
53) Lieberman A. Depression in Parkinson's disease -- A review. Acta Neurol Scand 2006 ; 113 : 1-8.
PubMed
54) Epping EA, et al ; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease : A Decade of Data. Am J Psychiatry 2016 ; 173 : 184-192.
 
55) Di Maio L, et al. Suicide risk in Huntington's disease. J Med Genet 1993 ; 30 : 293-295.
PubMed
56) Kanner AM, et al. Depression and epilepsy : Epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 2012 ; 24 : 156-168.
PubMed
57) Arora M, Daughton J. Mania in the medically ill. Curr Psychiatry Rep 2007 ; 9 : 232-235.
PubMed
58) Satzer D, Bond DJ. Mania secondary to focal brain lesions : Implications for understanding the functional neuroanatomy of bipolar disorder. Bipolar Disord 2016 ; 18 : 205-220.
PubMed
59) Celano CM, et al. Depressogenic effects of medications : A review. Dialogues Clin Neurosci 2011 ; 13 : 109-125.
PubMed
60) Peet M, Peters S. Drug-induced mania. Drug Saf 1995 ; 12 : 146-153.
PubMed
61) Fardet L, et al. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012 ; 169 : 491-497.
PubMed
62) 神庭瑠美子, 西村勝治. ステロイド誘発性精神障害. リウマチ科 2017 ; 57 : 496-500.
 
P.163 掲載の参考文献
1) 三木治. うつ病診療におけるかかりつけ医の役割と精神科医との連携. Current Therapy 2014 ; 36 : 529-534.
 
2) 石川華子, 川上憲人. 世界と日本のうつ病の疫学. 精神科治療学 2019 ; 34 : 5-9.
 
3) Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med 2000 ; 343 : 1942-1950.
PubMed
4) 染矢俊幸. 一般臨床医・精神科医のためのうつ病診療エッセンシャルズ. メディカルレビュー社 ; 2017.
 
5) 渡辺洋一郎. うつ病の薬物療法-一般科医が処方するときの注意と精神科に紹介するタイミング. 大阪府内科医会会誌 2015 ; 24 : 31-36.
Medical*Online
6) WHOによる自殺予防の手引き. 平成14年度厚生労働科学研究費補助金「こころの健康科学研究事業-自殺と防止対策の実態に関する研究」. 研究協力報告書. 2002.
 
7) 渡辺洋一郎. 一般科医・精神科医連携を考える-大阪におけるG-Pネット構築の経験より. 最新医学 2014 ; 69 : 880-883.
Medical*Online
8) 辻本哲士, 山田尚登. かかりつけ医におけるうつ病治療の現状に関する調査. 精神医学 2014 ; 56 : 221-228.
 
9) 白川治. 一般診療におけるうつ病治療のコツ. 臨牀と研究 2014 ; 91 : 605-608.
Medical*Online
10) 窪田幸久ほか. うつ自殺予防対策「富士モデル事業」5年間の報告. 精神科治療学 2014 ; 29 : 685-691.
 
染矢俊幸. 一般臨床医・精神科医のためのうつ病診療エッセンシャルズ. メディカルレビュー社 ; 2017.
 
日本うつ病学会. うつ病治療ガイドライン, 第2版. 医学書院 ; 2017.
 
日本医師会. 自殺予防マニュアル 第3版-地域医療を担う医師へのうつ状態・うつ病の早期発見と早期治療のために. 明石書店 ; 2014.
 
野村総一郎. 内科医のためのうつ病診療, 第2版. 医学書院 ; 2008.
 
白川治. 一般外来において必要な精神医学. 三好功峰 (編), <臨床精神医学講座> S7巻. 総合診療における精神医学. 中山書店 ; 2000, pp11-30.
 
P.167 掲載の参考文献
1) Bertolote M, Fleischmann A. Suicide and psychiatric diagnosis : A worldwide perspective. World Psychiatry 2002 ; 1 (3) : 181-185.
 
2) 厚生労働省. 平成28年版自殺対策白書, 2016. https://www.mhlw.go.jp/wp/hakusyo/jisatsu/16/dl/2-02.pdf
 
3) 三木治. プライマリ・ケアにおけるうつ病の実態と治療. 心身医学 2002 ; 42 (9) : 585-591.
Medical*Online
4) 厚生労働省. 自殺総合対策大綱, 2017. https://www.mhlw.go.jp/file/06-Seisakujouhou-12200000-Shakaiengokyokushougaihokenfukushibu/0000172329.pdf
 
5) Mattisson C, et al. The long-term course of depressive disorders in the Lundby Study. Psychol Med 2007 ; 37 : 883-891.
 
6) Angst F, et al. Mortality of patients with mood disorders : Follow-up over 34-38 years. J Affect Disord 2002 ; 68 : 167-181.
PubMed
7) Hawton K, et al. Risk factors for suicide in individuals with depression : A systematic review. J Affect Disord 2013 ; 147 : 17-28.
PubMed
8) Sullivan LE, et al. The prevalence and impact of alcohol problems in major depression : A systematic review. Am J Med 2005 ; 118 (4) : 330-341.
PubMed
9) Joiner Jr TE, et al. The Interpersonal Theory of Suicide : Guidance for Working With Suicidal Clients. American Psychological Association ; 2009/北村俊則 (監訳). 自殺の対人関係理論-予防・治療の実践マニュアル. 日本評論社 ; 2011.
 
10) Lu CY, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage : Quasi-experimental study. BMJ 2014 ; 348 : g3596.
PubMed
11) Bridge JA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment : A meta-analysis of randomized controlled trials. JAMA 2007 ; 297 (15) : 1683-1696.
PubMed
12) Kawanishi C, et al. Assertive case management versus enhanced usual care for people with mental health problems who had attempted suicide and were admitted to hospital emergency departments in Japan (ACTION-J) : A multicentre, randomised controlled trial. Lancet Psychiatry 2014 ; 1 : 193-201.
 
13) Kawakami N, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan : Preliminary finding from the World Mental Health Japan Survey 2002-2003. Psychiatry Clin Neurosci 2005 ; 59 (4) : 441-452.
PubMed
14) Nordentoft M, et al. Absolute risk of suicide after first hospital contact in mental disorder. Arch Gen Psychiatry 2011 ; 68 (10) : 1058-1064.
PubMed
15) Isometsa ET, et al. Suicide in bipolar disorder in Finland. Am J Psychiatry 1994 ; 151 (7) : 1020-1024.
PubMed
16) Hawton K, et al. Suicide and attempted suicide in bipolar disorder : A systematic review of risk factors. J Clin Psychiatry 2005 ; 66 (6) : 693-704.
PubMed
17) Grant BF, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders : Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004 ; 61 (8) : 807-816.
PubMed
18) Cardoso BM, et al. The impact of co-morbid alcohol use disorder in bipolar patients. Alcohol 2008 ; 42 (6) : 451-457.
PubMed
19) Schaffer A, et al. International Society for Bipolar Disorders Task Force on Suicide : Meta-analyses and meta-regression of correlates of suicide attempts and suicide deaths in bipolar disorder. Bipolar Disord 2015 ; 17 (1) : 1-16.
PubMed
20) Cipriani A, et al. Lithium in the prevention of suicide in mood disorders updated systematic review and meta-analysis. BMJ 2013 ; 346 : f3646.
PubMed
21) O'Connell RA, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991 ; 159 : 123-129.
 
22) Erlangsen A, et al. Hospital-diagnosed dementia and suicide : A longitudinal study using prospective, nationwide register data. Am J Geriatr Psychiatry 2008 ; 16 (3) : 220-228.
PubMed
23) Cipriani G, et al. Dementia and suicidal behavior. Aggress Violent Behav 2013 ; 18 (6) : 656-659.
 
24) Kawashima Y, et al. Prevalence of suicide attempters in emergency departments in Japan : A systematic review and meta-analysis. J Affect Disord 2014 ; 163 : 33-39.
PubMed
World Health Organizaion. Preventing Suicide : A global imperative. 2014/独立行政法人 国立精神・神経医療研究センター 精神保健研究所 自殺予防総合対策センター (訳). 自殺を予防する. 2014. https://apps.who.int/iris/bitstream/handle/10665/131056/9789241564779_jpn.pdf
 
日本自殺予防学会 (監修). 国立研究開発法人日本医療研究開発機構障害者対策総合研究開発事業 (精神障害分野) 「精神疾患に起因した自殺の予防法に関する研究」研究班 (編). 救急医療から地域へとつなげる自殺未遂者支援のエッセンス HOPEガイドブック. へるす出版 ; 2018.
 
松本俊彦. アルコールとうつ・自殺-「死のトライアングル」を防ぐために. 岩波ブックレット ; 2014.
 
P.176 掲載の参考文献
1) Stevens A, Price J. Evolutionary Psychiatry : A New Beginning. Routledge ; 1996/小山毅, 高畑圭輔 (訳). 進化精神医学-ダーウィンとユングが解き明かす心の病. 世論時報社 ; 2011.
 
2) Nesse, RM. "Is Depression an Adaptation?". Arch Gen Psychiat 2000 ; 57 : 14-20.
PubMed
3) Gilbert P. Evolution and depression : Issues and implications. Psychol Med 2006 ; 36 : 287-297.
PubMed
4) 神庭重信. 悲哀, うつ, うつ病. 内海健, 神庭重信 (編). 「うつ」の舞台. 弘文堂 ; 2018, pp180-189.
 
5) 豊嶋良一, 小山毅. 進化心理学からのインパクト-精神保健・自己実現・幸福感の条件. 精神医学 2009 ; 51 (3) : 265-274.
 
6) 豊嶋良一. 幸福はどこから来るのか? -幸福感の普遍性とその進化的起源. 最新精神医学 2012 ; 17 (4) : 301-308.
 
7) 豊嶋良一. 「新しい精神の科学」からみた生命現象としての「宗教と精神療法」. 最新精神医学 2016 ; 21 (1) : 13-20.
 
8) 豊嶋良一. 「新しい精神の科学」で語る「うつの起源と未来社会の物語」. 内海健, 神庭重信 (編). 「うつ」の舞台. 弘文堂 ; 2018, pp154-179.
 
9) 長谷川寿一, 長谷川眞理子. 進化と人間行動. 東京大学出版会 ; 2000.
 
10) 井原裕. うつ病のモデルとしての病時行動. 最新精神医学 2018 ; 23 (5) : 399-405.
Medical*Online
11) 豊嶋良一. 「了解可能/不能感」と「生物学的正常/異常」の対応関係についての試論. 精神経誌 2017 ; 119 (11) : 827-836.
 
12) 富高辰一郎. うつ病の常識はほんとうか. 日本評論社 ; 2011.
 
13) 池田一夫ほか. 自殺の発生病理と人口構造. 東京健安研セ年報 2008 ; 59 : 349-355.
 
14) 長谷川寿一, 長谷川眞理子. 進化からみた自殺. 最新精神医学 2019 ; 24 (1) : 3-11.
Medical*Online
15) 伊東俊太郎. 変容の時代. 麗澤大学出版会 ; 2013.
 
16) 広井良典. ポスト資本主義-科学・人間・社会の未来. 岩波書店 ; 2015.
 
17) 見田宗介. 現代社会はどこに向かうか-高原の見晴らしを切り開くこと. 岩波書店 ; 2018.
 
P.182 掲載の参考文献
1) 飯田真, 中井久夫. 天才の精神病理-科学的創造の秘密. 中央公論社 ; 1972, pp237-238.
 
2) Goodwin FK, Jamison KR. Manic-Depressive Illness : Bipolar Disorders and Recurrent Depression. Oxford University Press ; 2007, pp379-407.
 
3) 内海健. 双極II型障害という病-改訂版うつ病新時代. 勉誠出版 ; 2011, pp25-52.
 
4) 津田均. 気分障害は, いま-うつと躁を精神病理学から問い直す. 誠信書房 ; 2014, pp170-199.
 
5) 齋藤慎之介. 吉行淳之介の憂鬱-うつ病による創造と喪失について. 日本病跡学雑誌 2016 ; 91 : 7-19.
Medical*Online
6) Freud S. Trauer und Melancholie. In : Gesammelte Werke X. Fischer ; 1991/伊藤正博 (訳). 喪とメランコリー. フロイト全集 14. 岩波書店 ; 2010, pp273-293.
 
7) 内海健. 存在の耐えがたき空虚-ポスト・メランコリー型の精神病理. 広瀬徹也, 内海健 (編). うつ病論の現在-精緻な臨床をめざして. 星和書店 ; 2005, pp115-145.
 
8) 芝伸太郎. 内因性気分障害と神経症性抑うつの両価性の本質的差異について. 臨床精神病理 2019 ; 40 : 29-38.
 
9) 柏瀬宏隆. 病いと創造性 (第1報) -評論家・江藤淳の場合. 日本病跡学雑誌 2006 ; 72 : 80-84.
Medical*Online
10) 芝伸太郎. 双極II型障害の精神病理と精神療法-「メランコリー親和型への誘導」という戦略. 臨床精神病理 2010 ; 31 : 79-101.
 
中島らも. 心が雨漏りする日には. 青春出版社 ; 2002.
 
Jamison KR. An Unquiet Mind : A Memoir of Moods and Madness. Knopf ; 1995/田中啓子 (訳). 躁うつ病を生きる-私は残酷で魅惑的な病気を愛せるか? 新曜社 ; 1998.
 
福島章. 天才の精神分析. 新曜社 ; 1978.
 
Ghaemi N. A First-Rate Madness : Uncovering the Links Between Leadership and Mental Illness. Penguin Press ; 2011/山岸洋, 村井俊哉 (訳). 一流の狂気-心の病がリーダーを強くする. 日本評論社 ; 2016.
 
Lacan J. Texte etabli par Miller J-A. Le Seminaire, livre XI : Les quatres concepts fondamentaux de la psychanalyse. Seuil ; 1973/小出浩之ほか (訳). 精神分析の四基本概念. 岩波書店 ; 2000.
 
加藤敏. 構造論的精神病理学-ハイデガーからラカンへ. 弘文堂 ; 1995.
 
P.191 掲載の参考文献
1) 村松太郎. うつ病の医学と法学. 中外医学社 ; 2017.
 
2) 村松太郎. 妄想の医学と法学. 中外医学社 ; 2016.
 
3) 大審院判決 傷害被告事件竝附帯私訴[昭和六年 (れ) 第一三〇五号 同年十二月三日第一刑事部判決 棄却]大審院刑事判例集 法曹界
 
4) 東京地方裁判所昭和62年 (合わ) 第235号 平成元年5月19日刑事第20部判決
 
5) 村松太郎ほか. 心理のフローチャート-刑事責任能力判断に直結する鑑定書を目指して. 司法精神医学 2017 ; 12 : 28-32.
 
6) Jaspers, K. Allgemeine Psychopathologie. Julius Springer, 1913/西丸四方 (訳). 精神病理学原論. みすず書房 ; 1971.
 
7) 平成18～20年度厚生労働科学研究費補助金 (こころの健康科学研究事業) 他害行為を行った者の責任能力鑑定に関する研究班 (代表 : 岡田幸之). 刑事責任能力に関する精神鑑定書作成の手引き 平成18～20年度総括版 (ver.4.0). https://www.ncnp.go.jp/nimh/shihou/tebiki40_100108.pdf
 
8) American Academy of Psychiatry and the Law. Ethics Guidelines for the Practice of Forensic Psychiatry, 2005. Available at : http://www.aapl.org/ethics.html
 

3章 病態

P.197 掲載の参考文献
1) Hyde CL. et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nat Genet 2016 ; 48 : 1031-1036.
PubMed
2) Major Depressive Disorder Working Group of the Psychiatric GWAS Consortium, et al. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry 2013 ; 18 : 497-511.
 
3) Wray NR, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet 2018 ; 50 : 668-681.
PubMed
4) Howard DM, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci 2019 ; 22 : 343-352.
PubMed
5) Musliner KL, et al. Association of Polygenic Liabilities for Major Depression, Bipolar Disorder, and Schizophrenia With Risk for Depression in the Danish Population. JAMA Psychiatry 2019 ; 76 : 516-525.
PubMed
6) Cross-Disorder Group of the Psychiatric Genomics Consortium, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013 ; 45 : 984-994.
 
7) Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014 ; 511 : 421-427.
 
8) Gandal MJ, et al. The road to precision psychiatry : Translating genetics into disease mechanisms. Nat Neurosci 2016 ; 19 : 1397-1407.
 
9) Power RA, et al. Genome-wide Association for Major Depression Through Age at Onset Stratification : Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Biol Psychiatry 2017 ; 81 : 325-335.
 
10) Levey DF, et al. Genetic associations with suicide attempt severity and genetic overlap with major depression. Transl Psychiatry 2019 ; 9 : 22.
PubMed
11) Coon H, et al. Genome-wide significant regions in 43 Utah high-risk families implicate multiple genes involved in risk for completed suicide. Mol Psychiatry 2018. doi : 10.1038/s41380-018-0282-3.
 
12) Ikeda M, et al. Genome-wide environment interaction between depressive state and stressful life events. J Clin Psychiatry 2016 ; 77 : e29-30.
PubMed
13) Garriock HA, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010 ; 67 : 133-138.
PubMed
14) Uher R, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010 ; 167 : 555-564.
PubMed
15) Bousman CA, et al. Antidepressant prescribing in the precision medicine era : A prescriber's primer on pharmacogenetic tools. BMC Psychiatry 2017 ; 17 : 60.
 
Davies K. The $1,000 Genome : The Revolution in DNA Sequencing and the New Era of Personalized Medicine. Free Press ; 2010/篠田謙一 (監修), 武井摩利 (訳). 1000ドルゲノム-10万円でわかる自分の設計図. 創元社 ; 2014.
 
今川弘ほか. 遺伝. 井上猛 (編), うつ病と双極性障害 (最新醫學別冊 診断と治療のABC 141). 最新医学社 ; 2018.
 
西澤由貴ほか. うつ病って遺伝するのですか? 原因となる遺伝子はわかっているのですか? 樋口輝彦 (監修), 朝田隆ほか (編). DEPRESSION FRONTIER 2 うつ病臨床のこんな疑問に答える-脳科学からのアプローチ. 医薬ジャーナル社 ; 2016.
 
池田匡志ほか. 精神科領域の用語解説 Precision Medicine. 分子精神医学 2017 ; 17 (4) : 281-283.
 
P.203 掲載の参考文献
1) Campbell S, et al. Lower hippocampal volume in patients suffering from depression : A meta-analysis. Am J Psychiatry 2004 ; 161 : 598-607.
PubMed
2) Koolschijn PC, et al. Brain volume abnormalities in major depressive disorder : A meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp 2009 ; 30 : 3719-3735.
PubMed
3) Videbech P, Ravnkilde B. Hippocampal volume and depression : A meta-analysis of MRI studies. Am J Psychiatry 2004 ; 161 : 1957-1966.
PubMed
4) Goodkind M, et al. Identification of a common neurobiological substrate for mental illness. JAMA Psychiatry 2015 ; 72 : 305-315.
PubMed
5) Schmaal L, et al. Subcortical brain alterations in major depressive disorder : Findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry 2016 ; 21 : 806-812.
 
6) Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000 ; 57 : 925-935.
PubMed
7) Dohm K, et al. Trajectories of major depression disorders : A systematic review of longitudinal neuroimaging findings. Aust N Z J Psychiatry 2017 ; 51 : 441-454.
PubMed
8) Arnone D, et al. State-dependent changes in hippocampal grey matter in depression. Mol Psychiatry 2013 ; 18 : 1265-1272.
PubMed
9) Drevets WC, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997 ; 386 : 824-827.
PubMed
10) Hajek T, et al. Reduced subgenual cingulate volumes in mood disorders : A meta-analysis. J Psychiatry Neurosci 2008 ; 33 : 91-99.
PubMed
11) Lai CH. Gray matter volume in major depressive disorder : A meta-analysis of voxel-based morphometry studies. Psychiatry Res 2013 ; 211 : 37-46.
PubMed
12) Bora E, et al. Gray matter abnormalities in Major Depressive Disorder : A meta-analysis of voxel based morphometry studies. J Affect Disord 2012 ; 138 : 9-18.
PubMed
13) Machino A, et al. Possible involvement of rumination in gray matter abnormalities in persistent symptoms of major depression : An exploratory magnetic resonance imaging voxel-based morphometry study. J Affect Disord 2014 ; 168 : 229-235.
PubMed
14) Ota M, et al. Discrimination between schizophrenia and major depressive disorder by magnetic resonance imaging of the female brain. J Psychiatr Res 2013 ; 47 : 1383-1388.
 
15) Matsuo K, et al. Distinctive Neuroanatomical Substrates for Depression in Bipolar Disorder versus Major Depressive Disorder. Cereb Cortex 2019 ; 29 : 202-214.
PubMed
16) Diener C, et al. A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. Neuroimage 2012 ; 61 : 677-685.
PubMed
17) Okada G, et al. Attenuated left prefrontal activation during a verbal fluency task in patients with depression. Neuropsychobiology 2003 ; 47 : 21-26.
PubMed
18) Okada G, et al. Attenuated prefrontal activation during a verbal fluency task in remitted major depression. Psychiatry Clin Neurosci 2009 ; 63 : 423-425.
PubMed
19) Takamura M, et al. Disrupted Brain Activation and Deactivation Pattern during Semantic Verbal Fluency Task in Patients with Major Depression. Neuropsychobiology 2016 ; 74 : 69-77.
PubMed
20) Yoshimura S, et al. Rostral anterior cingulate cortex activity mediates the relationship between the depressive symptoms and the medial prefrontal cortex activity. J Affect Disord 2010 ; 122 : 76-85.
PubMed
21) Yoshimura S, et al. Cognitive behavioral therapy for depression changes medial prefrontal and ventral anterior cingulate cortex activity associated with self-referential processing. Soc Cogn Affect Neurosci 2014 ; 9 : 487-493.
PubMed
22) Yoshimura S, et al. Cognitive behavioral therapy changes functional connectivity between medial prefrontal and anterior cingulate cortices. J Affect Disord 2017 ; 208 : 610-614.
PubMed
23) Raichle ME, Snyder AZ. A default mode of brain function : A brief history of an evolving idea. Neuroimage 2007 ; 37 : 1083-1090 ; discussion 1097-1099.
 
24) Laird AR, et al. Behavioral interpretations of intrinsic connectivity networks. J Cogn Neurosci 2011 ; 23 : 4022-4037.
PubMed
25) Tavor I, et al. Task-free MRI predicts individual differences in brain activity during task performance. Science 2016 ; 352 : 216-220.
PubMed
26) Goulden N, et al. The salience network is responsible for switching between the default mode network and the central executive network : Replication from DCM. Neuroimage 2014 ; 99 : 180-190.
 
27) Mulders PC, et al. Resting-state functional connectivity in major depressive disorder : A review. Neurosci Biobehav Rev 2015 ; 56 : 330-344.
PubMed
28) Yamamura T, et al. Association of thalamic hyperactivity with treatment-resistant depression and poor response in early treatment for major depression : A resting-state fMRI study using fractional amplitude of low-frequency fluctuations. Transl Psychiatry 2016 ; 6 : e754.
PubMed
29) Kambeitz J, et al. Detecting Neuroimaging Biomarkers for Depression : A Meta-analysis of Multivariate Pattern Recognition Studies. Biol Psychiatry 2017 ; 82 : 330-338.
PubMed
30) Shimizu Y, et al. Toward Probabilistic Diagnosis and Understanding of Depression Based on Functional MRI Data Analysis with Logistic Group LASSO. PLoS One 2015 ; 10 : e0123524.
PubMed
31) Whelan R, Garavan H. When optimism hurts : Inflated predictions in psychiatric neuroimaging. Biol Psychiatry 2014 ; 75 : 746-748.
PubMed
32) Yahata N, et al. A small number of abnormal brain connections predicts adult autism spectrum disorder. Nat Commun 2016 ; 7 : 11254.
PubMed
33) Insel T, et al. Research domain criteria (RDoC) : Toward a new classification framework for research on mental disorders. Am J Psychiatry 2010 ; 167 : 748-751.
 
34) Kapur S, et al. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry 2012 ; 17 : 1174-1179.
 
35) Tokuda T, et al. Identification of depression subtypes and relevant brain regions using a data-driven approach. Sci Rep 2018 ; 8 : 14082.
PubMed
P.210 掲載の参考文献
1) World Health Organization. Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level. Provisional agenda item 6.2 : EXECUTIVE BOARD EB130/9, 2011.
 
2) Cain RA. Navigating the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study : Practical outcomes and implications for depression treatment in primary care. Prim Care 2007 ; 34 (3) : 505-519.
 
3) Thibault TR, et al. Neurofeedback with fMRI : A critical systematic review. NeuroImage 2018 ; 172 : 786-807.
 
4) Yucha and Gilbert's 2004 review of efficacy ratings for most of the disorders biofeedback is used to treat. (Yucha, C. & Gilbert, C. (2004) Evidence-Based Practice in Biofeedback and Neurofeedback. Association for Applied Psychophysiology and Biofeedback. Colorado Springs, CO.)
 
5) Rosenfeld JP, et al. Operant (biofeedback) control of left-right frontal alpha power differences : potential neurotherapy for affective disorders. Biofeedback Self Regul 1995 ; 20 : 241-258.
PubMed
6) Thilbault TR, et al. The self-regulating brain and neurofeedback : Experimental science and clinical promise. Cortex 2016 ; 74 : 247-261.
 
7) Linden DEG, Neurofeedback and networks of depression. Dialogues Clin Neurosci 2014 ; 16 : 103-112.
 
8) Young KD, et al. Randomized clinical trial of real-time fMRI amygdala neurofeedback for major depressive disorder : Effects on symptoms and autobiographical memory recall. Am J Psychiatry 2017 ; 174 : 748-755.
PubMed
9) Mehler DMA, et al. Targeting the affective brain-a randomized controlled trial of real-time fMRI neurofeedback in patients with depression. Neuropsychopharmacology 2018 ; 43 : 2578-2585.
 
10) Shibata K, et al. Perceptual learning incepted by decoded fMRI neurofeedback without stimulus presentation. Science 2011 ; 334 : 1413-1415.
PubMed
11) Cortese A, et al. Multivoxel neurofeedback selectively modulates confidence without changing perceptual performance. Nat Commun 2016 ; 7 : 13669.
PubMed
12) Taschereau-Dumouchel V, et al. Towards an unconscious neural reinforcement intervention for common fears. PNAS 2018 ; 115 (13) : 3470-3475.
PubMed
13) Yamada T, et al. Resting-State Functional Connectivity-Based Biomarkers and Functional MRI-Based Neurofeedback for Psychiatric Disorders : A Challenge for Developing Theranostic Biomarkers. Int J Neuroscychopharmacol 2017 ; 20 (10) : 769-781.
 
Shibata K, et al. Toward a comprehensive understanding of the neural mechanisms of decoded neurofeedback. NeuroImage 2019 ; 188 : 539-556.
 
Sitaram R, et al. Closed-loop brain training : the science of neurofeedback. Nat Rev Neurosci 2017 ; 18 (2) : 86-100.
PubMed
P.218 掲載の参考文献
1) Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder : A systematic review and network meta-analysis. Lancet 2018 ; 391 (10128) : 1357-1366.
PubMed
2) Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps : A STAR*D report. Am J Psychiat 2006 ; 163 (11) : 1905-1917.
PubMed
3) Friedman ES, et al. The implementation of cognitive therapy in STAR*D. Cognitive Ther Res 2004 ; 28 (6) : 819-833.
 
4) Howland RH. Sequenced treatment alternatives to relieve depression (STAR*D)-Part 2 : Study outcomes. J Psychosoc Nurs Men 2008 ; 46 (10) : 21-24.
 
5) Trivedi MH, et al. Medication augmentation after the failure of SSRIs for depression. New Engl J Med 2006 ; 354 (12) : 1243-1252.
PubMed
6) Trivedi MH, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D : Implications for clinical practice. Am J Psychiat 2006 ; 163 (1) : 28-40.
 
7) Rush AJ, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. New Engl J Med 2006 ; 354 (12) : 1231-1242.
 
8) Kato T, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder-the SUN D study : A pragmatic, multi-centre, assessor-blinded randomised controlled trial. Bmc Med 2018 ; 16 (1) : 103.
 
9) Cipriani A, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants : A multipletreatments meta-analysis. Lancet 2009 ; 373 (9665) : 746-758.
PubMed
10) Papakostas GI, et al. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychia 2010 ; 11 (2) : 300-307.
 
11) Furukawa TA, et al. Strategic use of new generation antidepressants for depression : SUN (boolean AND_boolean AND) D study protocol. Trials 2011 ; 12.
 
12) Geddes JR, et al. Relapse prevention with antidepressant drug treatment in depressive disorders : A systematic review. Lancet 2003 ; 361 (9358) : 653-661.
PubMed
13) Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 2000 ; 157 (4 Suppl) : 1-45.
 
14) Kennedy SH, et al. Clinical guidelines for the treatment of depressive disorders IV. Medications and other biological treatments. Can J Psychiat 2001 ; 46 : 38s-58s.
 
15) NICE. Depression : The treatment and management of depression in adults (partial update of NICE clinical guideline 23). National Institute for Clinical Excellence ; 2009.
 
16) Pinto-Meza A, et al. Assessing depression in primary care with the PHQ-9 : Can it be carried out over the telephone? J Gen Intern Med 2005 ; 20 (8) : 738-742.
PubMed
17) Furukawa TA, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression : A systematic review and dose-response meta-analysis. Lancet Psychiatry 2019 ; 6 (7) : 601-609.
PubMed
18) Saveanu R, et al. The International Study to Predict Optimized Treatment in Depression (iSPOT-D) : Outcomes from the acute phase of antidepressant treatment. J Psychiatr Res 2015 ; 61 : 1-12.
 
古川壽亮. エビデンス精神医療-EBPの基礎から臨床まで. 医学書院 ; 2000.
 
福原俊一. 臨床研究の道標 <上巻> <下巻>. 特定非営利活動法人 健康医療評価研究機構 ; 2017.
 
Guyatt G, et al (eds). Users' Guides to the Medical Literature : Essentials of Evidence-Based Clinical Practice. McGraw-Hill Education/古川壽亮ほか (監訳). 臨床のためのEBM入門-決定版JAMAユーザーズガイド. 医学書院 ; 2003.
 
Kenneth JR, et al. Modern Epidemiology, 3rd edition. Lippincott Williams & Wilkins ; 2012.
 
P.226 掲載の参考文献
1) Biomarkers Definitions Working Group. Biomarkers and surrogate endopoints : Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 ; 69 (3) : 89-95.
 
2) 竹林実. うつ病のバイオマーカー. 精神科治療学 2015 ; 30 (1) : 5-10.
 
3) Ising M, et al. Combined dexamethason/corticotrophin releasing hormone test predicts treatment response in major depression-a potential biomarker? Biol Psychiatry 2007 ; 62 (1) : 47-54.
 
4) Hori H, et al. Psychological coping in depressed outpatients : Association with cortisol response to the combined dexamethasone/CRH test. J Affect Disord 2014 ; 152-154 : 441-447.
 
5) 功刀浩, 堀弘明. うつ病のバイオマーカーと亜型-特に視床下部-下垂体-副腎系機能との関連について. 臨床精神医学 2013 ; 42 (8) : 991-998.
Medical*Online
6) Menke A, et al. Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav 2013 ; 12 (3) : 289-296.
PubMed
7) Hennings JM, et al. Polymorphisms in the BDNF and BDNFOS genes are associated with hypothalamuspituitary axis regulation in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2019 ; 95 : 109686.
 
8) Tyrka AR, et al. Methylation of the leukocyte glucocorticoid receptor gene promoter in adults : Associations with early adversity and depressive, anxiety and substance-use disorders. Transl Psychiatry 2016 ; 6 : e848.
PubMed
9) Kinoshita S, et al. Clinical application of DEX/CRH test and multi-channel NIRS in patients with depression. Behav Brain Funct 2016 ; 12 (1) : 25.
PubMed
10) Nestler EJ, et al. Neurobiology of depression. Neuron 2002 ; 34 (1) : 13-25.
PubMed
11) Kishi T, et al. Brain-derived neurotrophic factor and major depressive disorder : Evidence from meta-analysis. Front Psychiatry 2018 ; 8 : 308.
PubMed
12) Castren E, Kojima M. Brain-derived neurotrophic factor in mood disorders and antidepressant treatments. Neurobiol Dis 2017 ; 97 (Pt B) : 119-126.
PubMed
13) Haile CN, et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014 ; 17 (2) : 331-336.
PubMed
14) Chen D, et al. A review of DNA methylation in depression. J Clin Neurosci 2017 ; 43 : 39-46.
 
15) Kojima M, et al. BDNF pro-peptide : Physiological mechanisms and implications for depression. Cell Tissue Res 2019 ; 377 (1) : 73-79.
PubMed
16) Jiang H, et al. The serum protein levels of the tPA-BDNF pathway are implicated in depression and anti-depressant treatment. Transl Psychiatry 2017 ; 7 (4) : e1079.
 
17) Chen S, et al. Combined serum levels of multiple proteins in tPA-BDNF pathway may aid the diagnosis of five mental disorders. Sci Rep 2017 ; 7 (1) : 6871.
 
18) Takebayashi M, et al. Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 2006 ; 9 (5) : 607-612.
PubMed
19) Lin PY, Yseng PT. Decreased glial cell line-derived neurotrophic factor levels in patients with depression : A meta-analytic study. J Psychiatr Res 2015 ; 63 : 20-27.
 
20) Zhang Y, et al. The protein and mRNA expression levels of glial cell line-derived neurotrophic factor in post stroke depression and major depressive disorder. Sci Rep 2017 ; 7 (1) : 8674.
PubMed
21) Hisaoka-Nakashima K, et al. Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells. J Biol Chem 2015 ; 290 (22) : 13678-13691.
 
22) Zhang X, et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32 (3) : 886-890.
PubMed
23) Dowlati Y, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010 ; 67 (5) : 446-457.
PubMed
24) Lanquillon S, et al. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000 ; 22 (4) : 370-379.
PubMed
25) Enache D, et al. Markers of central inflammation in major depressive disorder ; A systematic review and meta-analysis of studies examining cerebrospinal fluid, positron emission tomography and post-mortem brain tissue. Brain Behav Immun 2019 ; 81 : 24-40.
PubMed
26) Bufalino C, et al. The role of immune genes in the association between depression and inflammation : A review of recent clinical studies. Brain Behav Immun 2013 ; 31 : 31-47.
PubMed
27) Bauer ME, Teixeira AL. Inflammation in psychiatric disorders : What comes first? Ann N Y Acad Sci 2019 ; 1437 (1) : 57-67.
PubMed
28) Najjar S, et al. Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder : A review of clinical and experimental evidence. J Neuroinflammation 2013 ; 10 : 142.
PubMed
29) Carlessi AS, et al. Gut microbiota-brain axis in depression : The role of neuroinflammation. Eur J Neurosci 2019 doi : 10.1111/ejn.14631.
 
30) Ogyu K, et al. Kynurenine pathway in depression : A systematic review and meta-analysis. Neurosci Biobehav Rev 2018 ; 90 : 16-25.
PubMed
31) Arteaga-Henriquez G, et al. Low-grade inflammation as a predictor of antidepressant and anti-inflammatory therapy response in MDD patients : A systematic review of the literature in combination with analysis of experimental data collected in the EU-MOODINFLAME consortium. Front Psychiatry 2019 ; 10 : 458.
PubMed
32) Pandya CD, et al. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2013 ; 46 : 214-223.
PubMed
33) Black CN, et al. Is depression associated with increased oxidative stress? A systematic review and meta-analysis. Psychoneuroendocrinology 2015 ; 51 : 164-175.
PubMed
34) Lin PY, et al. A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression. Biol Psychiatry 2010 ; 68 (2) : 140-147.
PubMed
35) Walther A, et al. Lipidomics in major depressive disorder. Front Psychiatry 2018 ; 9 : 459.
PubMed
36) Itagaki K, et al. Reduced serum and cerebrospinal fluid levels of autotaxin in major depressive disorder. Int J Neuropsychopharmacol 2019 ; 22 (4) : 261-269.
PubMed
37) Setoyama D, et al. Plasma metabolites predict severity of depression and suicidal ideation in psychiatric patients-a multicenter pilot analysis. PLoS One 2016 ; 11 (12) : e0165267.
PubMed
38) Ogawa S, et al. Plasma amino acid profile in major depressive disorder : Analyses in two independent case-control sample sets. J Psychiatr Res 2018 ; 96 : 23-32.
PubMed
39) Ogawa S, et al. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Sci Rep 2015 ; 5 : 7796.
PubMed
40) Kawamura N, et al. Plasma metabolome analysis of patients with major depressive disorder. Psychiatry Clin Neurosci 2018 ; 72 (5) : 349-361.
PubMed
41) Ogawa S, et al. Plasma L-tryptophan concentration in major depressive disorder : New data and meta-analysis. J Clin Psychiatry 2014 ; 75 (9) : e906-915.
PubMed
42) Ogawa S, et al. Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder : A meta-analysis of historic evidence. J Psychiatr Res 2018 ; 105 : 137-146.
PubMed
43) Schroeter ML, et al. Serum S100B represents a new biomarker for mood disorders. Curr Drug Targets 2013 ; 14 (11) : 1237-1248.
PubMed
44) Zhou X, et al. Astrocyte, a promising target for mood disorder interventions. Front Mol Neurosci 2019 ; 12 : 136.
PubMed
45) McGowan PO, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009 ; 12 (3) : 342-348.
PubMed
46) Higuchi F, et al. State-dependent changes in the expression of DNA methyltransferases in mood disorder patients. J Psychiatr Res 2011 ; 45 (10) : 1295-1300.
PubMed
47) Pena CJ, Nestler EJ. Progress in epigenetics of depression. Prog Mol Biol Transl Sci 2018 ; 157 : 41-66.
PubMed
48) van den Berg MMJ, et al. Circulating microRNAs as potential biomarkers for psychiatric and neurode-generative disorders. Prog Neurobiol 2020 ; 185 : 101732.
 
49) Huang X, et al. The link between long noncoding RNAs and depression. Prog Neuropsychopharmacol Biol Psychiatry 2017 ; 73 : 73-78.
PubMed
P.237 掲載の参考文献
1) Kempton MJ, et al. Meta-analysis, database, and meta-regression of 98 structural imaging studies in bipolar disorder. Arch Gen Psychiatry 2008 ; 65 (9) : 1017-1032.
PubMed
2) Drevets WC, et al. Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997 ; 386 (6627) : 824-827.
PubMed
3) Ellison-Wright I, Bullmore E. Anatomy of bipolar disorder and schizophrenia : A meta-analysis. Schizophr Res 2010 ; 117 (1) : 1-12.
PubMed
4) Bora E, et al. Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry 2010 ; 67 (11) : 1097-1105.
PubMed
5) Matsuo K, et al. Distinctive Neuroanatomical Substrates for Depression in Bipolar Disorder versus Major Depressive Disorder. Cereb Cortex 2019 ; 29 (1) : 202-214.
PubMed
6) Hibar DP, et al. Cortical abnormalities in bipolar disorder : An MRI analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. Mol Psychiatry 2018 ; 23 (4) : 932-942.
 
7) Nortje G, et al. Systematic review and voxel-based meta-analysis of diffusion tensor imaging studies in bipolar disorder. J Affect Disord 2013 ; 150 (2) : 192-200.
PubMed
8) Kato T, et al. Magnetic resonance spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci 1998 ; 10 (2) : 133-147.
PubMed
9) Stork C, Renshaw PF. Mitochondrial dysfunction in bipolar disorder : Evidence from magnetic resonance spectroscopy research. Mol Psychiatry 2005 ; 10 (10) : 900-919.
PubMed
10) Delvecchio G, et al. Evidence of diagnostic specificity in the neural correlates of facial affect processing in bipolar disorder and schizophrenia : A meta-analysis of functional imaging studies. Psychol Med 2013 ; 43 (3) : 553-569.
PubMed
11) Syan SK, et al. Resting-state functional connectivity in individuals with bipolar disorder during clinical remission : a systematic review. J Psychiatry Neurosci 2018 ; 43 (5) : 298-316.
PubMed
12) Mula M, et al. On the prevalence of bipolar disorder in epilepsy. Epilepsy Behav 2008 ; 13 (4) : 658-661.
PubMed
13) Onitsuka T, et al. Neurophysiological findings in patients with bipolar disorder. Suppl Clin Neurophysiol 2013 ; 62 : 197-206.
PubMed
14) Elashoff M, et al. Meta-analysis of 12 genomic studies in bipolar disorder. J Mol Neurosci 2007 ; 31 (3) : 221-243.
PubMed
15) Gandal MJ, et al. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 2018 ; 359 (6376) : 693-697.
 
16) Nishioka M, et al. Somatic mutations in the human brain : Implications for psychiatric research. Mol Psychiatry 2019 ; 24 (6) : 839-856.
PubMed
17) Munakata K, et al. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol Psychiatry 2005 ; 57 (5) : 525-532.
PubMed
18) Bundo M, et al. Increased l1 retrotransposition in the neuronal genome in schizophrenia. Neuron 2014 ; 81 (2) : 306-313.
PubMed
19) Kato T. Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium 2008 ; 44 (1) : 92-102.
PubMed
20) Mertens J, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature 2015 ; 527 (7576) : 95-99.
PubMed
21) Goodwin FK, Jamison KKR. Manic-Depressive Illness : Bipolar Disorders and Recurrent Depression. 2nd edition. Oxford University Press ; 2007.
 
22) Kato T, et al. Comprehensive gene expression analysis in bipolar disorder. Can J Psychiatry 2007 ; 52 (12) : 763-771.
PubMed
23) Andreazza AC, et al. Oxidative stress markers in bipolar disorder : A meta-analysis. J Affect Disord 2008 ; 111 (2-3) : 135-144.
 
24) Brown NC, et al. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 2014 ; 218 (1-2) : 61-68.
 
25) Sigitova E, et al. Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci 2017 ; 71 (2) : 77-103.
PubMed
26) Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipolar Disord 2010 ; 12 (5) : 459-472.
PubMed
27) Roybal K, et al. Mania-like behavior induced by disruption of CLOCK.. Proc Natl Acad Sci U S A 2007 ; 104 (15) : 6406-6411.
PubMed
28) 加藤忠史. 双極性障害-脳にとって, 気分とは何なのか? 甘利俊一 (監修), 加藤忠史 (編). 精神の脳科学 シリーズ脳科学 6. 東京大学出版会 ; 2008, pp157-188.
 
29) Aldinger F, Schulze TG. Environmental factors, life events, and trauma in the course of bipolar disorder. Psychiatry Clin Neurosci 2017 ; 71 (1) : 6-17.
PubMed
30) Palmier-Claus JE, et al. Relationship between childhood adversity and bipolar affective disorder : Systematic review and meta-analysis. Br J Psychiatry 2016 ; 209 (6) : 454-459.
PubMed
31) Horwitz AV, et al. The impact of childhood abuse and neglect on adult mental health : A prospective study. J Health Soc Behav 2001 ; 42 (2) : 184-201.
PubMed
32) Chudal R, et al. Perinatal factors and the risk of bipolar disorder in Finland. J Affect Disord 2014 ; 155 : 75-80.
PubMed
33) Parboosing R, et al. Gestational influenza and bipolar disorder in adult offspring. JAMA Psychiatry 2013 ; 70 (7) : 677-685.
PubMed
34) Talati A, et al. Maternal smoking during pregnancy and bipolar disorder in offspring. Am J Psychiatry 2013 ; 170 (10) : 1178-1185.
PubMed
35) Frans EM, et al. Advancing paternal age and bipolar disorder. Arch Gen Psychiatry 2008 ; 65 (9) : 1034-1040.
PubMed
36) Ikeda M, et al. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry 2018 ; 23 (3) : 639-647.
 
37) Stahl EA. Genomewide association study identifies 30 loci associated with bipolar disorder. BioRxiv 2018.
 
38) Leussis MP, et al. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol Psychiatry 2013 ; 73 (7) : 683-690.
PubMed
39) Lopez AY, et al. Ankyrin-G isoform imbalance and interneuronopathy link epilepsy and bipolar disorder. Mol Psychiatry 2017 ; 22 (10) : 1464-1472.
PubMed
40) Zhu S, et al. Genetic disruption of ankyrin-G in adult mouse forebrain causes cortical synapse alteration and behavior reminiscent of bipolar disorder. Proc Natl Acad Sci U S A 2017 ; 114 (39) : 10479-10484.
PubMed
41) Song JHT, et al. Characterization of a Human-Specific Tandem Repeat Associated with Bipolar Disorder and Schizophrenia. Am J Hum Genet 2018 ; 103 (3) : 421-430.
PubMed
42) Gordon-Smith K, et al. The Neuropsychiatric Phenotype in Darier Disease. Br J Dermatol 2010 ; 163 (3) : 515-522.
PubMed
43) Nakamura T, et al. Loss of function mutations in ATP2A2 and psychoses : A case report and literature survey. Psychiatry Clin Neurosci 2016 ; 70 (8) : 342-350.
PubMed
44) Kasahara T, et al. Depression-like episodes in mice harboring mtDNA deletions in paraventricular thalamus. Mol Psychiatry 2016 ; 21 (1) : 39-48.
PubMed
45) Kato TM, et al. Ant1 mutant mice bridge the mitochondrial and serotonergic dysfunctions in bipolar disorder. Mol Psychiatry 2018 ; 23 (10) : 2039-2049.
PubMed
P.244 掲載の参考文献
1) Ikeda M, et al. Genome-wide association studies of bipolar disorder : A systematic review of recent findings and their clinical implications. Psychiatry Clin Neurosci 2018 ; 72 (2) : 52-63.
PubMed
2) Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011 ; 43 (10) : 977-983.
 
3) Stahl EA, et al. Genomewide association study identifies 30 loci associated with bipolar disorder. Nat Genet 2019 ; 51 (5) : 793-803.
 
4) Howard DM, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci 2019 ; 22 (3) : 343-352.
PubMed
5) Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014 ; 511 (7510) : 421-427.
 
6) Ikeda M, et al. A genome-wide association study identifies two novel susceptibility loci and trans population polygenicity associated with bipolar disorder. Mol Psychiatry 2018 ; 23 (3) : 639-647.
 
7) International Schizophrenia Consortium, Purcell SM, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009 ; 460 (7256) : 748-752.
PubMed
8) Kato T. Whole genome/exome sequencing in mood and psychotic disorders. Psychiatry Clin Neurosci 2015 ; 69 (2) : 65-76.
PubMed
9) Kataoka M, et al. Exome sequencing for bipolar disorder points to roles of de novo loss-of-function and protein-altering mutations. Mol Psychiatry 2016 ; 21 (7) : 885-893.
PubMed
加藤忠史. 双極性障害のエクソーム解析. 分子精神医学 2016 ; 16 (3) : 174-179.
Medical*Online
高田篤. 統合失調症のエクソーム解析, その現在地. 分子精神医学 2016 ; 16 (3) : 167-173.
Medical*Online
Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet 2018 ; 50 : 1219-1224.
PubMed
Gandal MJ, et al. The road to precision psychiatry : Translating genetics into disease mechanisms. Nat Neurosci 2016 ; 19 : 1397-1407.
 
P.253 掲載の参考文献
1) Rose NS. The Politics of Life Itself : Biomedicine, Power, and Subjectivity in the Twenty-first Century. Princeton University Press ; 2006/檜垣立哉 (監訳), 小倉拓也 (訳). 生そのものの政治学-二十一世紀の生物医学, 権力, 主体性. 法政大学出版局 ; 2014.
 
2) 鈴木晃仁, 北中淳子 (編), 精神医学の歴史と人類学. 東京大学出版会 ; 2016.
 
3) Littlewood R, Dein S. Cultural Psychiatry & Medical Anthropology : An Introduction and Reader. Athlone Press ; 2000.
 
4) 阿部隆明. メランコリー概念とその周辺. 精神医学史研究 1998 ; 1 : 55.
Medical*Online
5) Jackson SW. Melancholia and depression : From hippocratic times to modern times. Yale University Press ; 1986.
 
6) Radden J (ed). The Nature of Melancholy : From Aristotle to Kristeva. Oxford University Press ; 2002.
 
7) White GM. The Role of Cultural Explanations in 'Somatization' and 'Psychologization'. Soc Sci Med 1982 ; 16 : 1519-1530.
PubMed
8) Light D. Becoming Psychiatrists : the Professional Transformation of Self. Norton ; 1980.
 
9) 加藤敏. 統合失調症の語りと傾聴-EBMからNBMへ. 金剛出版 ; 2005.
 
10) 木村敏. 比較文化論的精神病理学. 高橋良ほか (編), 躁うつ病 II 現代精神医学大系 9巻B. 中山書店 ; 1979, pp145-146.
 
11) Obeyesekere G. Depression, Buddhism, and the Work of Culture in Sri Lanka. In : Kleinman A, Good B (eds). Culture and Depression : Studies in the Anthropology and Cross-Cultural Psychiatry of Affect and Disorder. University of California Press ; 1985.
 
12) Brown G, Harris T. Social Origins of Depression. Tavistock ; 1978.
 
13) Kleinman A. Social origins of distress and disease : Depression, neurasthenia, and pain in modern china. Yale University Press ; 1986.
 
14) Kleinman A. Rethinking Psychiatry : From Cultural Category to Personal Experience Free Press ; 1988/江口重幸ほか (訳). 精神医学を再考する-疾患カテゴリーから個人的経験へ. みすず書房 ; 2012.
 
15) Habermas J. The Theory of Communicative Action. Vol. 2 : Lifeworld and System : a Critique of Fundamental Reason. Beacon Press ; 1987.
 
16) Horwitz AV, Wakefield JC. The Loss of Sadness : How Psychiatry Transformed Normal Sorrow Into Depressive Disorder. Oxford University Press ; 2007.
 
17) Kleinman A. Culture, bereavement, and psychiatry. Lancet 2012 ; 379 (9816) : 608-609.
PubMed
18) 北中淳子. うつの医療人類学. 日本評論社 ; 2014. : Kitanaka J. Depression in Japan : Psychiatric Cures for a Society in Distress. Princeton University Press ; 2011.
 
19) Young A. The Harmony of Illusions : Inventing Post-traumatic Stress Disorder. Princeton University Press ; 1995/中井久夫ほか (訳). PTSDの医療人類学. みすず書房 ; 2001.
 
20) 中井久夫. 再建の倫理としての勤勉と工夫. 笠原嘉 (編), 躁うつ病の精神病理 1. 弘文堂 ; 1976, p118.
 
21) 飯田真 (編集・解説). 躁うつ病 現代のエスプリ No.88. 至文堂 ; 1974, pp5-6.
 
22) 平澤一. 軽症うつ病の臨床と予後. 医学書院 ; 1966.
 
23) 笠原嘉. うつ病 (病相期) の小精神療法. 季刊精神療法 1978 ; 4 (2) : 118-124.
 
24) 笠原嘉 (編). 躁うつ病の精神病理 1. 弘文堂 ; 1976, pvi.
 
25) Lock MM. Encounters with Aging : Mythologies of Menopause in Japan and North America. University of California Press ; 1993/江口重幸ほか (訳). 更年期-日本女性が語るローカル・バイオロジー. みすず書房 ; 2005.
 
26) 神田橋條治. うつ病診療のための物語私案. 神庭重信ほか (編著), 現代うつ病の臨床. 創元社 ; 2009.
 
27) Hacking I, The Social Construction of What?. Harvard University Press ; 1999/出口康夫, 久米暁 (訳). 何が社会的に構成されるのか. 岩波書店 ; 2006.
 
28) Frances A. Saving Normal : An Insider's Revolt against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life. William Morro ; 2013/大野裕 (監修), 青木創 (訳). <正常> を救え-精神医学を混乱させるDSM-5への警告. 講談社 ; 2013.
 
29) Ehrenberg A. The Weariness of the self : Diagnosing the history of depression in the contemporary age. McGill-Queen's University Press ; 2009, p233.
 
P.261 掲載の参考文献
1) Sadock BJ, et al. Kaplan and Sadock's Synopsis of Psychiatry : Behavioral Science/Clinical Psychiatry, 11th edition. Lippincott Williams & Wilkins ; 2014/井上令一 (監修), 四宮滋子ほか (監訳). カプラン臨床精神医学テキスト 第3版-DSM-5 診断基準の臨床への展開. メディカル・サイエンス・インターナショナル ; 2016.
 
2) Broadhead WE, et al. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990 ; 264 (19) : 2524-2528.
 
3) Whooley MA, et al ; CARDIA Study. Depressive symptoms, unemployment, and loss of income : The CARDIA Study. Arch Intern Med 2002 ; 162 (22) : 2614-2620.
PubMed
4) Lepine JP, Briely M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011 : 7 (Suppl 1) : 3-7.
 
5) Evans-Lacko S, Knapp M. Global patterns of workplace productivity for people with depression : Absenteeism and presenteeism costs across eight diverse countries. Soc Psychiatry Psychiatr Epidemiol 2016 ; 51 (11) : 1525-1537.
PubMed
6) Okumura Y, Higuchi T. Cost of depression among adults in Japan. Prim Care Companion CNS Disord 2011 : 13 (3).
PubMed
7) Weissman MM, Olfson M. Translating intergenerational research on depression into clinical practice. JAMA 2009 ; 302 (24) : 2695-2696.
PubMed
8) Rugulies R, et al. Effort-reward imbalance at work and risk of depressive disorders. A systematic review and meta-analysis of prospective cohort studies. Scand J Work Environ Health 2017 ; 43 (4) : 294-306.
PubMed
9) Giorgi G, et al. Work-Related Stress in the Banking Sector : A Review of Incidence, Correlated Factors, and Major Consequences. Front Psychol 2017 ; 8 : 2166.
PubMed
10) Madsen IEH, et al ; IPD-Work Consortium. Job strain as a risk factor for clinical depression : Systematic review and meta-analysis with additional individual participant data. Psychol Med 2017 ; 47 (8) : 1342-1356.
PubMed
11) 藤野善久ほか. 労働時間と精神的負担との関連についての体系的文献レビュー. 産業衛生学雑誌 2006 : 48 : 87-97.
Medical*Online
12) Watanabe K, et al. Working hours and the onset of depressive disorder : A systematic review and meta-analysis. Occup Environ Med 2016 ; 73 (12) : 877-884.
PubMed
13) Virtanen M, et al. Overtime work as a predictor of major depressive episode : A 5-year follow-up of the Whitehall II study. PLoS One 2012 ; 7 (1) : e30719.
PubMed
14) Kato R, et al. Heavy overtime work and depressive disorder among male workers. Occup Med (Lond) 2014 ; 64 (8) : 622-628.
PubMed
15) Lee Y, et al. Efficacy of antidepressants on measures of workplace functioning in major depressive disorder : A systematic review. J Affect Disord 2018 ; 227 : 406-415.
PubMed
16) Rosenblat JD, et al. The Cognitive Effects of Antidepressants in Major Depressive Disorder : A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Int J Neuropsychopharmacol 2015 ; 19 (2).
 
17) Baune BT, et al. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2018 ; 21 (2) : 97-107.
PubMed
18) Nieuwenhuijsen K, et al. Interventions to improve return to work in depressed people. Cochrane Database Syst Rev 2014 ; (12) : CD006237.
PubMed
19) Joyce S, et al. Workplace interventions for common mental disorders : A systematic meta-review. Psychol Med 2016 ; 46 (4) : 683-697.
PubMed
20) Hellstrom L, et al. Effect on return to work or education of Individual Placement and Support modified for people with mood and anxiety disorders : Results of a randomised clinical trial. Occup Environ Med 2017 ; 74 (10) : 717-725.
 
21) Morres ID, et al. Aerobic exercise for adult patients with major depressive disorder in mental health services : A systematic review and meta-analysis. Depress Anxiety 2019 ; 36 (1) : 39-53.
PubMed
22) Dinoff A, et al. The effect of exercise on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF) in major depressive disorder : A meta-analysis. J Psychiatr Res 2018 ; 105 : 123-131.
PubMed
23) 吉村玲児. 「うつ病患者の復職成功の鍵は何か」に関する研究. 平成26年度-平成28年度 労災疾病臨床研究事業費補助金収支報告書.
 
P.267 掲載の参考文献
1) Beyond Blue. https://www.beyondblue.org.au
 
2) 厚生労働省. 患者調査. https://www.mhlw.go.jp/toukei/list/10-20.html
 
3) Ishikawa H, et al. Prevalence, treatment, and the correlates of common mental disorders in the mid 2010's in Japan : The results of the world mental health Japan 2nd survey. J Affect Disord 2018 ; 241 : 554-562.
 
4) Angst J, et al. Suicide risk in patients with major depressive disorder. J Clin Psychiatry 1999 ; 60 (Suppl 2) : 57-62.
 
5) Bostwick JM, Pankratz VS. Affective disorders and suicide risk : A reexamination. Am J Psychiatry 2000 ; 157 (12) : 1925-1932.
 
6) 松本俊彦ほか. 心理学的剖検における精神医学的診断の妥当性と数量的分析に関する研究 (3) 精神科治療の有無からみた検討. 平成21年度厚生労働科学研究 (こころの健康科学研究事業). 2010, pp95-109.
 
7) 野村総一郎, 樋口輝彦 (監修), 尾崎紀夫ほか (編). 標準精神医学 第6版. 医学書院 ; 2015, pp322-323.
 
8) Furukawa TA, et al. Time to recovery of an inception cohort with hitherto untreated unipolar major depressive episodes. Br J Psychiatry 2000 ; 177 : 331-335.
PubMed
9) Kanai T, et al. Time to recurrence after recovery from major depressive episodes and its predictors. Psychol Med 2003 ; 33 (5) : 839-845.
PubMed
10) Furukawa TA, et al. How many well vs. unwell days can you expect over 10 years, once you become depressed? Acta Psychiatr Scand 2009 ; 119 (4) : 290-297.
PubMed
11) 厚生労働省. 平成29年労働安全衛生調査 (実態調査). https://www.mhlw.go.jp/toukei/list/h29-46-50.html
 
12) 平成22年度厚生労働省障害者福祉総合推進事業補助金「精神疾患の社会的コストの推計」事業実績報告書. https://www.mhlw.go.jp/bunya/shougaihoken/cyousajigyou/dl/seikabutsu30-2.pdf
 

4章 治療

P.276 掲載の参考文献
1) 神庭重信. うつ病の論理と臨床. 弘文堂 ; 2014.
 
2) 神庭重信. 気分障害-その治療と診断の概説 1. 治療-その知と技の世界. 神庭重信 (編), <新世紀の精神科治療 新装版> 2. 気分障害の診療学-初診から治療終了まで. 中山書店 ; 2008, pp3-14.
 
3) 神庭重信ほか. 気分障害の臨床を語る-変わること, 変わらないこと. 創元社 ; 2018.
 
4) 神庭重信. 思量と願い-精神医学の風景. 第一部 精神医学との対話 うつの心理療法-いくつかの覚え書き. 九州大学出版会 ; 2019. pp45-49.
 
5) 笠原嘉. 予診・初診・初期治療. 診療新社 ; 1980.
 
6) Kleinman A. The Illness Narratives : Suffering, Healing and the Human Condition. Basic Books ; 1988/江口重幸ほか (訳). 病いの語り-慢性の病いをめぐる臨床人類学. 誠信書房 ; 1996.
 
7) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン II.うつ病 (DSM-5)/大うつ病性障害 2016. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724.pdf
 
8) 神田橋條治. 九大精神科での面接実技指導にて.
 
9) 森山成. 精神療法を底支えするもの. 臨床精神医学 2010 ; 39 (12) : 1485-1489.
Medical*Online
神庭重信, 内海健 (編). 「うつ」の構造. 弘文堂 ; 2011.
 
神庭重信 (編). うつ病の臨床-現代の病理と最新の治療. 最新医学社 ; 2016.
 
内海健, 神庭重信 (編). 「うつ」の舞台. 弘文堂 ; 2018.
 
笠原嘉. うつ病臨床のエッセンス. みすず書房 ; 2009.
 
P.281 掲載の参考文献
1) American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 ; 159 (Suppl) : 1-50.
PubMed
2) Judd LL, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 ; 59 : 530-537.
 
3) Judd LL, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 ; 60 : 261-269.
 
4) MacQueen GM, et al. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand 2000 ; 101 : 374-381.
PubMed
5) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン I. 双極性障害 2017. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/180125.pdf
 
6) 山田和男. 双極性障害治療のスタンダード. 医薬ジャーナル 2012 ; 48 : 1107-1110.
 
7) Miklowitz DJ, et al. Effects of family-focused therapy vs enhanced usual care for symptomatic youths at high risk for bipolar disorder : A randomized clinical trial. JAMA Psychiatry 2020 (in press).
 
Colom F, Vieta E. Psychoeducation Manual for Bipolar Disorder/秋山剛, 尾崎紀夫 (監訳). 双極性障害の心理教育マニュアル-患者に何を, どう伝えるか. 医学書院 ; 2012.
 
Miklowitz DJ. Bipolar Disorder : A famiy-focused treatment approach/大野裕, 三村將 (監訳), 中川敦夫 (訳). 双極性障害の家族焦点化療法. 金剛出版 ; 2017.
 
P.289 掲載の参考文献
1) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5)/大うつ病性障害 2016. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724.pdf
 
2) 渡邊衡一郎. 抗うつ薬の安全性. 樋口輝彦 (編). 別冊・医学のあゆみ 最新うつ病のすべて. 医歯薬出版 ; 2010, pp70-77.
 
3) 渡邊衡一郎. 第41章 抗精神病薬,抗うつ薬, その他. 浦部晶夫ほか (編). 今日の治療薬 2020 解説と便覧. 南江堂 ; 2020, pp843-884.
 
4) Taylor D, et al. The Maudsley Prescribing Guidelines in Psychiatry, 12th edition. Wiley-Blackwell ; 2015/内田裕之ほか (監訳). Chapter 4 うつと不安. モーズレイ処方ガイドライン 第12版. ワイリー・パブリッシング・ジャパン ; 2016, pp209-313.
 
5) Anderson IM, et al. Evidence-based guidelines for treating depressive disorders with antidepressants : A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 ; 22 (4) : 343-396.
PubMed
6) American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. American Psychiatric Association ; 2010.
 
7) Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 3. Pharmacological Treatments. Can J Psychiatry 2016 ; 61 (9) : 540-560.
PubMed
8) Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder, a systematic review and network meta-analysis. Lancet 2018 ; 391 (10128) : 1357-1366.
PubMed
9) Furukawa TA, et al. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2001 ; (2) : CD001026.
PubMed
10) Sakurai H, et al. Trajectories of individual symptoms in remitters versus non-remitters with depression. J Affect Disord 2013 ; 151 (2) : 506-513.
PubMed
11) Kocsis JH. Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo. Arch Gen Psychiatry 2002 ; 59 (8) : 723-728.
PubMed
12) Keller MB, et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study : Outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007 ; 68 (8) : 1246-1256.
PubMed
13) Parker GB. Identifying "paradigm failures" contributing to treatment-resistant depression. J Affect Disord 2005 ; 87 (2-3) : 185-191.
 
14) Rush AJ, et al. Combining medications to enhance depression outcomes (CO-MED) : Acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011 ; 168 (7) : 689-701.
PubMed
15) Nelson J, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder : A meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009 ; 166 (9) : 980-991.
PubMed
16) 渡邊衡一郎. 国内外のうつ病治療ガイドラインにみる薬物治療の立ち位置, そしてその適切な使用方法とは. カレントテラピー 2014 ; 32 (6) : 29-35.
 
17) Kato M. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT. J Psychiatr Res 2017 ; 89 : 97-104.
PubMed
18) 渡邊衡一郎, 菊地俊暁.抗うつ薬服用者を対象としたウェブ調査2008の結果に見る患者の気持ち. 臨床精神薬理 2008 ; 12 : 2295-2304.
 
19) Sinclair LI. Antidepressant-induced jitteriness/anxiety syndrome : Systematic review. Br J Psychiatry 2009 ; 194 (6) : 483-490.
PubMed
20) Wittstein IS. Depression, anxiety, and platelet reactivity in patients with coronary heart disease. Eur Heart J 2010 ; 31 (13) : 1548-1550.
PubMed
21) Dalton SO, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding : A population-based cohort study. Arch Intern Med 2003 ; 163 (1) : 59-64.
PubMed
22) Wang YP, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry 2014 ; 171 (1) : 54-61.
PubMed
23) Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage : A meta-analysis. Neurology 2012 ; 79 (18) : 1862-1865.
PubMed
24) Auerbach AD, et al. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. JAMA Intern Med 2013 ; 173 (12) : 1075-1081.
PubMed
25) Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants : A meta-analysis. J Clin Psychopharmacol 2009 ; 29 (3) : 259-266.
PubMed
26) Montejo AL, et al. Sexual side-effects of antidepressant and antipsychotic drugs. Curr Opin Psychiatry 2015 ; 28 (6) : 418-423.
PubMed
27) Gafoor R, et al. Antidepressant utilisation and incidence of weight gain during 10 years' follow-up : Population based cohort study. BMJ 2018 ; 361 : k1951.
PubMed
28) Voican CS, et al. Antidepressant-induced liver injury : A review for clinicians. Am J Psychiatry 2014 ; 171 (4) : 404-415.
PubMed
29) Castro VM, et al. QT interval and antidepressant use : A cross sectional study of electronic health records. BMJ 2013 ; 346 : f288.
PubMed
30) Hawton K, et al. Toxicity of antidepressants : Rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010 ; 196 (5) : 354-358.
PubMed
31) Telang S, et al. Meta-analysis, Second generation antidepressants and headache. J Affect Disord 2018 ; 236 : 60-68.
PubMed
32) Kelly CM, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen : A population based cohort study. BMJ 2010 ; 340 : c693.
PubMed
Taylor DM, et al (eds). Maudsley Prescribing Guidelines in Psychiatry, 13th edition. Wiley-Blackwell : 2018/内田裕之ほか (訳). モーズレイ処方ガイドライン 第13版 日本語版. ワイリー・パブリッシング・ジャパン ; 2019.
 
Kennedy SH, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 3. Pharmacological Treatments. Can J Psychiatry 2016 ; 61 (9) : 540-560.
PubMed
P.294 掲載の参考文献
1) Hill LL, et al. Depression, antidepressants and driving safety. Inj Epidemiol 2017 ; 4 : 10.
PubMed
2) Vaa T. Impairments, diseases, age and their relative risks of accident involvement : Results from meta-analysis. TOI report 2003 ; 1-48.
 
3) 宮田明美ほか. 気分障害と自動車運転-疾患と治療薬が運転技能に及ぼす影響. 臨床精神薬理 2015 ; 18 : 527-535.
 
4) Orriols L, et al. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry 2012 ; 73 : 1088-1094.
PubMed
5) Chang CM, et al. Psychotropic drugs and risk of motor vehicle accidents : A population-based case-control study. Br J Clin Pharmacol 2013 ; 75 : 1125-1133.
PubMed
6) Ramaekers JG. Antidepressants and driver impairment : Empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003 ; 64 : 20-29.
 
7) Sasada K, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol 2013 ; 28 : 281-286.
PubMed
8) Iwamoto K, et al. Effects of low-dose mirtazapine on driving performance in healthy volunteers. Hum Psychopharmacol 2013 ; 28 : 523-528.
PubMed
9) van der Sluiszen N, et al. Driving Performance of Depressed Patients who are Untreated or Receive Long-Term Antidepressant (SSRI/SNRI) Treatment. Pharmacopsychiatry 2017 ; 50 : 182-188.
PubMed
10) Brunnauer A, et al. The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patients. J Clin Psychiatry 2008 ; 69 : 1880-1886.
PubMed
11) Brunnauer A, et al. Driving performance and psychomotor function in depressed patients treated with agomelatine or venlafaxine. Pharmacopsychiatry 2015 ; 48 : 65-71.
PubMed
12) Brunnauer A, et al. Antidepressants and driving ability : Results from a clinical study. J Clin Psychiatry 2006 ; 67 : 1776-1781.
PubMed
13) Miyata A, et al. Driving performance of stable outpatients with depression undergoing real-world treatment. Psychiatry Clin Neurosci 2018 ; 72 : 399-408.
PubMed
Iwata M, et al. Evaluation method regarding the effect of psychotropic drugs on driving performance : A literature review. Psychiatry Clin Neurosci 2018 ; 72 : 747-773.
PubMed
Ramaekers JG. Drugs and Driving Research in Medicinal Drug Development. Trends Pharmacol Sci 2017 ; 38 : 319-321.
PubMed
Ravera S, et al. A European approach to categorizing medicines for fitness to drive : Outcomes of the DRUID project. Br J Clin Pharmacol 2012 ; 74 : 920-931.
PubMed
P.305 掲載の参考文献
1) Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013 ; 381 : 1672-1682.
PubMed
2) Miura T, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder : A systematic review and network meta-analysis. Lancet Psychiatry 2014 ; 1 : 351-359.
PubMed
3) Keller MB, et al. Bipolar I : A five-year prospective follow-up. J Nerv Ment Dis 1993 ; 181 : 238-245.
PubMed
4) Plans L, et al. Association between completed suicide and bipolar disorder : A systematic review of the literature. J Affect Disord 2019 ; 242 : 111-122.
PubMed
5) Gerhard T, et al. Lithium treatment and risk for dementia in adults with bipolar disorder : Populationbased cohort study. Br J Psychiatry 2015 ; 207 : 46-51.
 
6) Kessing LV, et al. Does lithium protect against dementia? Bipolar Disord 2010 ; 12 : 87-94.
PubMed
7) Kessing LV, et al. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008 ; 65 : 1331-1335.
PubMed
8) Nunes PV, et al. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007 ; 190 : 359-360.
PubMed
9) McGirr A, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression : A systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016 ; 3 : 1138-1146.
 
10) Terao T, et al. Preventive Effects of Lamotrigine in Bipolar II Versus Bipolar I Disorder. J Clin Psychiatry 2017 ; 78 : e1000-e1005.
PubMed
11) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン I. 双極性障害 2017. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/180125.pdf
 
12) Yildiz A, et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of anti-manic treatments in acute bipolar mania. Psychol Med 2015 ; 45 (2) : 299-317.
 
13) Allen MH, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006 ; 163 (2) : 272-275.
PubMed
14) Geddes JR, et al. Lamotrigine for treatment of bipolar depression : Independent meta-analysis and metaregression of individual patient data from five randomised trials. Br J Psychiatry 2009 ; 194 : 4-9.
 
15) Datto C, et al. Bipolar II compared with bipolar I disorder : Baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Ann Gen Psychiatry 2016 ; 15 : 9.
 
16) Murasaki M, et al. Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extendedrelease formulation in Japanese patients with bipolar depression. Psychopharmacology (Berl) 2018 ; 235 : 2859-2869.
 
17) Dell'Osso B, et al. Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from quetiapine immediate release to extended release. Int Clin Psychopharmacol 2012 ; 27 : 310-313.
 
18) Geddes JR, et al ; CEQUEL Investigators and Collaborators. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL) : A 2×2 factorial randomised trial. Lancet Psychiatry 2016 ; 3 (1) : 31-39.
 
19) Florio V, et al. Escitalopram plasma levels and antidepressant response. Eur Neuropsychopharmacol 2017 ; 27 : 940-944.
PubMed
20) Jukic MM, et al. Impact of CYP2C19 Genotypeon Escitalopram Exposure and Therapeutic Failure : A Retrospective Study Based on 2,087 Patients. Am J Psychiatry 2018 ; 175 : 463-470.
PubMed
21) Joas E, et al. Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 2017 ; 210 (3) : 197-202.
PubMed
22) Lahteenvuo M, et al. Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. JAMA Psychiatry 2018 ; 75 (4) : 347-355.
 
23) Lindstrom L, et al. Maintenance therapy with second generation antipsychotics for bipolar disorder-A systematic review and meta-analysis. J Affect Disord 2017 ; 213 : 138-150.
PubMed
24) Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018 ; 20 (2) : 97-170.
PubMed
P.308 掲載の参考文献
1) Barbini B, et al. Dark therapy for mania : A pilot study. Bipolar Disord 2005 ; 7 (1) : 98-101.
 
2) Henriksen TE, et al. Blocking blue light during mania-markedly increased regularity of sleep and rapid improvement of symptoms : A case report. Bipolar Disord 2014 ; 16 (8) : 894-898.
PubMed
3) Henriksen TE, et al. Blue-blocking glasses as additive treatment for mania : A randomized placebo-controlled trial. Bipolar Disord 2016 ; 18 (3) : 221-232.
 
4) Hirakawa H, et al. Relationship between ambient light and glucose metabolism in healthy subjects. BMC Neurosci 2018 ; 19 (1) : 44.
 
5) Shirahama M, et al. Use of gray sunglasses to alleviate hypomanic state in two patients with bipolar II disorder. Bipolar Disord 2019 ; 21 (2) : 182-184.
 
P.312 掲載の参考文献
1) Onishi Y, et al. Psychotropic Prescription Patterns Among Patients Diagnosed With Depressive Disorder Based on Claims Database in Japan. Clin Drug Investig 2013 ; 33 : 597-605.
PubMed
2) Nakagawa A, et al. Comparison of treatment selections by Japanese and US psychiatrists for major depressive disorder : A case vignette study. Psychiatry Clin Neurosci 2015 ; 69 : 553-562.
PubMed
3) EGUIDEプロジェクト. https://byoutai.ncnp.go.jp/eguide/
 
4) 日本うつ病学会 (監修), 気分障害の治療ガイドライン作成委員会 (編). うつ病治療ガイドライン 第2版. 医学書院 ; 2017.
 
5) 日本神経精神薬理学会 (編). 統合失調症薬物治療ガイドライン. 医学書院 ; 2016.
 
6) Takaesu Y, et al. Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)" project : A nationwide dissemination, education and evaluation study. Psychiatry Clin Neurosci 2019 ; 73 : 642-648.
 
P.320 掲載の参考文献
1) Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006 ; 59 : 1116-1127.
PubMed
2) Walsh JJ, et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. Nat Neurosci 2014 ; 17 : 27-29.
PubMed
3) Wook Koo J, et al. Essential Role of Mesolimbic Brain-Derived Neurotrophic Factor in Chronic Social Stress-Induced Depressive Behaviors. Biol Psychiatry 2016 ; 80 : 469-478.
PubMed
4) Deyama S, et al. Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor. Biol Psychiatry 2018 : S0006-3223 (18) 32099-7.
 
5) Skolnick P, et al. Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment : Implications for the pharmacotherapy of depression. Pharmacopsychiatry 1996 ; 29 : 23-26.
 
6) Alt A, et al. A role for AMPA receptors in mood disorders. Biochem Pharmacol 2006 ; 71 : 1273-1288.
 
7) Duman RS, et al. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001 ; 25 : 836-844.
PubMed
8) Santarelli L, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003 ; 301 : 805-809.
PubMed
9) Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression : Implications for therapy. J Affect Disord 2001 ; 62 : 77-91.
PubMed
10) Ising M, et al. The combined dexamethasone/CRH test as a potential surrogate marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005 ; 29 : 1085-1093.
PubMed
11) Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases : The end of the beginning? Nat Rev Drug Discov 2012 ; 11 : 462-478.
PubMed
12) Krystal JH, et al. Rapid-acting glutamatergic antidepressants : The path to ketamine and beyond. Biol Psychiatry 2013 ; 73 : 1133-1141.
PubMed
13) Maguire J. Neuroactive Steroids and GABAergic Involvement in the Neuroendocrine Dysfunction Associated With Major Depressive Disorder and Postpartum Depression. Front Cell Neurosci 2019 ; 13 : 83. doi : 10.3389/fncel.2019.00083. eCollection 2019.
 
14) Yang C, et al. R-ketamine : A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 2015 ; 5 : e632. doi : 10.1038/tp.2015.136.
 
15) Zanos P, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016 ; 533 : 481-486.
PubMed
16) Yamaguchi JI, et al. (2R,6R) -Hydroxynorketamine is not essential for the antidepressant actions of (R) -ketamine in mice. Neuropsychopharmacology 2018 ; 43 : 1900-1907.
 
17) Chaki S. mGlu2/3 Receptor Antagonists as Novel Antidepressants. Trends Pharmacol Sci 2017 ; 38 : 569-580.
PubMed
18) Gould TD, Manji HK. Glycogen synthase kinase-3 : A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005 ; 30 : 1223-1237.
PubMed
19) Du J, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization : Relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007 ; 32 : 793-802.
PubMed
Nestler EJ, et al. Neurobiology of depression. Neuron 2002 ; 34 : 13-25.
PubMed
Shirayama Y, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002 ; 22 : 3251-3261.
PubMed
Shimizu E, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003 ; 54 : 70-75.
PubMed
Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000 ; 47 : 351-354.
PubMed
Kishimoto T, et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression : A meta-analysis of efficacy, safety and time trajectories. Psychol Med 2016 ; 46 : 1459-1472.
PubMed
Shirayama Y, Chaki S. Neurochemistry of the nucleus accumbens and its relevance to depression and antidepressant action in rodents. Curr Neuropharmacol 2006 ; 4 : 277-291.
PubMed
P.326 掲載の参考文献
1) Domino EF. Taming the ketamine tiger. Anesthesiology 2010 ; 113 (3) : 678-686.
PubMed
2) Krystal JH, et al. Subanesthetic effects of noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatry 1994 ; 51 (3) : 199-214.
PubMed
3) Krystal JH, et al. Ketamine : A paradigm shift for depression research and treatment. Neuron 2019 ; 101 (5) : 774-778.
 
4) Berman RM, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000 ; 47 (2) : 351-354.
PubMed
5) Zarate CA Jr, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006 ; 63 (8) : 856-864.
 
6) DiazGranados N, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010 ; 67 (8) : 793-802.
 
7) Newport DJ, et al. Ketamine and other NMDA antagonists : Early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015 ; 172 (10) : 950-966.
PubMed
8) Kishimoto T, et al. Single-dose infusion of ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression : A meta-analysis of efficacy, safety and time trajectories. Psychol Med 2016 ; 46 (7) : 1459-1472.
PubMed
9) DiazGranados N, et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-Daspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010 ; 71 : 1605-1611.
 
10) Wilkinson ST, et al. The effect of a single dose of intravenous ketamine on suicidal ideation : A systematic review and individual participant data meta-analysis. Am J Psychiatry 2018 ; 175 (2) : 150-158.
PubMed
11) Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates : A historical overview and future perspective. Psychiatry Clin Neurosci 2019 ; 73 (10) : 613-627.
PubMed
12) Yang C, et al. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites. Transl Psychiatry 2019 ; 9 (1) : 280.
PubMed
13) Turner EH. Esketamine for treatment-resistant depression : seven concerns about efficacy and FDA approval. Lancet Psychiatry 2019 ; 6 (12) : 977-979.
PubMed
14) Zhang JC, et al. R (-) -Ketamine shows greater potency and longer lasting antidepressant effects than S (+) -ketamine. Pharmacol Biochem Behav 2014 ; 116 : 137-143.
 
15) Yang C, et al. R-ketamine : A rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 2015 ; 5 : e632.
 
16) Yang C, et al. Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 2016 ; 239 : 281-283.
 
17) Tian Z, et al. Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R, S) -ketamine and (S) -ketamine, but not (R) -ketamine. Pharmacol Biochem Behav 2018 ; 172 : 17-21.
 
18) Hashimoto K, et al. Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine : A PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 2017 ; 267 (2) : 173-176.
 
19) Hashimoto K. R-ketamine : A rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 2016 ; 46 (11) : 2449-2451.
PubMed
20) Hashimoto K. Detrimental side effects of repeated ketamine infusions in the brain. Am J Psychiatry 2016 ; 173 (10) : 1044-1045.
 
21) Zanos P, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016 ; 533 (7604) : 481-486.
PubMed
22) Zanos P, et al. Ketamine and ketamine metabolite pharmacology : Insights into therapeutic mechanisms. Pharmacol Rev 2018 ; 70 (3) : 621-660.
PubMed
23) Leal GC, et al. Intravenous arketamine for treatment-resistant depression : Open-label pilot study. Eur Arch Psychiatry Clin Neurosci (in press). doi : 10.1007/s00406-020-01110-5.
 
24) Wilkinson ST, Sanakora G. Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA 2017 ; 318 (9) : 793-794.
 
25) Sanacora G, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017 ; 74 (4) : 399-405.
PubMed
橋本謙二. 難治性うつ病治療に対するケタミンへの期待. 医学のあゆみ 2020 ; 272 (5) : 495-499.
Medical*Online
橋本謙二. 難治性うつ病の画期的治療薬として期待されるケタミン. 精神神経学雑誌 (印刷中).
 
P.334 掲載の参考文献
1) Cipriani A, et al. Conceptual and Technical Challenges in Network Meta-analysis. Ann Intern Med 2013 ; 159 (2) : 130-137.
PubMed
2) Walsh BT, et al. Placebo response in studies of major depression : Variable, substantial, and growing. JAMA 2002 ; 287 (14) : 1840-1847.
PubMed
3) Kirsch I, et al. Initial severity and antidepressant benefits : A meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008 ; 5 (2) : e45.
 
4) Furukawa TA, et al. Placebo response rates in antidepressant trials : A systematic review of published and unpublished double-blind randomized controlled studies. Lancet Psychiatry 2016 ; 3 (11) : 1059-1066.
PubMed
5) Cipriani A, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants : A multiple treatments meta-analysis. Lancet 2009 ; 373 (9665) : 746-758.
PubMed
6) Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorders : A systematic review and network meta-analysis. Lancet 2018 ; 391 (10128) : 1357-1366.
PubMed
7) Zhou X, et al. Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents : Protocol for a network meta-analysis. BMJ Open 2017 ; 7 (8) : e016608.
PubMed
8) Cipriani A, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents : A network meta-analysis. Lancet 2016 ; 388 (10047) : 881-890.
PubMed
9) Barth J, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression : A network meta-analysis. PLoS Med 2013 ; 10 (5) : e1001454.
PubMed
10) Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania : A multiple-treatments meta-analysis. Lancet 2011 ; 378 (9799) : 1306-1315.
 
11) Taylor DM, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression : A multiple-treatments eta-analysis. Acta Psychiatr Scand 2014 ; 130 (6) : 452-469.
 
12) Miura T, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder : A systematic review and network meta-analysis. Lancet Psychiatry 2014 ; 1 (5) : 351-359.
PubMed
Guyatt G, et al (eds). User's Guides to the Medical Literature : A Manual for Evidence-Based Clinical Practice, 3rd edition. McGraw-Hill Education ; 2014/相原守夫 (訳). 医学文献ユーザーズガイド-根拠に基づく診療のマニュアル 第3版. 中外医学社 ; 2018.
 
Murad M, et al. How to read a systematic review and meta-analysis and apply the results to patient care : User's guides to the medical literature. JAMA 2014 ; 312 (2) : 171-179.
 
相原守夫. 診療ガイドラインのためのGRADEシステム 第3版. 中外医学社 ; 2018.
 
Mavridis D, et al. A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health 2015 ; 18 (2) : 40-46.
PubMed
Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions Version 5.1.0. http://training.cochrane.org/handbook
 
P.342 掲載の参考文献
1) 井村恒郎. <臨床心理学叢書> 第2. 心理療法. 世界社 ; 1952.
 
2) 土居健郎. 方法としての面接-臨床家のために. 医学書院 ; 1977, 新訂版, 1992.
 
3) 山下格. 精神医学ハンドブック 第7版. 日本評論社 ; 2010.
 
4) 青木省三. 精神科治療の進め方. 日本評論社 ; 2014.
 
5) 青木省三. こころの病を診るということ-私の伝えたい精神科診療の基本. 医学書院 ; 2017.
 
6) 中井久夫. こんなとき私はどうしてきたか. 医学書院 ; 2007.
 
7) Schulte W. Studien zur heutigen Psychotherapie. Quelle & Meyer ; 1964/飯田真ほか (訳). 精神療法研究. 岩崎学術出版社 ; 1995.
 
神田橋條治. 精神療法面接のコツ. 岩崎学術出版社 ; 1990.
 
村瀬嘉代子. 心理療法の気づきと想像-生活を視野に入れた心理臨床. 金剛出版 ; 2015.
 
村上伸治. 現場から考える精神療法-うつ, 統合失調症, そして発達障害. 日本評論社 ; 2017.
 
P.352 掲載の参考文献
1) Brown GW, Rutter M. The measurement of family activities and relationships : A methodological study. Hum Relat 1966 ; 19 (3) : 241-263.
 
2) Brown GW, et al. Influence of family life on course of schizophrenic disorders : A replication. Br J Psychiatry 1972 ; 121 : 241-258.
PubMed
3) Magana AB, et al. A brief method for assessing expressed emotion in relatives of psychiatric patients. Psychiatry Res 1986 ; 17 (3) : 203-212.
PubMed
4) Fujita H, et al. Family attitude scale : Measurement of criticism in the relatives of patients with schizophrenia in Japan. Psychiatry Res 2002 ; 110 (3) : 273-280.
PubMed
5) 伊藤順一郎ほか. 家族の感情表出 (EE) と分裂病患者の再発との関連. 精神医学 1994 ; 36 : 1023-1031.
 
6) Ito J, Oshima I. Distribution of EE and its relationship to relapse in Japan. Int J Ment Health 1995 ; 24 (2) : 23-37.
 
7) Tanaka S, et al. Expressed emotion and the course of schizophrenia in Japan. Br J Psychiatry 1995 ; 167 (6) : 794-798.
PubMed
8) 上原徹ほか. Five Minute Speech Sample (FMSS) によって評価された家族の感情表出 (EE) の特徴および再発との関連性-精神分裂病についての検討. 精神医学 1997 ; 39 : 31-37.
 
9) Uehara T, et al. Expressed emotion from the five-minute speech sample and relapse of out-patients with schizophrenia. Acta Psychiatr Scand 1997 ; 95 (5) : 454-456.
PubMed
10) 心理教育・家族教室ネットワーク. http://jnpf.net
 
11) 厚生労働省精神・神経疾患研究委託費13指2 統合失調症の治療およびリハビリテーションのガイドライン作成とその実証的研究 (主任研究者 : 浦田重治郎). 心理教育を中心とした心理社会的援助プログラムガイドライン. 2004年1月. https://www.ncnp.go.jp/nimh/chiiki/documents/psycho_education_guide_line.pdf
 
12) Mino Y, et al. Expressed emotion of families and the course of mood disorders : a cohort study in Japan. J Affect Disord 2001 ; 63 (1-3) : 43-49.
PubMed
13) Morokuma I, et al. Psychoeducation for major depressive disorders : A randomised controlled trial. Psychiatry Res 2013 ; 210 (1) : 134-139.
PubMed
14) Shimazu K, et al. Family psychoeducation for major depression : Randomised controlled trial. Br J Psychiatry 2011 ; 198 (5) ; 385-390.
PubMed
15) 後藤雅博 (編). 家族教室のすすめ方-心理教育的アプローチによる家族援助の実際. 金剛出版 ; 1998, pp9-10.
 
P.368 掲載の参考文献
1) 原田誠一. 慢性化したうつ病への認知行動療法の工夫. 臨床精神医学 2017 ; 46 : 547-557.
Medical*Online
2) 神田橋條治ほか. うつ病診療-現場の工夫より. メディカルレビュー社 ; 2010.
 
3) 神田橋條治. 古稀記念「現場からの治療論」という物語. 岩崎学術出版社 ; 2006.
 
4) 原田誠一. 複雑性PTSD～軽症・複雑性PTSDの心理教育と精神療法の試み-気分障害と不安障害を例にあげて. 精神療法 2019 ; 45 : 360-368.
 
5) 原田誠一. 「コミュニケーション強迫」と「接触強迫」に関する覚書. 精神療法 2013 ; 39 : 714-717.
 
6) 原田誠一. 新しい精神科診断学の提案-「伝統的な診断学」と「操作的診断」を補完する内容とは? 原田誠一 (編), <外来精神科診療シリーズ> 診断の技と工夫. 中山書店 ; 2017. pp2-9.
 
7) 原田誠一. 精神療法の現状に「活」を入れる-西園先生の「一喝」を機に, 自他の精神療法に気弱に「活」を入れてみた. 精神療法 2014 ; 40 : 11-20.
 
8) 土居健郎. リハビリテーションと精神医学. 臨床精神医学の方法. 岩崎学術出版社 ; 2009. pp93-104.
 
9) 原田誠一. 短時間の外来診療における複雑性PTSDへの対応-「複雑性外傷記憶」概念を導入して行う心理教育と精神療法の試み. 精神療法 2018 ; 44 : 533-535.
 
10) 貝谷久宣. 不安・抑うつ発作とは何か. 精神科 2019 ; 34 : 418-420.
 
11) 原田誠一. 不安・抑うつ発作と複雑性PTSDの関連についての私見. 不安症研究 2019 ; 11 (1) : 47-51.
 
12) 原田誠一. 現代の心的外傷体験考-我が国が抱える "変化した/変化していない" 問題点から考える. 精神療法 2018 ; 44 : 837-839.
 
13) 原田誠一. 解離性健忘と離人症性障害の治療. 原田誠一ほか (編), <外来精神科診療シリーズ> 不安障害, ストレス関連障害, 身体表現性障害, 嗜癖症, パーソナリティ障害. 中山書店 ; 2016. pp136-141.
 
14) Clark, DA. Cognitive-behavioral therapy for OCD. Guilford ; 2004/原田誠一ほか (監訳), 勝倉りえこほか (訳). 強迫性障害の認知行動療法. 金剛出版 ; 2019.
 
15) 原田誠一. 恐怖症の治療-限局性恐怖症と失敗恐怖の診療の工夫. 原田誠一ほか (編), <外来精神科診療シリーズ> 不安障害, ストレス関連障害, 身体表現性障害, 嗜癖症, パーソナリティ障害. 中山書店 ; 2016. pp27-33.
 
精神療法 2019 ; 45 (3). 特集「複雑性PTSDの臨床- "心的外傷～トラウマ" の診断力と対応力を高めよう」
 
P.374 掲載の参考文献
1) 吉田裕. 日本軍兵士-アジア・太平洋戦争の現実. 中公新書 ; 2017.
 
2) 野間宏. 真空地帯. 岩波文庫 ; 1956.
 
3) 原田誠一. 現代の成人期の不安をいかに理解して, 対応を試みるか-現在の社会生活の特徴～2種類のPTSD～発達障害をふまえた試論. 精神療法 2019 ; 45 (5) : 665-671.
 
P.382 掲載の参考文献
1) Kabat-Zinn J. Wherever You Go, There You Are : Mindfulness Meditation in Everyday Life. Hyperion ; 1994.
 
2) Teasdale JD, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000 ; 68 : 615-623.
PubMed
3) Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression : Replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004 ; 72 : 31-40.
PubMed
4) Kuyken W, et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008 ; 76 : 966-978.
PubMed
5) Kuyken W, et al. Efficacy of Mindfulness-Based Cognitive Therapy in Prevention of Depressive Relapse : An Individual Patient Data Meta-analysis From Randomized Trials. JAMA Psychiatry 2016 ; 73 (6) : 565-574.
PubMed
6) Strauss C, et al. Mindfulness-based interventions for people diagnosed with a current episode of an anxiety or depressive disorder : A meta-analysis of randomised controlled trials. PLoS One 2014 ; 9 (4) : e96110.
PubMed
7) Segal ZV, et al. Mindfulness-Based Cognitive Therapy for Depression : A new approach to preventing relapse. Guilford Press ; 2002/越川房子 (監訳). マインドフルネス認知療法-うつを予防する新しいアプローチ. 北大路書房 ; 2007.
 
8) Shapiro SL, et al. Mechanisms of mindfulness. J Clin Psychol 2006 ; 62 (3) : 373-386.
PubMed
9) Segal ZV, et al. Mindfulness-Based Cognitive Therapy for Depression, 2nd edition. Guilford Press ; 2013.
 
10) Oxford Mindfulness Centre. Pre-requisites for training to teach MBCT. http://oxfordmindfulness.org/about-us/training/pre-requisites-training-teach-mbct/ (accessed 9th May 2019)
 
11) Williams M, Penman D. Mindfulness : A practical guide to finding peace in a frantic world. Piatkus ; 2011/佐渡充洋ほか (監訳). 自分でできるマインドフルネス-安らぎへと導かれる8週間のプログラム. 創元社 ; 2016.
 
Segal Z, et al. Mindfulness-Based Cognitive Therapy for Depression. 2nd edition. Guilford Press ; 2013.
 
Segal ZV, et al. Mindfulness-Based Cognitive Therapy for Depression : A new approach to preventing relapse. Guilford Press ; 2002/越川房子 (監訳). マインドフルネス認知療法-うつを予防する新しいアプローチ. 北大路書房 ; 2007.
 
Williams M, Penman D. Mindfulness : A practical guide to finding peace in a frantic world. Piatkus ; 2011/佐渡充洋ほか (監訳). 自分でできるマインドフルネス-安らぎへと導かれる8週間のプログラム. 創元社 ; 2016.
 
P.388 掲載の参考文献
1) Wilfley DE, et al. Interpersonal Psychotherapy for Group. Basic Books ; 2000/水島広子 (訳). グループ対人関係療法. 創元社 ; 2006.
 
2) Elkin I, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. Arch Gen Psychiatry 1989 ; 46 (11) : 971-982.
PubMed
3) Weissman MM, et al. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 1979 ; 136 (4B) : 555-558.
PubMed
4) Parsons T. Illness and the role of the physician : A sociological perspective. Am J Orthopsychiatry 1951 ; 21 (3) : 452-460.
PubMed
5) Zlotnick C, et al. Postpartum depression in women receiving public assistance : Pilot study of an interpersonal-therapy-oriented group intervention. Am J Psychiatry 2001 ; 158 (4) : 638-640.
PubMed
6) Frank E. Treating Bipolar Disorder : A Clinician's Guide to Interpersonal and Social Rhythm Therapy. Guilford Press ; 2005/阿部又一郎 (監訳), 大賀健太郎 (監修). 双極性障害の対人関係社会リズム療法. 星和書店 ; 2016.
 
7) Frank E, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry 2005 ; 62 (9) : 996-1004.
PubMed
8) Miklowitz DJ, et al. Psychosocial treatments for bipolar depression : A 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007 ; 64 (4) : 419-426.
PubMed
9) Miklowitz DJ, et al. Intensive psychosocial intervention enhances functioning in patients with bipolar depression : Results from a 9-month randomized controlled trial. Am J Psychiatry 2007 ; 164 (9) : 1340-1347.
PubMed
10) Swartz HA, et al. Psychotherapy as monotherapy for the treatment of bipolar II depression : A proof of concept study. Bipolar Disord 2009 ; 11 (1) : 89-94.
PubMed
11) Swartz HA, et al. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord 2012 ; 14 (2) : 211-216.
PubMed
12) Markowitz JC, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry 1998 ; 55 (5) : 452-457.
PubMed
13) Markowitz JC. Interpersonal Psychotherapy for Posttraumatic Stress Disorder. Oxford University Press ; 2017/水島広子 (監訳). PTSDのための対人関係療法. 創元社 ; 2019.
 
14) Mufson L, et al. Interpersonal Psychotherapy for Depressed Adolescents, 2nd edition. Guilford Press ; 2004.
 
15) Mufson L, et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 2004 ; 61 (6) : 577-584.
PubMed
16) Rossello J, Bernal G. The efficacy of cognitive-behavioral and interpersonal treatments for depression in Puerto Rican adolescents. J Consult Clin Psychol 1999 ; 67 (5) : 734-745.
PubMed
17) Cuijpers P, et al. Interpersonal Psychotherapy for Mental Health Problems : A Comprehensive Meta-Analysis. Am J Psychiatry 2016 ; 173 (7) : 680-687.
PubMed
18) 水島広子. 対人関係カウンセリング (IPC) の進め方. 創元社 ; 2011.
 
19) Barth J, et al. Comparative efficacy of seven psychotherapeutic interventions for patients with depression : A network meta-analysis. PLoS Med 2013 ; 10 (5) : e1001454.
PubMed
20) 水島広子. 対人関係療法 (IPT) の有効性に関する研究. 厚生労働科学研究費補助金 (こころの健康科学研究事業) 精神療法の実施方法と有効性に関する研究. 平成21年度 総括・分担研究報告書. 2010, pp76-82.
 
21) Klerman GL, et al. Interpersonal Psychotherapy of Depression. Basic Books ; 1984/水島広子ほか (訳). うつ病の対人関係療法. 岩崎学術出版社 ; 1997.
 
22) Weissman MM, et al. Comprehensive Guide to Interpersonal Psychotherapy. Basic Books ; 2000/水島広子 (訳). 対人関係療法総合ガイド. 岩崎学術出版社 ; 2009.
 
23) Weissman MM, et al. Clinician's Quick Guide to Interpersonal Psychotherapy. Oxford University Press ; 2007/水島広子 (訳). 臨床家のための対人関係療法クイックガイド. 創元社 ; 2008.
 
24) 水島広子. 臨床家のための対人関係療法入門ガイド. 創元社 ; 2009.
 
Markowitz JC. Interpersonal Psychotherapy for Posttraumatic Stress Disorder. Oxford University Press ; 2017/水島広子 (監訳). PTSDのための対人関係療法. 創元社 ; 2019.
 
水島広子. 摂食障害の不安に向き合う-対人関係療法によるアプローチ. 創元社 ; 2015.
 
水島広子. 拒食症・過食症を対人関係療法で治す. 紀伊國屋書店 ; 2007.
 
水島広子. 対人関係療法マスターブック. 金剛出版 ; 2009.
 
P.396 掲載の参考文献
1) Kraepelin, E. Psychiatrie, Ein Lehrbuch fur Studierende und Arzte. Verlag von Johann Ambrosius Barth ; 1913/西丸四方ほか (訳). 躁うつ病とてんかん. みすず書房 ; 1986.
 
2) Janet P. La medecine psychologique. Ernest Flammarion, Editeur Paris, 1923/松本雅彦 (訳). 心理学的医学. みすず書房 ; 1981.
 
3) 中井久夫, 永安朋子. 養生を念頭においた精神科治療. 精神科治療学 1994 ; 9 : 799-807.
 
4) 森田正馬. 精神療法の基礎. 森田正馬全集 1. 白揚社 ; 1974, pp152-171.
 
5) 中村敬. 森田療法によるうつ病の養生と治療. こころの科学 2001 ; 97 : 67-71.
 
6) 中村敬. うつ病の森田療法. 福岡行動医学雑誌 2002 ; 9 : 9-15.
 
7) 中村敬. うつ病の森田療法・序論-主として内因性の病態を念頭に. 森田療法学会誌 2009 ; 20 : 21-25.
 
8) 中村敬. 回復の時期に応じた養生指導のコツ. 中村敬 (編). うつ病における精神療法-10分間で何ができるか. 星和書店 ; 2018, pp35-47.
 
9) 松浪克文, 山下喜弘.社会変動とうつ病.社会精神医学 1991 ; 14 : 193-200.
 
10) 樽味伸. 現代社会が生む "ディスチミア親和型". 臨床精神医学 2005 ; 34 : 687-694.
Medical*Online
11) 中村敬. 「現代的な抑うつ」は, どこから来て, どこに行くのか. 臨床精神病理 2018 ; 39 (1) : 71-80.
 
12) Frank JD, Frank JB. Persuasion and Healing : A Comparative Study of Psychotherapy, 3rd edition. Johns Hopkins University Press ; 1991.
 
13) 谷井一夫. 気分障害患者における臥褥の意義についての検討. 森田療法学会誌 2017 ; 28 ; 39-43.
 
P.404 掲載の参考文献
1) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition : DSM-5. America Psychiatric Association Publishing ; 2013/日本精神神経学会 (監修), 高橋三郎ほか (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
2) Fonagy P. The effectiveness of psychodynamic psychotherapies. World Psychiatry 2015 ; 14 : 137-150.
PubMed
3) Fonagy P, et al. Pragmatic randomized controlled trial of long-term psychoanalytic psychotherapy for treatment-resistant depression : The Tavistock Adult Depression Study (TADS). World Psychiatry 2015 ; 14 : 312-321.
PubMed
4) Freud S. Mourning and Melancholia. The Standard Edition of the Complete Psychological Works of Sigmund Freud, Volume XIV (1914-1916) : On the History of the Psycho-Analytic Movement, Papers on Metapsychology and Other Works. Hogarth Press ; 1917, pp237-258/伊藤正博 (訳). <フロイト全集> 第14巻. 喪とメランコリー. 岩波書店 ; 2010.
 
5) Klein M. Notes on Some Schizoid Mechanisms. Int J Psycho-Anal 1946 ; 27 : 99-110/小此木啓吾ほか (編訳). 分裂的機制についての覚書. <メラニー・クライン著作集> 4. 妄想的・分裂的世界. 誠信書房 ; 1985.
 
6) Rosenfeld H. Impasse and Interpretation : Therapeutic and Anti-Therapeutic Factors in the Psycho-Analytic Treatment of Psychotic, Borderline, and Neurotic Patients. Routledge ; 1987/神田橋條治ほか (訳). 治療の行き詰まりと解釈-精神分析療法における治療的/反治療的要因. 誠信書房 ; 2001.
 
7) Steiner E. Psychic Retreats : Pathological Organizations in Psychotic, Neurotic and Borderline Patients. Routledge ; 1993/衣笠隆幸 (訳). こころの退避-精神病・神経症・境界例患者の病理的組織化. 岩崎学術出版社 ; 1997.
 
8) Swartz HA, Frank E. Psychotherapy for Bipolar Depression : Psychotherapy for Bipolar Depression : A Phase-Specific Treatment Strategy? Bipolar Disorder 2001 ; 3 : 11-22.
PubMed
9) Jones S. Psychotherapy of Bipolar Disorder : A Review. J Affect Disord 2004 ; 80 : 101-114.
PubMed
小此木啓吾. 対象喪失-悲しむということ. 中公新書 (557) ; 1979.
 
Fairbairn R. Psychoanalytic Studies of the Personality. Routledge & Kegan Paul Limited ; 1952/山口泰司 (訳). 人格の精神分析学. 講談社学術文庫 (1173) ; 1995, pp22-68.
 
Gabbard GO. Long Term Psychodynamic Psychotherapy : A Basic Text, 2nd edition. American Psychiatric Association Publishing ; 2010/狩野力八郎 (監訳), 池田曉史 (訳). 精神力動的精神療法-基本テキスト. 岩崎学術出版社 ; 2012.
 
Gabbard GO. Psychodynamic Psychiatry in Clinical Practice, 5th edition. American Psychiatric Association Publishing ; 2014/奥寺崇ほか (監訳). 精神力動的精神医学-その臨床実践, 第5版. 岩崎学術出版社 ; 2019.
 
P.410 掲載の参考文献
1) 一般社団法人日本作業療法士協会 (編). 3-2 医療における作業療法. 作業療法白書 2015. 一般社団法人日本作業療法士協会 ; 2017, pp37-57.
 
2) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. うつ病治療ガイドライン-精神科作業療法. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/guideline_20181119.pdf
 
3) 香山明美. 第6章 作業療法士が遭遇することの多い疾患の知識と対応の基本 第1節 気分障害. 香山明美ほか (編), 生活を支援する 精神障害作業療法 第2版-急性期から地域実践まで. 医歯薬出版 ; 2014, pp260-269.
 
4) 日本うつ病学会 (監修), 気分障害の治療ガイドライン作成委員会 (編). 第3章 中等症・重症うつ病. うつ病治療ガイドライン 第2版. 医学書院 ; 2017, pp51-70.
 
5) 大西あゆみほか. 修正型電気けいれん療法後の記憶と気分の障害に対する個別作業プログラムの効果. 作業療法 2013 ; 32 : 4-13.
Medical*Online
6) 小林正義ほか. 統合失調症の主観的体験の評価-気分と疲労のチェックリスト (Inventory Scale for Mood and Sense of Fatigue : SMSF) の評価項目の因子構造. 作業療法 2011 ; 30 : 698-706.
 
7) 島田岳ほか. 気分と疲労のチェックリスト (Inventory Scale for Mood and Sense of Fatigue : SMSF) の信頼性と妥当性の検討. 作業療法 2012 ; 31 : 540-549.
Medical*Online
8) 田中佐千恵ほか. うつ病患者に対する修正型電気けいれん療法 (mECT) 後の作業療法. 作業療法ジャーナル 2017 ; 51 : 1099-1104.
 
9) Hees HL, et al. Adjuvant occupational therapy improves long-term depression recovery and return-to-work in good health in sick-listed employees with major depression : Results of a randomised controlled trial. Occup Environ Med 2013 ; 70 : 252-260.
PubMed
10) Schene AH, et al. Adjuvant occupational therapy for work-related major depression works : Randomized trial including economic evaluation. Psychol Med 2007 ; 37 : 351-362.
PubMed
11) 一般社団法人日本作業療法士協会. 作業療法の定義. http://www.jaot.or.jp/about/definition.html
 
香山明美. OTがうつ病に取り組む意義. 作業療法ジャーナル 2011 ; 45 : 427-434.
 
河埜康二郎ほか. うつ病患者の再発予防に関連する因子の検討-作業療法の視点から. 作業療法 2015 ; 34 : 437-446.
Medical*Online
Hees HL, et al. Effectiveness of adjuvant occupational therapy in employees with depression : Design of a randomized controlled trial. BMC Public Health 2010 ; 10 : 558.
PubMed
P.418 掲載の参考文献
1) 秋山剛. 医療機関におけるリワークプログラム発展の歴史と最新の知見. 最新精神医学 2018 ; 23 (3) : 163-168.
Medical*Online
2) 有馬秀晃. 職場復帰をいかに支えるか-リワークプログラムを通じた復職支援の取り組み. 日本労働研究雑誌 2010 ; 601 : 74-85.
 
3) Margot CWJ, et al. An international comparison of occupational health guidelines for the management of mental disorders and stress-related psychological symptoms. Occup Environ Med 2015 ; 72 (5) : 313-322. (oemed-2013-101626 Published Online First : 18 November 2014)
 
4) Cohen D. 'Sick note or bust' the development of an e learning programme for general practitioners about work and health. European Journal of Public Health 2007 ; 17 (Suppl 2) : 47-48.
PubMed
5) Hussey S, et al. Sickness certification system in the United Kingdom : Qualitative study of views of general practitioners in Scotland. BMJ 2004 ; 328 (7431) : 88. [Epub 2003 Dec 22]
 
6) Allen J, Cohen DA. Attitudes to work and health in doctors in training. Occup Med (Lond) 2010 ; 60 (8) : 640-644. (10.1093/occmed/kqq147)
 
7) Jong-Min W, Seong-Kyeon L. The effect of psychological rehabilitation program based on positive psychology for the workers with occupational injury. XVI World Congress of Psychiatry, Final program 2014 ; 271.
 
8) 有馬秀晃ほか. 復職支援プログラムほかオランダにおける先進的な産業保健の取り組み. 産業医学ジャーナル 2016 ; 39 (3) : 62-68.
 
9) 有馬秀晃. うつ病リワーク研究会の国内での実績及びオランダの復職支援との比較考察. 産業ストレス研究 (Job Stress Res) 2015 ; 22 : 249-254.
 
10) van der Klink JJL, et al. Reducing long sickness absence by an activating intervention in adjustment disorders : A cluster randomized controlled design. Occup Environ Med 2003 ; 60 : 429-437.
 
11) Blonk RWB, et al. Return to work : A comparison of two cognitive behavioural interventions in case of work-related psychological complaints among the self-employed. Work Stress 2006 ; 20 : 129-144.
 
12) 大木洋子, 五十嵐良雄. リワークプログラム利用者の復職後の就労継続性に関する効果研究. 産業精神保健 2012 ; 20 (4) : 335-345.
 
13) 五十嵐良雄. リワークプログラム利用者の復職後の就労予後に関する調査研究. 平成26年度厚生労働科学研究費補助金 (障害者対策総合研究事業 精神障害分野) うつ病患者に対する復職支援体制の確立. うつ病患者に対する社会復帰プログラムに関する研究 2014 : 67-73.
 
14) 酒井佳永ほか. 気分障害患者の復職後の予後と関連する要因の検討. 平成25年度厚生労働科学研究費補助金こころの健康科学研究事業「うつ病患者に対する復職支援体制の確立 うつ病患者に対する社会復帰プログラムに関する研究」 2014 : 31-39.
 
有馬秀晃, 秋山剛. うつ病患者に対する復職支援体制の確立. 産業ストレス研究 2015 ; 22 (2) : 97-105.
Medical*Online
秋山剛 (監修). うつ病の人の職場復帰を成功させる本-支援のしくみ「リワーク・プログラム」活用術. 講談社 ; 2013.
 
秋山剛 (監修). 誰にも書けなかった復職支援のすべて. 日本リーダーズ協会 ; 2010.
 
Colom F, Vieta E. Psychoeducation Manual for Bipolar Disorder. Cambridge University Press ; 2010/秋山剛, 尾崎紀夫 (編). 双極性障害の心理教育マニュアル-患者に何を, どう伝えるか. 医学書院 ; 2012.
 
有馬秀晃 (監修). うつ病の人に言っていいこと・いけないこと (健康ライブラリーイラスト版). 講談社 ; 2014.
 
P.429 掲載の参考文献
1) CLAMP. なかよし60周年記念版 カードキャプターさくら (1). 講談社 ; 2015.
 
2) Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev 2007 ; 27 : 959-985.
PubMed
3) Eaton WW, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008 ; 65 : 513-520.
PubMed
4) Seemuller F, et al. Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. BMC Psychiatry 2016 ; 16 : 153.
 
5) American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association ; 2013.
 
6) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン II. うつ病 (DSM-5)/大うつ病性障害 2016. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724.pdf
 
7) Frank E, et al. Conceptualization and Rationale for Consensus Definitions of Terms in Major Depressive Disorder : Remission, Recovery, Relapse, and Recurrence. JAMA Psychiatry 1991 ; 48 : 851-855.
 
8) Rush AJ, et al. Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder. Neuropsychopharmacology 2006 ; 31 : 1841-1853.
PubMed
9) Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991 ; 52 (Suppl) : 28-34.
 
10) Baldessarini RJ, et al. Duration of initial antidepressant treatment and subsequent relapse of major depression. J Clin Psychopharmacol 2015 ; 35 : 75-76.
PubMed
11) Sim K, et al. Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder : Systematic Review and Meta-Analyses of Controlled Trials. Int J Neuropsychopharmacol 2015 : 19.
 
12) Bauer M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1 : Update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013 ; 14 : 334-385.
PubMed
13) Cleare A, et al. Evidence-based guidelines for treating depressive disorders with antidepressants : A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015 ; 29 : 459-525.
PubMed
14) Malhi GS, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015 ; 49 : 1087-1206.
PubMed
15) National Institute for Health and Care Excellence (NICE). Depression in adults : Recognition and management (CG90) ; 2016. https://www.nice.org.uk/guidance/cg90/resources/depression-in-adults-recognition-and-management-975742636741. Accessed 10 Jan 2017.
 
16) Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Introduction and Methods. Can J Psychiatry 2016 ; 61 : 506-509.
PubMed
17) Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 1. Disease Burden and Principles of Care. Can J Psychiatry 2016 ; 61 : 510-523.
PubMed
18) MacQueen GM, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 6. Special Populations : Youth, Women, and the Elderly. Can J Psychiatry 2016 ; 61 : 588-603.
PubMed
19) Milev RV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 4. Neurostimulation Treatments. Can J Psychiatry 2016 ; 61 : 561-575.
PubMed
20) Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 2. Psychological Treatments. Can J Psychiatry 2016 ; 61 : 524-539.
PubMed
21) Ravindran AV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 5. Complementary and Alternative Medicine Treatments. Can J Psychiatry 2016 ; 61 : 576-587.
PubMed
22) Oestergaard S, Moldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression : A meta-analysis. J Affect Disord 2011 ; 131 : 24-36.
PubMed
23) Karyotaki E, et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord 2016 ; 194 : 144-152.
 
24) Clarke K, et al. Can non-pharmacological interventions prevent relapse in adults who have recovered from depression? A systematic review and meta-analysis of randomised controlled trials. Clin Psychol Rev 2015 ; 39 : 58-70.
PubMed
25) Bockting CLH, et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study) : A three-group, multicentre, randomised controlled trial. Lancet Psychiatry 2018 ; 5 : 401-410.
PubMed
26) Bockting CL, et al. A lifetime approach to major depressive disorder : The contributions of psychological interventions in preventing relapse and recurrence. Clin Psychol Rev 2015 ; 41 : 16-26.
PubMed
27) Romera I, et al. Individual residual symptoms and functional impairment in patients with depression. Psychiatry Res 2014 ; 220 : 258-262.
PubMed
28) Benvenuti A, et al. Relationship of residual mood and panic-agoraphobic spectrum phenomenology to quality of life and functional impairment in patients with major depression. Int Clin Psychopharmacol 2010 ; 25 : 68-74.
PubMed
29) Sheehan DV, et al. Restoring function in major depressive disorder : A systematic review. J Affect Disord 2017 ; 215 : 299-313.
PubMed
30) IsHak WW, et al. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). J Affect Disord 2013 ; 151 : 59-65.
 
31) Saragoussi D, et al. Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study. Neuropsychiatr Dis Treat 2017 ; 13 : 2151-2165.
PubMed
32) Saragoussi D, et al. Long-term follow-up on health-related quality of life in major depressive disorder : A 2-year European cohort study. Neuropsychiatr Dis Treat 2018 ; 14 : 1339-1350.
PubMed
33) Bukh JD, et al. Personality and the Long-Term Outcome of First-Episode Depression : A Prospective 5-Year Follow-Up Study. J Clin Psychiatry 2016 ; 77 : e704-710.
 
34) Nicolson S, et al. Comorbid pain, depression, and anxiety : Multifaceted pathology allows for. Harv Rev Psychiatry 2009 ; 17 : 407-420.
PubMed
35) Salagre E, et al. Treatment of neurocognitive symptoms in unipolar depression : A systematic review and future perspectives. J Affect Disord 2017 ; 221 : 205-221.
PubMed
36) Barker MJ, et al. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use : A meta-analysis. Arch Clin Neuropsychol 2004 ; 19 : 437-454.
 
37) Shimazu K, et al. Family psychoeducation for major depression : Randomised controlled trial. Br J Psychiatry 2011 ; 198 : 385-390.
PubMed
38) Shimodera S, et al. Cost-effectiveness of family psychoeducation to prevent relapse in major depression : Results from a randomized controlled trial. BMC Psychiatry 2012 ; 12 : 40.
PubMed
39) Motter JN, et al. Computerized cognitive training and functional recovery in major depressive disorder : A meta-analysis. J Affect Disord 2016 ; 189 : 184-191.
PubMed
40) Berk M, et al. Lifestyle management of unipolar depression. Acta Psychiatr Scand 2013 ; 127 : 38-54.
 
41) Strand M, et al. Emotional Information Processing in Major Depression Remission and Partial Remission : Faces Come First. Appl Neuropsychol Adult 2013 ; 20 : 110-119.
PubMed
42) Penninx B, et al. Understanding the somatic consequences of depression : Biological mechanisms and the role of depression symptom profile. BMC Med 2013 ; 11 : 129.
PubMed
43) Kluczniok D, et al. Emotional availability in mother-child interaction : The effects of maternal depression in remission and additional history of childhood abuse. Depress Anxiety 2016 ; 33 : 648-657.
PubMed
44) Agosti V. Predictors of remission from chronic depression : A prospective study in a nationally representative sample. Compr Psychiatry 2014 ; 55 : 463-467.
 
45) Sumiyoshi T, et al. Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder in Japan (PERFORM-J) : Protocol for a Prospective Cohort Study. JMIR Res Protoc 2018 ; 7 : e161.
PubMed
46) Zimmerman M, et al. Why do some depressed outpatients who are in remission according to the Hamilton Depression Rating Scale not consider themselves to be in remission? J Clin Psychiatry 2012 ; 73 : 790-795.
 
47) Nease DE, et al. Toward a more comprehensive assessment of depression remission : The Remission Evaluation and Mood Inventory Tool (REMIT). Gen Hosp Psychiatry 2011 ; 33 : 279-286.
 
48) Waugh CE, Koster EHW. A resilience framework for promoting stable remission from depression. Clin Psychol Rev 2015 ; 41 : 49-60.
 
49) Ghaemi SN, et al. "Cade's disease" and beyond : Misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. Can J Psychiatry 2002 ; 47 : 125-134.
 
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. American Psychiatric Association ; 2013/日本精神神経学会 (日本語版用語監修), 高橋三郎ほか (監訳). DSM-5 精神疾患の診断・統計マニュアル. 医学書院 ; 2014.
 
日本うつ病学会 (監修), 気分障害の治療ガイドライン作成委員会 (編). うつ病治療ガイドライン 第2版. 医学書院 ; 2017.
 
上島国利ほか (編). 気分障害. 医学書院 ; 2008.
 
伊藤真也ほか (編). 向精神薬と妊娠・授乳 改訂2版. 南山堂 ; 2017.
 
細川貂々. ツレがうつになりまして. 幻冬舎文庫 ; 2009.
 
P.436 掲載の参考文献
1) 厚生労働省. 平成30年度診療報酬改定関係資料 (医科・調剤). https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000196430.pdf (参照2019-04-01)
 
2) 公認心理師法. https://www.mhlw.go.jp/file/06-Seisakujouhou-12200000-Shakaiengokyokushougaihokenfukushibu/0000121345.pdf (参照2019-04-01)
 
3) 下山晴彦. 公認心理師と認知行動療法の活用. 精神療法 2019 ; 45 (1) : 7-12.
 
4) 文部科学省, 厚生労働省. 公認心理師法第42条第2項に係る主治の医師の指示に関する運用基準について. https://www.mhlw.go.jp/file/06-Seisakujouhou-12200000-Shakaiengokyokushougaihokenfukushibu/0000192943.pdf (参照2019-04-01)
 
5) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン II. 大うつ病性障害. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/20190724.pdf
 
6) Tolin DF. Is cognitive-behavioral therapy more effective than other therapies? A meta-analytic review. Clin Psychol Rev 2010 ; 30 (6) : 710-720.
PubMed
7) 濱家由美子. 認知行動療法面接の基本構造. 精神療法 2019 ; 45 (1) : 18-23.
 
8) 堀英太郎. 学校における公認心理師と医療機関との連携. 精神経誌 2018 ; 120 (10) : 928-934.
 
9) 金井篤子. 産業領域における精神医学と心理学の協働. 精神経誌 2018 ; 120 (10) : 935-941.
 
10) 丹野義彦. 公認心理師の課題と展望. 最新精神医学 2017 ; 22 (4) : 301-307.
Medical*Online
村瀬嘉代子. 公認心理師法の成立と今後の課題. 精神神経学雑誌 2017 ; 117 (2) : 114-119.
 
臨床心理学 18巻4号. 金剛出版 ; 2018.
 
精神療法 43巻6号. 金剛出版 ; 2017.
 
P.442 掲載の参考文献
1) 本橋伸高ほか. 電気けいれん療法 (ECT) 推奨事項 改訂版. 精神経誌 2013 ; 115 (6) : 586-600.
 
2) 本橋伸高. 電気けいれん療法のゆくえ. 精神経誌 2012 ; 114 (10) : 1208-1214.
 
3) 日本うつ病学会 (監修), 気分障害の治療ガイドライン作成委員会 (編). 大うつ病性障害・双極性障害治療ガイドライン. 医学書院 ; 2013.
 
4) UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders : A systematic review and meta-analysis. Lancet 2003 ; 361 : 799-808.
PubMed
5) Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005 ; (2) : CD000076.
PubMed
6) Abrams R. Electroconvulsive Therapy, 4th edition. Oxford University Press ; 2002/一瀬邦弘ほか (監訳). 電気けいれん療法. へるす出版 ; 2005.
 
7) Weiner RD ; American Psychiatric Association Committee on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy : Recommendations for treatment, training, and privileging : a task force report of the American Psychiatric Association. American Psychiatric Association ; 2001/日本精神神経学会電気けいれん療法の手技と適応基準の検討小委員会 (監訳). 米国精神医学会タスクフォースレポート-ECT実践ガイド. 医学書院 ; 2002.
 
8) 安田和幸. 電気けいれん療法. 日本臨床精神神経薬理学会専門医制度委員会 (編), 臨床精神薬理学テキスト改訂3版. 星和書店 ; 2014, pp306-315.
 
Mankad MV, et al. Clinical Manual of Electroconvulsive Therapy. American Psychiatric Association ; 2010/本橋伸高ほか (訳). パルス波ECTハンドブック. 医学書院 ; 2012.
 
日本総合病院精神医学会 (監修). 修正型電気けいれん療法 (ECT) の基礎と実践-より安全に, より確実に. 日本総合病院精神医学会事務局 ; 2013.
 
Shorter E, Healy D. Shock therapy : A history of electroconvulsive treatment in mental illness. University of Toronto Press ; 2007/川島啓嗣ほか (訳). <電気ショック> の時代-ニューロモデュレーションの系譜. みすず書房 ; 2018.
 
Ottosson JO, Fink M. Ethics in Electroconvulsive Therapy. Taylor & Francis ; 2004/中村満 (訳). 電気けいれん療法の実践的倫理. 星和書店 ; 2006.
 
Schwartz CM. Electroconvulsive and Neuromodulation Therapies. Cambridge University Press ; 2009.
 
Weiss A. The Electroconvulsive Therapy Workbook : Clinical Applications. Routledge ; 2018.
 
P.449 掲載の参考文献
1) 日本精神神経学会. 反復経頭蓋磁気刺激 (rTMS) 適正使用指針. https://www.jspn.or.jp/uploads/uploads/files/activity/Guidelines_for_appropriate_use_of_rTMS.pdf
 
2) 鬼頭伸輔. ニューロモデュレーション治療の可能性. 精神神経疾患へのrTMS療法と展望. 精神科 2019 ; 34 : 612-617.
 
3) 鬼頭伸輔ほか (編). うつ病のTMS療法. 金原出版 ; 2016.
 
4) Rossi S, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009 ; 120 : 2008-2039.
PubMed
5) Kito S, et al. Changes in regional cerebral blood flow after repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in treatment-resistant depression. J Neuropsychiatry Clin Neurosci 2008 ; 20 : 74-80.
PubMed
6) Kito S, et al. Neuroanatomical correlates of therapeutic efficacy of low-frequency right prefrontal transcranial magnetic stimulation in treatment-resistant depression. Psychiatry Clin Neurosci 2011 ; 65 : 175-182.
PubMed
7) Fox MD, et al. Resting-state networks link invasive and noninvasive brain stimulation across diverse psychiatric and neurological diseases. Proc Natl Acad Sci U S A 2014 ; 111 : E4367-E4375.
PubMed
8) Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014 ; 125 : 2150-2206.
 
9) Drevets WC, et al. Brain structural and functional abnormalities in mood disorders : Implications for neurocircuitry models of depression. Brain Struct Funct 2008 ; 213 : 93-118.
PubMed
10) Fitzgerald PB, et al. An analysis of functional neuroimaging studies of dorsolateral prefrontal cortical activity in depression. Psychiatry Res 2006 ; 148 : 33-45.
PubMed
11) George MS, et al. Prefrontal cortex dysfunction in clinical depression. Depression 1994 ; 2 : 59-72.
 
12) Mayberg HS, et al. Reciprocal limbic-cortical function and negative mood : Converging PET findings in depression and normal sadness. Am J Psychiatry 1999 ; 156 : 675-682.
PubMed
13) Kito S, et al. Cerebral blood flow ratio of the dorsolateral prefrontal cortex to the ventromedial prefrontal cortex as a potential predictor of treatment response to transcranial magnetic stimulation in depression. Brain Stimul 2012 ; 5 : 547-553.
 
14) Kito S, et al. Cerebral blood flow in the ventromedial prefrontal cortex correlates with treatment response to low-frequency right prefrontal repetitive transcranial magnetic stimulation in the treatment of depression. Psychiatry Clin Neurosci 2012 ; 66 : 138-145.
PubMed
15) Huang YZ, et al. Theta burst stimulation of the human motor cortex. Neuron 2005 ; 45 : 201-206.
 
16) Hamada M, et al. Bidirectional long-term motor cortical plasticity and metaplasticity induced by quadripulse transcranial magnetic stimulation. J Physiol 2008 ; 586 : 3927-3947.
PubMed
17) George MS, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder : A sham-controlled randomized trial. Arch Gen Psychiatry 2010 ; 67 : 507-516.
PubMed
18) Slotema CW, et al. Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. J Clin Psychiatry 2010 ; 71 : 873-884.
PubMed
19) Brunoni AR, et al. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes : a systematic review with network meta-analysis. JAMA Psychiatry 2017 ; 74 : 143-152.
PubMed
20) George MS, et al. The expanding evidence base for rTMS treatment of depression. Curr Opin Psychiatry 2013 ; 26 : 13-18
 
21) 鬼頭伸輔ほか. 気分障害への反復経頭蓋磁気刺激 (rTMS). 機能的脳神経外科 2017 ; 56 : 15-22.
Medical*Online
22) 鬼頭伸輔. 国内外におけるrTMSの現況, 安全性に関する留意点. 精神神経学雑誌 2015 ; 117 : 103-109.
 
23) Perera T, et al. The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul 2016 ; 9 : 336-346.
PubMed
24) Levkovitz Y, et al. Deep transcranial magnetic stimulation over the prefrontal cortex : evaluation of antidepressant and cognitive effects in depressive patients. Brain Stimul 2009 ; 2 : 188-200.
PubMed
25) Levkovitz Y, et al. Efficacy and safety of deep transcranial magnetic stimulation for major depression : A prospective multicenter randomized controlled trial. World Psychiatry 2015 ; 14 : 64-73.
PubMed
26) Our Treatments-Brainsway https://www.brainsway-global.com/patients/our-treatments/
 
27) Judd LL, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 ; 59 : 530-537.
 
28) Judd LL, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 ; 60 : 261-269.
 
29) 日本うつ病学会 気分障害の治療ガイドライン作成委員会. 日本うつ病学会治療ガイドライン I. 双極性障害 2017. https://www.secretariat.ne.jp/jsmd/iinkai/katsudou/data/180125.pdf
 
30) Kito S, et al. A 6-month follow-up case study of low-frequency right prefrontal repetitive transcranial magnetic stimulation in treatment-resistant bipolar depression. J ECT 2017 ; 33 : e43-e44.
PubMed
鬼頭伸輔ほか (編). うつ病のTMS療法. 金原出版 ; 2016.
 
日本精神神経学会. 反復経頭蓋磁気刺激 (rTMS) 適正使用指針. https://www.jspn.or.jp/uploads/uploads/files/activity/Guidelines_for_appropriate_use_of_rTMS.pdf
 
Rossi S, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009 ; 120 (12) : 2008-2039.
PubMed
Lefaucheur JP, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol 2014 ; 125 (11) : 2150-2206.
PubMed
Perera T, et al. The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul 2016 ; 9 (3) : 336-346.
PubMed
P.456 掲載の参考文献
1) Sugiyama K, et al. The present indication and future of deep brain stimulation. Neurol Med Chir (Tokyo) 2015 ; 55 : 416-421.
PubMed
2) 杉山憲嗣, 旭雄士. 定位脳手術の合併症. 難波宏樹ほか (編), 定位・機能神経外科治療ガイドライン 第3版. マイライフ社 ; 2019, pp104-115.
 
3) Rosin B, et al. Closed-loop deep brain stimulation is superior in ameliorating parkinsonism. Neuron 2011 ; 72 : 370-384.
PubMed
4) Mayberg HS, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005 ; 45 (5) : 651-660.
 
5) Kisely S, et al. A systematic review and meta-analysis of deep brain stimulation for depression. Depress Anxiety 2018 ; 35 (5) : 468-480.
PubMed
6) Holtzheimer PE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression : A multisite, randomised, sham-controlled trial. Lancet Psychiatry 2017 ; 4 (11) : 839-849.
PubMed
7) Dandekar MP, et al. Deep brain stimulation for treatment-resistant depression : An integrative review of preclinical and clinical findings and translational implications. Mol Psychiatry 2018 ; 23 (5) : 1094-1112.
PubMed
8) Zhou C, et al. A systematic review and meta-analysis of deep brain stimulation in treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 2018 ; 82 : 224-232.
 
9) Alonso P, et al. Deep Brain Stimulation for Obsessive-Compulsive Disorder : A Meta-Analysis of Treatment Outcome and Predictors of Response. PLoS One 2015 ; 10 (7) : e0133591.
PubMed
Riva-Posse P, et al. A connectomic approach for subcallosal cingulate deep brain stimulation surgery : prospective targeting in treatment-resistant depression. Mol Psychiatry 2018 ; 23 (4) : 843-849.
PubMed
開道貴信ほか. 難治性チックに対する視床刺激療法. 機能的脳神経外科 2015 ; 54 : 33-38.
Medical*Online
Figee M, et al. Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nat Neurosci 2013 ; 16 (4) : 386-387.
PubMed
中前貴. 強迫症に対するニューロモデュレーション. 不安症研究 2017 ; 9 (1) : 50-56.
 
Fayad SM, et al. Six-Nine Year Follow-Up of Deep Brain Stimulation for Obsessive-Compulsive Disorder. PLoS One 2016 ; 11 (12) : e0167875.
PubMed
P.460 掲載の参考文献
1) Kadosh RC (ed). The Stimulated Brain, 1st edition. Academic Press ; 2014.
 
2) 田中悟. 経頭蓋直流電気刺激の脳卒中リハビリテーションへの応用. The Japanese Journal of Rehabilitation Medicine 2016 ; 53 (6) : 446-451.
Medical*Online
3) Meron D, et al. Transcranial direct current stimulation (tDCS) in the treatment of depression : Systematic review and meta-analysis of efficacy and tolerability. Neurosci Biobehav Rev 2015 ; 57 : 46-62.
PubMed
4) Milev RV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 4. Neurostimulation Treatments. Can J Psychiatry 2016 ; 61 (9) : 561-575.
PubMed
5) Nikolin S, et al. Effects of TDCS dosage on working memory in healthy participants. Brain Stimul 2018 ; 11 (3) : 518-527.
PubMed
6) Donde C, et al. Transcranial direct-current stimulation (tDCS) for bipolar depression : A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2017 ; 78 : 123-131.
PubMed
7) Sampaio-Junior B, et al. Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression : A Randomized Clinical Trial. JAMA Psychiatry 2018 ; 75 (2) : 158-166.
PubMed
8) Martin DM, et al. Transcranial direct current stimulation to enhance cognition in euthymic bipolar disorder. Bipolar Disord 2015 ; 17 (8) : 849-858.
PubMed
9) Brunoni AR, et al. Treatment-emergent mania/hypomania during antidepressant treatment with transcranial direct current stimulation (tDCS) : A systematic review and meta-analysis. Brain Stimul 2017 ; 10 (2) : 260-262.
PubMed
10) 宇川義一ほか, 日本臨床神経生理学会 脳刺激法に関する委員会. 経頭蓋直流電気刺激 (transcranial direct current stimulation, tDCS) の安全性について. 臨床神経生理学 2011 ; 39 (1) : 59-60.
 
11) Shiozawa P, et al. Transcranial direct current stimulation for major depression : An updated systematic review and meta-analysis. Int J Neuropsychopharmacol 2014 ; 17 (9) : 1443-1452.
PubMed
12) Brunoni AR, et al. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol 2011 ; 14 (8) : 1133-1145.
PubMed
13) 西田圭一郎, 木下利彦. うつ病におけるtDCS (経頭蓋直流電気刺激) の可能性. 臨床精神薬理 2018 ; 21 (7) : 941-946.
 
Kadosh RC (ed). The Stimulated Brain, 1st edition. Academic Press ; 2014.
 
Milev RV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder : Section 4. Neurostimulation Treatments. Can J Psychiatry 2016 ; 61 (9) : 561-575.
PubMed
Brunoni AR, et al. Transcranial direct current stimulation for acute major depressive episodes : Meta-analysis of individual patient data. Br J Psychiatry 2016 ; 208 (6) : 522-531.
PubMed
Brunoni AR, et al. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol 2011 ; 14 (8) : 1133-1145.
PubMed
宇川義一ほか, 日本臨床神経生理学会 脳刺激法に関する委員会. 経頭蓋直流電気刺激 (transcranial direct current stimulation, tDCS) の安全性について. 臨床神経生理学 2011 ; 39 (1) : 59-60.
 
P.467 掲載の参考文献
1) Jobsis FF. Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 1977 ; 198 : 1264-1267.
PubMed
2) 酒谷薫. 近赤外分光法の基礎原理 Q&A. 日本脳代謝モニタリング研究会, 片山容一ほか (編). 臨床医のための近赤外分光法. 新興医学出版社 ; 2002, pp1-9.
 
3) Hoshi Y, et al. Interpretation of near-infrared spectroscopy signals. A study with a newly developed perfused rat brain model. J Appl Physiol 2001 ; 90 : 1657-1662.
 
4) Watanabe E, et al. Non-invasive assessment of language dominance with near-infrared spectroscopic mapping. Neurosci Lett 1998 ; 256 : 49-52.
PubMed
5) Hoshi Y. Functional near-infrared optical imaging : Utility and limitation in human brain mapping. Psychophysiology 2003 ; 40 : 511-520.
PubMed
6) Takahashi T, et al. Influence of skin blood flow on near-infrared spectroscopy signals measured on the forehead during a verbal fluency task. Neuroimage 2011 ; 57 : 991-1002.
PubMed
7) Sato H, et al. A NIRS-fMRI investigation of prefrontal cortex activity during a working memory task. Neuroimage 2013 ; 83 : 158-173.
 
8) Moriguchi Y, et al. Validation of brain-derived signals in near-infrared spectroscopy through multivoxel analysis of concurrent functional magnetic resonance imaging. Hum Brain Mapp 2017 ; 38 : 5274-5291.
PubMed
9) Funane T, et al. Quantitative evaluation of deep and shallow tissue layers' contribution to fNIRS signal using multi-distance optodes and independent component analysis. Neuroimage 2014 ; 85 : 150-165.
PubMed
10) Okada F, et al. Dominance of the 'nondominant' hemisphere in depression. J Affect Disord 1996 ; 37 : 13-21.
PubMed
11) Matsuo K, et al. Prefrontal hemodynamic response to verbal-fluency task and hyperventilation in bipolar disorder measured by multi-channel near-infrared spectroscopy. J Affect Disord 2004 ; 82 : 85-92.
PubMed
12) Suto T, et al. Multichannel near-infrared spectroscopy in depression and schizophrenia : Cognitive brain activation study. Biol Psychiatry 2004 ; 55 : 501-511.
PubMed
13) Herrmann MJ, et al. Bilaterally reduced frontal activation during a verbal fluency task in depressed patients as measured by near-infrared spectroscopy. J Neuropsychiatry Clin Neurosci 2004 ; 16 : 170-175.
PubMed
14) Kameyama M, et al. Frontal lobe function in bipolar disorder : A multichannel near-infrared spectroscopy study. Neuroimage 2006 ; 29 : 172-184.
PubMed
15) Takizawa R, et al. Neuroimaging-aided differential diagnosis of the depressive state. Neuroimage 2014 ; 85 : 498-507.
PubMed
16) Azuma T. Working memory and perseveration in verbal fluency. Neuropsychology 2004 ; 18 : 69-77.
PubMed
17) Henry JD, Crawford JR. A meta-analytic review of verbal fluency performance following focal cortical lesions. Neuropsychology 2004 ; 18 : 284-295.
PubMed
18) Zhang H, et al. Near-infrared spectroscopy for examination of prefrontal activation during cognitive tasks in patients with major depressive disorder : A meta-analysis of observational studies. Psychiatry Clin Neurosci 2015 ; 69 : 22-33.
PubMed
19) 厚生労働省 保医発 0305 第3号 平成30年3月5日. 特掲診療料の施設基準等及びその届出に関する手続きの取扱いについて. 別添1 特掲診療料の施設基準等. https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000203034.pdf
 
20) 日本うつ病学会. 双極性障害およびうつ病の診断における光トポグラフィー検査の意義についての声明 (2016年11月29日). https://www.secretariat.ne.jp/jsmd/iinkai/working/data/nirs_statement.pdf
 
福田正人. 「抑うつ状態の鑑別診断補助」としての光トポグラフィー検査-精神疾患の臨床検査を保険診療として実用化する意義. 精神神経学雑誌 2015 ; 117 : 79-93.
 
福田正人 (監修), 西村幸香 (編集). 光トポグラフィー検査ガイドブック-NIRS波形の臨床判読 改訂第2版. 中山書店 ; 2017.
 
P.474 掲載の参考文献
1) 令和元年版情報通信白書. https://www.nik-prt.co.jp/wp_site/ebook/jouhoutsushin/index2019.html
 
2) 厚生労働省. 医療分野の情報化の推進について. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/johoka/index.html
 
3) Jones SH, et al. Actigraphic assessment of circadian activity and sleep patterns in bipolar disorder. Bipolar Disord 2005 ; 7 (2) : 176-186.
PubMed
4) Berle JO, et al. Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression. BMC Res Notes 2010 ; 3 : 149.
PubMed
5) Tazawa Y, et al. Actigraphy for evaluation of mood disorders : A systematic review and meta-analysis. J Affect Disord 2019 ; 253 : 257-269.
PubMed
6) Licht CMM,et al. Association Between Major Depressive Disorder and Heart Rate Variability in the Netherlands Study of Depression and Anxiety (NESDA). Arch Gen Psychiatry 2008 ; 65 : 1358.
 
7) Avila Moraes CT, et al. A new chronobiological approach to discriminate between acute and chronic depression using peripheral temperature, rest-activity, and light exposure parameters. BMC Psychiatry 2013 ; 13 : 77.
 
8) Faedda GL, et al. Actigraph measures discriminate pediatric bipolar disorder from attention-deficit/hyperactivity disorder and typically developing controls. J Child Psychol Psychiatry 2016 ; 57 (6) : 706-716.
PubMed
9) Dogan E, et al. Smartphone-Based Monitoring of Objective and Subjective Data in Affective Disorders: Where Are We and Where Are We Going? Systematic Review. J Med Internet Res 2017 ; 19 : e262.
 
10) World Health Organization. Telemedicine : Opportunities and developments in Member States : report on the second global survey on eHealth 2009. http://www.who.int/goe/publications/goe_telemedicine_2010.pdf
 
11) REACH Health. 2018 U.S. Telemedicine Industry Benchmark Survey. March 2018. https://www.healthlawinformer.com/wp-content/uploads/2017/05/2017-telemed-us-industry-survey.pdf
 
12) Shore JH, et al. Diagnostic reliability of telepsychiatry in American Indian veterans. Am J Psychiatry 2007 ; 164 : 115-118.
PubMed
13) Yoshida K, et al. Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale : A validation study. J Telemed Telecare 2019 May 8 [Epub ahead of print]
 
14) Iiboshi K, et al. A Validation Study of the Remotely Administered Montreal Cognitive Assessment Tool in the Elderly Japanese Population. Telemed J E Health 2019 Nov 19 [Epub ahead of print]
 
15) Ruskin PE, et al. Treatment outcomes in depression : comparison of remote treatment through telepsychiatry to in-person treatment. Am J Psychiatry 2004 ; 161 : 1471-1476.
PubMed
16) O'Reilly R, et al. Is telepsychiatry equivalent to face-to-face psychiatry? Results from a randomized controlled equivalence trial. Psychiatr Serv 2007 ; 58 (6) : 836-843.
 
17) Proudfoot J, et al. Computerized, interactive, multimedia cognitive-behavioural program for anxiety and depression in general practice. Psychol Med 2003 ; 33 (2) : 217-227.
PubMed
18) Proudfoot J, et al. Clinical efficacy of computerised cognitive-behavioural therapy for anxiety and depression in primary care : Randomised controlled trial. Br J Psychiatry 2004 ; 185 (1) : 46-54.
 
19) Andrews G, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care : An updated meta-analysis. J Anxiety Disord 2018 ; 55 : 70-78.
PubMed
20) Richards D, Richardson T. Computer-based psychological treatments for depression : A systematic review and meta-analysis. Clin Psychol Rev 2012 ; 32 (4) : 329-342.
PubMed
21) Thase ME, et al. Improving the Efficiency of Psychotherapy for Depression : Computer-Assisted Versus Standard CBT. Am J Psychiatry 2018 ; 175 (3) : 242-250.
PubMed
22) Fitzpatrick KK, et al. Delivering Cognitive Behavior Therapy to Young Adults With Symptoms of Depression and Anxiety Using a Fully Automated Conversational Agent (Woebot) : A Randomized Controlled Trial. JMIR Ment Health 2017 ; 4 (2) : e19.
PubMed

書評

最近チェックした商品履歴

Loading...